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In eukaryotes, the first step of interpreting the genetic information is the 
transcription of DNA into RNA. For protein-coding genes, such transcription is carried 
out by RNA polymerase II. A special domain of RNA polymerase II, called the C-
terminal domain (CTD), functions as a master controller for the transcription process by 
providing a platform to recruit regulatory proteins to nascent mRNA (Chapter 1-2). The 
modifications and conformational states of the CTD, termed the ‘CTD code’, represent a 
critical regulatory checkpoint for transcription. The CTD, found only in eukaryotes, 
consists of 26–52 tandem heptapeptide repeats with the consensus sequence, 
Tyr1Ser2Pro3Thr4Ser5Pro6Ser7. Phosphorylation of the serines and prolyl isomerization of 
the prolines represent two major regulatory mechanisms of the CTD. Interestingly, the 
phosphorylation sites are typically close to prolines, thus the conformation of the adjacent 
proline could impact the specificity of the corresponding kinases and phosphatases. 
Understanding how those modifying enzymes recognize and regulate the CTD is 
important for expanding our knowledge on the transcription regulation and deciphering 
the ‘CTD code’. 
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During my PhD study, I studied the function of CTD phosphatases and prolyl 
isomerase in the CTD regulation using Scp1, Ssu72 and Pin1 as model regulators. Scp1 
and Ssu72 are both Ser5 phosphatases. However, Ssu72 is an essential protein and 
regulates the global transcription while Scp1 epigenetically silences the expression of 
specific neuronal genes. Pin1 is a highly conserved phosphorylation-specific prolyl 
isomerase that recognizes the phospho-Ser/Thr-Pro motif within the CTD as one of its 
primary substrates in vivo. Among these enzymes, Scp1 is the focal point of this 
dissertation, as it was studied from different angles, such as enzymatic mechanism 
(Chapter 3 describes the capture of phospho-aspartyl intermediate of Scp1 as a direct 
evidence for the proposed two-step mechanism), specific inhibition (Chapter 4 describes 
the identification and characterization of the first specific inhibitor of Scp1), and its non-
active-site contact with the CTD (Chapter 5 describes the structural basis of this contact). 
These studies are of great importance towards understanding the molecular mechanism of 
the dephosphorylation process of the CTD by Scp1. 
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 1 
C-TERMINAL DOMAIN (CTD) OF EUKARYOTIC RNA 
POLYMERASE II 
Chapter 1:  Introduction to the CTD of Eukaryotic RNA Polymerase 
II 
Biological systems have long served as a source of inspiration for engineering, 
resulting in numerous inventions based on biomimetics. During the last few decades, as 
electronics-based information technology has matured and flourished, our understanding 
of the biological system has also proceeded to the molecular and informational level. 
Such understanding has enabled researchers to reprogram cells to undertake unnatural 
tasks, such as the production of proteins and metabolites for medical and industrial 
purposes. Recent development of systems and synthetic biology promises the 
development of cells with even more complex artificial functions that will require the 
collaboration of a large number of genes. With a similar philosophy, information-based 
molecular programming has also been established as a new path for nanotechnology. 
Central to all these new technologies, cellular or acellular, is the encoding and decoding 
of information at the molecular level, particularly using DNA as the information carrier. 
Therefore, from both a scientific and engineering point of view, it is important to 
understand how biological systems read information from DNA. 
In biology, the major interpretation of this genetic information is through 
transcription regulation where eukaryotic RNA polymerase II plays the central role of 
transcribing the genetic information to the expressed protein. A special domain called the 
CTD of RNA polymerase II functions as a master controller for the transcription process 
by providing the template to recruit regulatory proteins to nascent mRNA (Corden 1990). 
The conformational states of the CTD, termed the CTD code, represent a critical 
regulatory check point for transcription (Dahmus 1996; Palancade et al. 2003; Meinhart 
 2 
et al. 2005). The CTD, found only in eukaryotes, consists of 26–52 tandem heptapeptide 
repeats generally with the consensus sequence, Tyr1Ser2Pro3Thr4Ser5Pro6Ser7 (Corden 
1990). Alterations of the sequence or the copy number of the heptapeptide may lead to 
distinguishable phenotypes or cell death (Chapman et al. 2007; Rogers et al. 2010). The 
CTD can spatially and temporally recruit different regulatory and processing factors to 
the transcriptional machinery, reviewed in Corden (Corden 1990) (Figure 1-1) but the 
domain is disordered in X-ray crystal structures. The CTD phosphorylation is a major 
mechanism by which cells regulate gene expression, with serines at position 2 and 5 as 
major phosphorylation sites (Phatnani et al. 2006). Recently, Ser7 was also found to be 
phosphorylated in vivo although its function is still elusive (Chapman et al. 2007). A 
secondary mechanism for CTD regulation is prolyl-isomerization of the two prolines in 
the CTD heptapeptide sequence. By adjusting the cis–trans conformation of a proline 
adjacent to a phosphorylated serine, interaction of the CTD and binding partners it 
recruits can be modulated. 
Coordinately regulated phosphorylation and dephosphorylation of the CTD plays 
an essential role not only in the recruitment and assembly of transcription complexes but 
also in temporal control of transcription and mRNA processing, reviewed in Refs 
(Buratowski 2009; Fuda et al. 2009). Evidence points to the phosphorylation state of Ser2 
and Ser5 as the trigger for transcriptional process modulation (Figure 1-2). Ser5 
phosphorylation is required for assembly of the preinitiation complex (PIC) and 
facilitates mRNA capping via recruitment of capping enzymes (Cho et al. 1997; 
Komarnitsky et al. 2000). During the transition when the transcription complex moves 
away from the initiation site, Ser5 gradually becomes dephosphorylated, whereas Ser2 is 
phosphorylated. Ser2 phosphorylation is the predominant CTD pattern on both elongating 
and terminating RNA Polymerase II, which ensures efficient 3’–RNA processing by 
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triggering the recruitment of 3’–RNA processing machinery (Fuda et al. 2009). At the 
end of transcription, CTDs are free of phosphate groups; non-phosphorylated CTDs are 
required for RNA polymerase II to recycle and bind a promoter for the next cycle of 
transcription (Fuda et al. 2009). Little is known about the timing of Ser7 phosphorylation 
and how it affects the transcription but it appears to be an essential event specific for 
snRNA expression (Egloff et al. 2007). 
 
Figure 1-1: Model of the CTD of RNA polymerase II.1 
                                                 
1 The RNA polymerase II is colored with purple. Different shapes bound to the CTD indicate various 
proteins that are recruited by the CTD. Magenta circles labeled with ‘P’ indicate phosphorylation on the 
CTD. One repeat in the black circle is zoomed in to show its primary sequence ‘YSPTSPS’. The Ser2 and 
Ser5 (colored with magenta) are always phosphorylated in each round of transcription, and Tyr1 and Ser7 
(colored with yellow) are also detected as phosphorylation sites in vivo. 
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Figure 1-2: Schematic diagram of RNA polymerase II-mediated transcription.2 
One central question for CTD-directed transcription regulation is how high 
resolution recognition of different states of Ser2 and Ser5 are identified. Residues flanking 
Ser2 and Ser5 are highly similar, so it is puzzling how the transcription regulation is 
managed with such precision in location and timing. The most direct way to visualize and 
identify molecular elements in binding specificity is X-ray crystallography. A careful 
examination of the primary sequence of the CTD reveals the possibility that the CTD 
might have little secondary structure until its association with binding partners. In the 
next chapter, we will discuss our current understanding of the CTD structure and how the 
CTD is recognized by its binding partners (Table 1-1). 
                                                 
2 The figure was adapted from (Fuda et al. 2009). Ser5 phosphorylation (indicated by magenta blobs) 
occurs in promoter-proximal regions coincident with initiation and facilitates mRNA capping via recruiting 
capping enzymes (step 4). When the transcription complex moves away from the initiation site, Ser5 
gradually becomes hypophosphorylated (indicated by only one magenta blob), whereas Ser2 gradually 
becomes hyperphosphorylated (indicated by blue blobs) (step 5). After termination, the CTD is 
dephosphorylated to reinitiate a new round of transcription (step 7). The colored-shapes indicate some 
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Table 1-1: Summary of CTD interacting proteins/domains. 
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Chapter 2:  CTD Interacting Proteins 
PIN1 AND THE CTD 
The first glimpse of the CTD structure was through its interaction with human 
Pin1, a unique prolyl isomerase that catalyzes cis/trans isomerization of specific 
phospho.Ser/Thr-Pro motifs in signaling proteins (Lu et al. 1996; Ranganathan et al. 
1997; Yaffe et al. 1997; Lu et al. 1999). Identification and characterization of this novel 
peptidyl-prolyl cis/trans isomerase (PPIase), Pin1, led to the discovery of a novel post-
phosphorylation regulatory mechanism, in which regulation is achieved by 
conformational changes of a phosphorylated Ser/Thr-Pro peptide bond upon proline 
isomerization (Figure 2-1). This change in the configuration of the polypeptide has a 
profound effect on Pin1 targets and therefore modulates various signaling pathways at 
both transcriptional and post-translational levels. Specifically, prolyl-isomerization 
activity of Pin1 can interconvert the cis/trans conformation of the phospho.Ser/Thr-Pro 
motif of target proteins and make them better or worse substrates for conformation-
specific signaling kinases (such as cyclin-dependent protein kinase, glycogen synthetase 
kinase 3 beta, and mitogen-activated protein kinase) and phosphatases (such as PP2A and 
Cdc25). Recent studies also provide substantial evidence implicating Pin1 in progression 
of malignant tumor cells (Lu 2004) and development of Alzheimer’s disease (Etzkorn 
2006). High affinity inhibitory unnatural peptides have been developed as a good 
template for chemical compounds targeting Pin1 for antineoplastic effects (Zhang et al. 
2007). 
Compelling data have implicated human Pin1 as a key modulator in the 
transcription mechanism. The yeast homologue of Pin1, Ess1, interacts physiologically 
and genetically with the CTD (Wu et al. 2000). Furthermore, hyperphosphorylated RNA 
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polymerase II appears to be the dominant binding target in yeast extracts (Morris et al. 
1999). Considering the high local concentration of the phospho.Ser/Thr-Pro motif in the 
hyperphosphorylated CTD, it is plausible that the CTD is the major substrate of Pin1 in 
vivo. The Kd of a single CTD repeat that is phosphorylated at Ser5 was reported to be 30 
µM (Verdecia et al. 2000). Presumably, the CTD tail containing 26–52 such repeats 
localizes a substantial amount of Pin1. 
Figure 2-1: Cis and trans conversion of proline in a phospho.Ser-Pro motif. 
Pin1 is a 163 amino acid polypeptide that can be divided into two domains based 
on topology and function, a C-terminal PPIase domain and an N-terminal WW domain. 
Structure of the WW domain reveals three antiparallel β-strands forming a shallow 
interface with the PPIase domain for substrate peptide binding (Macias et al. 1996; 
Huang et al. 2000). It has long been realized that WW domains recognize proline-
containing sequences but it was not clear until recently that WW domains join a group of 
modules that bind to protein ligands in a phosphorylation-dependent manner (Lu et al. 
1999; Lu et al. 2002); these domains include SH2, PTB, 14-3-3, WD40, FHA, and FF 
domains. The modular nature of WW domain interactions leads to a classification into 
 
 11 
four distinct groups based on binding specificity (Sudol et al. 2000). Group I WW 
domains, such as dystrophin and the Yes-associated protein YAP65, recognize ‘PpxY’ 
motifs (Chen et al. 1997). Group II, such as FE65 and formin binding proteins (FBPs), 
bind the ‘PPLP’ motif (Ermekova et al. 1997). A subset of FBPs interacts with ‘PGM’ 
motifs (Bedford et al. 1998). Group III WW domains select poly-proline motifs flanked 
by arginine or lysine (Komuro et al. 1999; Bedford et al. 2000). Group IV WW domains, 
including human Pin1 and Nedd4, specifically recognize a phospho.Ser/Thr-Pro motif 
(Lu et al. 1999; Verdecia et al. 2000; Myers et al. 2001). 
The molecular detail of recognition of the CTD by Pin1 was elucidated by a 
structure of human Pin1 in complex with one doubly phosphorylated CTD repeat 
(Verdecia et al. 2000) (Figure 2-2a). So far, this is the only structure available for a full-
length Pin1 binding to its target at the recognition module WW domain. The structure is 
consistent with the thermodynamic data, which showed that the phosphorylated Ser5 in 
the CTD repeat is the major binding element in recognition. Loop 1 of the WW domain 
has been shown to be highly flexible in apo Pin1 (Kowalski et al. 2002) but this loop is 
essential for specificity recognition (Jager et al. 2006). In the complex structure, this loop 
warps toward the substrate peptide to ensure binding and results in an exaggerated twist 
in the triple-stranded β-sheet (Verdecia et al. 2000) (Figure 2-2a). This twist is coupled 
to a contraction of the WW domain ligand binding surface formed between the WW and 
PPIase domains. The two essential elements for peptide recognition include binding of 
phosphate by loop 1 residues and hydrophobic stacking of proline by Tyr23 and Trp34 
(Verdecia et al. 2000). The binding of Pin1 to the CTD can modulate the regulatory effect 
of other CTD-binding proteins. In vitro experiments showed that Pin1 can influence the 
phosphorylation status of the CTD by inhibiting the transcription factor IIF-interacting 
CTD phosphatase 1 (Fcp1) and stimulating CTD phosphorylation by cdc2/cyclinB (Xu et 
 12 
al. 2003; Palancade et al. 2004). The Rsp5, a ubiquitin ligase that binds to the CTD, also 
functions to oppose Pin1 effects on RNA polymerase II (Wu et al. 2001). The biological 
and structural results of Pin1 effects on RNA polymerase II function support a model that 
Pin1 works in a processive manner on the CTD with the WW domain acting as a binding 
element restricting movement to an efficient one dimensional walk and with the PPIase 
acting much like a reading head to processively isomerize the peptide bonds. The binding 
of Pin1 prolongs the phosphorylated state of the CTD by suppressing dephosphorylation, 
thereby enhancing the regulatory effect of CTD binding proteins. 
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Figure 2-2: Ribbon representation of four CTD recognition modules.3 
CTD-INTERACTING DOMAIN (CID) AND THE CTD 
Recognition of the phosphorylated CTD by Pin1 is mediated by its WW domain, 
a modular domain of around 40 residues that is essential for recognition of proline-rich 
motifs by the PPIase domain. However, the Pin1 WW domain also recognizes other 
substrates in addition to the CTD. A more specific recognition domain for the CTD is the 
CTD-interacting domain (CID) identified in multiple RNA processing and termination 
factors in eukaryotes (Meinhart et al. 2004; Noble et al. 2005) (Figure 2-3). 
                                                 
3 (a) WW domain of Pin1 in complex with a short CTD peptide (1f8a); (b) CID domain of Pcf11 in 




In yeast, the effective termination of transcription relies on the recruitment of 
cleavage factors by Pcf11. The Pcf11 is a yeast protein of 70 kD with a CID domain 
directly targeted to the CTD of RNA polymerase II, which gives us the first glance of 
how a CID recognizes heptad repeats of the CTD. Interestingly, the CID domain of Pcf11 
can bind to both unphosphorylated or phospho.Ser2 CTD in biophysical binding assays 
(Meinhart et al. 2004). Consistent with the biochemical data for such preferences, the co-
crystal structure of the Pcf11 CID and a CTD peptide shows no direct interaction between 
the phosphate group of phospho.Ser2 and Pcf11, indicating no pre-requirement of 
phosphorylation of the CTD for protein binding (Meinhart et al. 2004) (Figure 2-2b). 
The CID domain, as an eight-helical bundle, recognizes a span of two heptad repeats in 
the CTD with a conserved groove, whereas the phosphate group of phospho.Ser2 actually 
forms an intramolecular hydrogen bond with Thr4 of the CTD and stabilizes the sharp β-
turn formed by CTD, presenting the side chain to the binding groove (Figure 2-2b). 
Hydrogen bondings between the CID domain and the CTD peptide are distributed 
between the CID side chain and the main chain amide and carbonyl group of the CTD 
peptide. Importantly, hydrophobic interaction by Tyr1 of the CTD to CID might 
contribute greatly for the specificity for phospho.Ser2 over phospho.Ser5. Meinhart and 
Cramer (Meinhart et al. 2004) conclude that Ser2 phosphorylation stabilizes the CTD β-
spiral that is incorporated into the transcription complex. Ser5 phosphorylation would 
unwind the spiral resulting in an extended region that binds the capping enzyme. Overall, 
the binding of Pcf11 is not particularly strong but is consistent with its dynamic role 
involved in dismantling the elongation complex (Zhang et al. 2005; Hollingworth et al. 
2006). 
Another CID containing protein Nrd1 is an essential player in the termination 
pathway for RNA polymerase II-mediated transcription for snoRNA, snRNA as well as 
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cryptic unstable transcripts (CUT). The complex of Nrd1-Nab3-Sen1 is recruited to the 
transcription machinery through the CTD by the CID domain of Nrd1 of the complex. 
The CID domain derived from Nrd1 (Figure 2-3) has a very similar overall fold and a 
strong conservation of residues involved in CTD peptide binding with Pcf11, but Nrd1 
shows a different specificity profile in which a much stronger preference for 
phospho.Ser5 over phospho.Ser2 in the CTD sequence is detected for the CID from Nrd1 
by in vitro binding assays (Vasiljeva et al. 2008). Using yeast-two hybrid and 
fluorescence anisotropy, Vasiljeva showed a tenfold improvement in binding affinity for 
singly phosphorylated CTD double repeats at Ser5 over Ser2 (Kd = 40 µM for 
phospho.Ser5 vs. 390 µM for phospho.Ser2) and a slight improvement when the peptide is 
doubly phosphorylated (Kd = 16 µM upon double phosphorylation for both Ser2 and Ser5 
sites). Specificity for phospho.Ser5 on the protein is essential to understand how different 
termination pathways are selected. A potential different phosphate binding site was 
proposed but more insightful information about specificity will only be available with a 
structure of the Nrd1–CID complexed with the CTD peptide. Since the Nrd1-dependent 
termination pathway is usually associated with much shorter transcripts (a few hundred 
base-pairs), upon which point dephosphorylation of Ser5 is not complete, a logical 
hypothesis is that phosphorylation at Ser5 favors the selection of Nrd1 complex as a 
termination pathway in yeast. Indeed, Gudipati et al. (Gudipati et al. 2008) showed that 
reducing phosphorylation of Ser5 using a mutant of kin28, a CTD Ser5 kinase, will 
hamper Nrd-dependent termination. The selectivity for phospho.Ser5 over phospho.Ser2 
might be the determining factor for the selection of termination pathways. A functional 
model for how the phosphorylation pattern of the CTD determines the transcriptional 
pathways suggests that termination by the Nrd1-Nab3-Sen1 complex is enforced when 
the CTD is still highly phosphorylated at Ser5 (Rondon et al. 2008). The structure of a 
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complex of the CID of Nrd1 with the CTD domain will help provide a molecular 
explanation of transcription termination. 
Figure 2-3: Superimposition of CID domains from Pcf11, Nrd1 and SCAF8.4 
Another CID containing protein human SCAF8 was crystallized with different 
phosphorylated forms of CTD peptides (Figure 2-3), providing more clues about how 
registration of a phosphate group on the CTD is encoded in target recognition for CID 
domains (Becker et al. 2008). The SCAF8 is implicated in splicing with a preference of 
phospho.Ser2, similar to mRNA 3’-processing factor Pcf11. Indeed, a similar 
conformation of β-turn adapted by the CTD is observed in SCAF8 upon peptide binding 
but with one major distinction: phospho.Ser2 is directly recognized by a basic residue, 
Arg112, through salt bridge interaction (Becker et al. 2008). At a similar position in 
Pcf11, a methionine residue was placed with no direct interaction with the CTD peptide. 
                                                 
4 CID domain from Pcf11 is shown in light blue (PDB code: 1sza), the one from Nrd1 is shown in light 
pink (PDB code: 3clj), and the one from SCAF8 is shown in white (PDB code: 3d9i). 
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The replacement of methionine by arginine in SCAF8 distinguishes the phospho.Ser2 
CTD from the unphosphorylated form and might explain a tighter interaction for SCAF8 
toward phosphoryl-peptide (Kd = 68 µM). In the study of Becker et al. (Becker et al. 
2008), an issue was raised whether phosphorylated Ser7 contributes to recognition by the 
CID domain of SCAF8. Binding affinity measured by fluorescence anisotropy showed no 
advantage with additional Ser7 phosphorylation (Kd = 68 µM for phospho.Ser2 and Kd = 
90 µM for doubly phosphorylated Ser2 and Ser7). Consistent with the binding interaction 
measurement, the complex structure of the SCAF8 CID and the peptide presents no 
interaction between the phosphate group of phospho.Ser7 and the protein. 
SMALL C-TERMINAL DOMAIN PHOSPHATASES (SCPS)/FCP PHOSPHATASES AND THE 
CTD 
A wide range of enzymes participate in dynamic modifications of the CTD, 
including kinases and phosphatases responsible for addition and removal of phosphates. 
The CTD is principally phosphorylated by cyclin-dependent kinases (CDKs) with their 
associated cyclins. Specifically, Ser5 phosphorylation is mainly catalyzed by Cdk7/cyclin 
H subunits of transcription factor IIH (TFIIH) (Lu et al. 1992; Hengartner et al. 1998; 
Fouillen et al. 2010); Ser2 phosphorylation is mainly catalyzed by P-TEFb, which 
contains Cdk9/cyclin T subunits (Zhou et al. 2000; Shim et al. 2002). Intriguingly, it is 
suggested that Cdk9 also makes a contribution to Ser5 phosphorylation and the relative 
contribution of TFIIH-associated Cdk7 varies between different genes based on 
experimental observations (Glover-Cutter et al. 2009). Moreover, the CTD can also be 
phosphorylated at both Ser2 and Ser5 by Cdk8 as part of the mediator complex, and 
preferentially phosphorylated at Ser5 by MAPK2/Erk2 (Trigon et al. 1998). Recently, 
TFIIH-associated Cdk7 kinase has also been shown to phosphorylate Ser7 in vivo (Akhtar 
et al. 2009; Glover-Cutter et al. 2009). Even though structural information has been 
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obtained for Cdk7 (Lolli et al. 2004) and Cdk9/cyclin T (Baumli et al. 2008), how they 
recognize the CTD peptide and label the phosphorylation mark on the CTD is still 
elusive. It is assumed that specificity is achieved by other associated proteins in the 
multiprotein complexes they are involved (Cdk7 in TFIIH, Cdk8 in mediator, and Cdk9 
in P-TEFb). 
Dephosphorylation is essential for recycling RNA polymerase II, because after 
each round of transcription, the CTD has to be dephosphorylated in order to actively 
restart a new round of transcription. In humans, Fcp1, which is required for general 
transcription and cell viability, was the first discovered CTD-specific phosphatase with a 
catalytic preference for phospho.Ser2. The Fcp1 is conserved among eukaryotes and was 
shown to be essential for cell survival in budding and fission yeast (Archambault et al. 
1997; Kimura et al. 2002). The conserved region of Fcp1 is composed of two domains: 
an N-terminal FCP homology (FCPH) domain with phosphatase activity and a C-terminal 
breast cancer protein related C-terminal (BRCT) domain (Ghosh et al. 2008) (Figure 2-
4). 
Recently, a family of small CTD phosphatases (Scps) with activities preferential 
for phospho.Ser5 was identified (Yeo et al. 2003; Yeo et al. 2005). This family includes 
three highly similar proteins designated Scp1, Scp2, and Scp3. The Scps also contain the 
FCPH catalytic domain that includes the DXDX(T/V) motif, the signature of a 
superfamily of phosphotransferases and phosphohydrolases called the haloacid 
dehalogenase (HAD) superfamily (Collet et al. 1998). Therefore, Fcp/Scp family 
members are classified as HAD superfamily enzymes. Interestingly, outside the signature 
motif, Scps share very little sequence similarity with the other enzymes in the HAD 
superfamily (Zhang et al. 2010). In humans, Scp1 has more than 20% sequence identity 
to Fcp1 in the FCPH domain but lacks the C-terminal BRCT domain that exists in Fcp1. 
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Moreover, Scp2 and Scp3, which also lack the BRCT domain, share more than 90% 
similarity with Scp1 in the FCPH domain (Yeo et al. 2003) (Figure 2-4). 
 
Figure 2-4: Surface representation of Scp1 and Fcp1 FCPH domains.5 
The apo structure of Scp1 solved by Kamenski et al. (Kamenski et al. 2004) 
showed a central parallel β sheet flanked by two α helices, a two-stranded β sheet, and a 
short 310 helix. The conserved DXDX(T/V) signature motif lines part of a central crevice, 
which forms the active site and coordinates the Mg2+ ion that is essential to Scp1 
phosphatase activity. The first aspartate in the signature motif is involved in Mg2+-
assisted phosphoryl transfer and acts as the phosphoryl acceptor. Mutation of this residue 
(Asp96 in Scp1) to alanine or asparagine abolished the activity of Scp1. The second 
aspartate (Asp98 in Scp1) also contributes to metal ion-binding and could possibly 
function as a general acid/base (Kamenski et al. 2004). The proposed phosphoryl transfer 
                                                 
5 (a) Scp1 in complex with a short CTD peptide (2ght). The zoom-in picture shows the Pro3 binds to the 
hydrophobic pocket with the aromatic residues shown in stick. (b) Fcp1 FCPH domain (3ef0). In both 
structures, the active site signature motif is colored with pale green, and the insertion domain is colored 
with light pink. Notably, the additional helical domain (light cyan) covers the ‘insertion domain’ in Fcp1 
and makes it much less accessible for substrates. 
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mechanism for the Scp/Fcp family involves a phosphoryl-aspartate intermediate. 
Existence of this phosphoryl-enzyme intermediate was confirmed in a recent structural 
and functional study when we successfully trapped the phosphoryl-aspartate intermediate 
in the crystal structure of an Scp1D206A mutant soaked with para-nitrophenyl phosphate 
(pNPP) (see Chapter 3). The steady-state kinetic analysis of a variety of Scp1 mutants 
revealed the importance of Asp206 in Mg2+ coordination mediated by a water molecule. 
Moreover, snapshots of the phosphoryl transfer reaction at each stage of Scp1-mediated 
catalysis were also captured in this study (see Chapter 3). 
In order to understand the discrimination of phospho.Ser5 over phospho.Ser2 as a 
substrate by Scp1, the complex structure of a dominant negative form of human Scp1 
(Scp1D96N) bound with Ser2/Ser5-phosphorylated CTD peptide was obtained by crystal 
soaking (Zhang et al. 2006). The defined complex structure revealed a unique binding 
mode of the peptide in which Ser2Pro3Thr4(phospho.Ser5) forms a β-turn. The 
phospho.Ser5 binds to the active site groove through Mg
2+ coordination. The Pro3 is 
recognized by an aromatic-rich hydrophobic pocket near the active site that further 
confers substrate specificity (Zhang et al. 2006). Notably, Scp1 shows remarkable 
specificity toward the trans peptide-bond configuration of the two prolines in the CTD 
repeat, which can adopt both cis and trans configurations. Such configuration switching is 
known to modulate the structure of the CTD and its accessibility to kinases or 
phosphatases (Morris et al. 1999; Verdecia et al. 2000). An insertion domain formed by a 
three-stranded β sheet directly follows the signature motif (Figure 2-4). This insertion 
domain is unique to Fcp1/Scp1 family phosphatases and may assist in substrate 
recognition. Consistent with the known specificity of Scp1 toward phospho.Ser5 instead 
of phospho.Ser2, in the complex structure the phospho.Ser2 flips out of the active site, 
making no direct interaction with the protein. 
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Even though Scp and Fcp share similar phosphatase active sites, their strategies 
for substrate recognition might be different, as suggested by the recent crystal structure of 
apo Schizosaccharomyces pombe Fcp1 (SpFcp1) (Ghosh et al. 2008) (Figure 2-4). The 
minimal effective CTD substrate for SpFcp1 is a single heptad CTD peptide: 
Ser5Pro6Ser7Tyr1(phospho.Ser2)Pro3Thr4, among which the Tyr1 and Pro3 flanking the 
phospho.Ser2 are critical determinants of Fcp1 activity (Hausmann et al. 2004). The 
SpFcp1 structure revealed that it is a Y-shaped protein composed of three structural 
domains (Ghosh et al. 2008). The stem of the Y is the FCPH domain that contains a 
globular catalytic phosphatase core similar to that of Scp1. One major difference is that 
the three-stranded β sheet in Scp1 (insertion domain) is accessible for substrate 
recognition, whereas in Fcp1 it is buried by a helical insertion domain, suggesting a 
different binding interface between Fcp and the CTD with phospho.Ser2 (Figure 2-4). 
MRNA CAPPING ENZYME CGT1 AND THE CTD 
Even though 26–52 heptad repeats exist in the CTD primary sequence, 
recognition of the CTD by proteins in all the complex structures discussed above only 
show a spanning of one or two repeats. This is understandable since a balance between 
favorable interactions of the CTD with its binding partners versus the entropy cost for 
binding a disordered peptide needs to be achieved. This leads to the proposed mechanism 
that a double repeat of the CTD sequence is the functional unit for transcription. To 
explore if such rule is consistent with the mRNA capping enzyme Cgt1, a four-heptad-
repeat peptide with each Ser5 phosphorylated was used in a cocrystallization experiment 
(Fabrega et al. 2003). Interestingly, a long span of CTD peptide consisting of 17 amino 
acids was modeled in the density of one of the two monomers with an extensive buried 
surface of 1,600 A2 (Fabrega et al. 2003). Three of the four phosphorylated Ser5 residues 
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were visible in this structure with both the first and third phosphate group recognized by 
positively charged patches on the Cgt1 surface. Consistent with a previous study of Cgt1, 
the Tyr1 position in the CTD sequence is essential for recognition by the protein (West et 
al. 1995). On the other hand, a single mutation of the Cgt protein for the recognition 
interface did not show obvious deleterious effects during yeast mutation screening 
(Fabrega et al. 2003), possibly due to the extended binding surface without one 
interaction dominating binding. Since the other monomer in the asymmetric unit shows a 
much smaller interface, it suggests that multiple phosphorylation sites are not a 
prerequisite for ligand binding. Further affinity measurements with a different length and 
registration of the phospho.Ser5 would elucidate whether interaction with multiple repeats 
of the CTD is essential for the effective binding by Cgt1. 
NUCLEAR MAGNETIC RESONANCE (NMR) STRUCTURE OF SET2  
The identification of the histone methyltransferase Set2 as a novel CTD binding 
partner bridges the CTD code to the histone code by implicating the regulatory effect of 
the CTD on histone modification and epigenetic control (Gerber et al. 2003; Hampsey et 
al. 2003) (Figure 2-2c). In eukaryotes, large genomes are efficiently organized into 
nucleosomes that are fundamental repeat units of chromatin. The nucleosome is 
composed of a histone octamer consisting of two copies of each of the core histones 
H2A, H2B, H3, and H4, around which 147 bp of DNA is wrapped. Such a structure is not 
only a strategy to compress large genomic DNA, but also provides a potential solution for 
tight regulation of DNA replication, repair, and transcription. During transcription, for 
example, the binding sites for a variety of transcription factors can be occluded by 
histones, leading to transcriptional silencing (Kornberg et al. 1999). Access to specific 
loci on the nucleosomal DNA is dynamically regulated by many factors including 
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chromatin modifiers and chromatin remodelers. Histones can be covalently modified by 
chromatin modifiers at particular loci, most of which are concentrated in the relatively 
unstructured N-terminal tails of histones. These modifications include acetylation, 
methylation, phosphorylation, ubiquitination, and sumoylation (Kouzarides 2007). The 
histone code, which is defined by covalent modifications, represents a fundamental 
regulatory mechanism of gene expression and repression (Strahl et al. 2000). 
Furthermore, the histone code can be interpreted by different modules in a modification-
dependent manner to decide whether a gene is to be transcribed. 
A novel Rpb1-binding domain of Set2, called Set2–Rpb1 interacting (SRI) 
domain, mediates the recognition and interaction with the phosphoryl CTD (Figure 2-
2c). Lys4 of histone 3 is methylated by the proteins of the Set1 family, while Lys36 is 
methylated by proteins of the Set2 family (Gerber et al. 2003). Both Set1 and Set2 
associate with the CTD but at different stages of transcription: Set1 binds to 
phosphorylated CTD enriched with Ser5 at the promoter region through the mediation of 
the Paf complex (Krogan et al. 2003; Ng et al. 2003); whereas the recognition of the CTD 
by Set2 relies on the phosphorylation of Ser2 in heptad repeats (Xiao et al. 2003). The 
SRI domains from both human (Li et al. 2005) and yeast (Vojnic et al. 2006) Set2 were 
determined by NMR and the binding interface mapped by phosphoryl-peptide titration. 
The study of affinity with peptides that have different length and phosphorylation 
registration showed that single repeats are not sufficient for SRI recognition and a strong 
preference for doubly phosphorylated peptide was observed. Five residues were 
identified as essential for the effective association between Set2 SRI and the CTD using 
NMR and mutagenesis (Krogan et al. 2003). One can assume the positively charged 
residues, Lys54, Arg58, and His62 of the Set2 SRI, are involved in phosphate binding 
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whereas Val31 and Phe53 are important for hydrophobic interaction with the side chain 
residues of the CTD, possibly tyrosine or proline. 
In addition, the FF domain is a protein-protein interaction module existing in 
several CTD interaction proteins such as human transcription factor CA150 (Carty et al. 
2000) and splicing factor Prp40 (Morris et al. 2000). Like the SRI domain, the FF domain 
exhibits a structure of three-helical bundle (Figure 2-2d). The FF domains usually are 
arranged as tandem arrays in proteins and such architecture might account for interaction 
with the CTD with each module contributing very weakly to binding. Identification of the 
specificity of phosphorylation states of the CTD recognized by FF domains has been 
challenging due to the weak binding. In vitro binding assays and NMR titration 
experiments did not detect interaction with a CTD peptide with the FF domain arrays 
derived from Prp40 (Gasch et al. 2006) or CA150 (Murphy et al. 2009). A binding 
constant of 50 µM was reported for the mammalian homologue of Prp40, FBP11, using 
isothermal titration calorimetry (Allen et al. 2002) but detailed information about the 
interaction between molecules is yet to be elucidated. 
CONCLUSION  
Recognition of the phosphorylation states of the CTD is essential for mediation of 
the expression of genetic information. Proteins that are highly selective toward specific 
phosphorylated forms of the CTD decipher the ‘CTD code’ and synchronize the 
transcriptional events accordingly. Communication of the CTD and histone codes 
provides an exquisite regulatory network for the precise control of transcription at 
multiple levels. Some CTD interacting proteins function as global transcriptional 
regulators non-discriminatingly. The inactivation of such molecules will lead to the 
shutdown of transcription machinery and eventually, cell death. For example, the deletion 
 25 
of the CTD Ser2 phosphatase Fcp1 is lethal for yeast due to the abolishment of RNA 
polymerase II recycling (Kobor et al. 1999; Kimura et al. 2002). Similar effects on yeast 
are observed when the CTD Ser5 phosphatase Ssu72 is eliminated (Sun et al. 1996). On 
the other hand, evidence has indicated that CTD-interacting proteins can control gene 
expression at an epigenetic level and regulate expression of specific genes based on 
timing and the developmental needs. Human Scps are only found in higher eukaryotes 
and their expression is limited to neuronal stem cells or nonneural tissues. Consistent 
with their unique expression profile, Scps are identified as a component of the neuronal 
chromatin remodeling complex, REST (Yeo et al. 2005). The inactivation of Scp activity 
leads to the inappropriate differentiation of neuronal stem cells (Yeo et al. 2005). Another 
example of epigenetic regulation of a CTD-interacting protein is the Cdk8/cyclin C pair, 
which has been linked to transcriptional repression (Hengartner et al. 1998). Histone 
methyltransferases Set1 (Ng et al. 2003) and Set2 (Krogan et al. 2003) can identify the 
different phosphorylation stages of CTD. The phosphorylation of Ser7 of CTD itself also 
occurs in a gene-specific fashion (Egloff et al. 2007). The apparent simple primary 
sequence of CTD integrates genetic and epigenetic information and plays a pivotal role in 
transcriptional activation or repression. Understanding how such coding is deciphered at 
the molecular level is essential to the interpretation of the central role of RNA 
polymerase II and its regulatory domains. The application of the CTD code provides a 
unique opportunity to engineer the transcriptional process in an epigenetic level in tissue-
specificity manner. 
REFERENCES 
Akhtar, M. S., M. Heidemann, J. R. Tietjen, D. W. Zhang, R. D. Chapman, D. Eick and 
A. Z. Ansari (2009). "TFIIH kinase places bivalent marks on the carboxy-terminal 
domain of RNA polymerase II." Mol Cell 34(3): 387-393. 
 26 
Allen, M., A. Friedler, O. Schon and M. Bycroft (2002). "The structure of an FF domain 
from human HYPA/FBP11." J Mol Biol 323(3): 411-416. 
Archambault, J., R. S. Chambers, M. S. Kobor, Y. Ho, M. Cartier, D. Bolotin, B. 
Andrews, C. M. Kane and J. Greenblatt (1997). "An essential component of a C-
terminal domain phosphatase that interacts with transcription factor IIF in 
Saccharomyces cerevisiae." Proc Natl Acad Sci U S A 94(26): 14300-14305. 
Baumli, S., G. Lolli, E. D. Lowe, S. Troiani, L. Rusconi, A. N. Bullock, J. E. Debreczeni, 
S. Knapp and L. N. Johnson (2008). "The structure of P-TEFb (CDK9/cyclin T1), 
its complex with flavopiridol and regulation by phosphorylation." Embo J 27(13): 
1907-1918. 
Becker, R., B. Loll and A. Meinhart (2008). "Snapshots of the RNA processing factor 
SCAF8 bound to different phosphorylated forms of the carboxyl-terminal domain 
of RNA polymerase II." J Biol Chem 283(33): 22659-22669. 
Bedford, M. T., R. Reed and P. Leder (1998). "WW domain-mediated interactions reveal 
a spliceosome-associated protein that binds a third class of proline-rich motif: the 
proline glycine and methionine-rich motif." Proc Natl Acad Sci U S A 95(18): 
10602-10607. 
Bedford, M. T., D. Sarbassova, J. Xu, P. Leder and M. B. Yaffe (2000). "A novel pro-
Arg motif recognized by WW domains." J Biol Chem 275(14): 10359-10369. 
Carty, S. M., A. C. Goldstrohm, C. Sune, M. A. Garcia-Blanco and A. L. Greenleaf 
(2000). "Protein-interaction modules that organize nuclear function: FF domains 
of CA150 bind the phosphoCTD of RNA polymerase II." Proc Natl Acad Sci U S 
A 97(16): 9015-9020. 
Chen, H. I., A. Einbond, S. J. Kwak, H. Linn, E. Koepf, S. Peterson, J. W. Kelly and M. 
Sudol (1997). "Characterization of the WW domain of human yes-associated 
protein and its polyproline-containing ligands." J Biol Chem 272(27): 17070-
17077. 
 27 
Collet, J. F., V. Stroobant, M. Pirard, G. Delpierre and E. Van Schaftingen (1998). "A 
new class of phosphotransferases phosphorylated on an aspartate residue in an 
amino-terminal DXDX(T/V) motif." J Biol Chem 273(23): 14107-14112. 
Egloff, S., D. O'Reilly, R. D. Chapman, A. Taylor, K. Tanzhaus, L. Pitts, D. Eick and S. 
Murphy (2007). "Serine-7 of the RNA polymerase II CTD is specifically required 
for snRNA gene expression." Science 318(5857): 1777-1779. 
Ermekova, K. S., N. Zambrano, H. Linn, G. Minopoli, F. Gertler, T. Russo and M. Sudol 
(1997). "The WW domain of neural protein FE65 interacts with proline-rich 
motifs in Mena, the mammalian homolog of Drosophila enabled." J Biol Chem 
272(52): 32869-32877. 
Etzkorn, F. A. (2006). "Pin1 flips Alzheimer's switch." ACS Chem Biol 1(4): 214-216. 
Fabrega, C., V. Shen, S. Shuman and C. D. Lima (2003). "Structure of an mRNA capping 
enzyme bound to the phosphorylated carboxy-terminal domain of RNA 
polymerase II." Mol Cell 11(6): 1549-1561. 
Fouillen, L., W. Abdulrahman, D. Moras, A. Van Dorsselaer, A. Poterszman and S. 
Sanglier-Cianferani (2010). "Analysis of recombinant phosphoprotein complexes 
with complementary mass spectrometry approaches." Anal Biochem 407(1): 34-
43. 
Gasch, A., S. Wiesner, P. Martin-Malpartida, X. Ramirez-Espain, L. Ruiz and M. J. 
Macias (2006). "The structure of Prp40 FF1 domain and its interaction with the 
crn-TPR1 motif of Clf1 gives a new insight into the binding mode of FF 
domains." J Biol Chem 281(1): 356-364. 
Gerber, M. and A. Shilatifard (2003). "Transcriptional elongation by RNA polymerase II 
and histone methylation." J Biol Chem 278(29): 26303-26306. 
Ghosh, A., S. Shuman and C. D. Lima (2008). "The structure of Fcp1, an essential RNA 
polymerase II CTD phosphatase." Mol Cell 32(4): 478-490. 
 28 
Glover-Cutter, K., S. Larochelle, B. Erickson, C. Zhang, K. Shokat, R. P. Fisher and D. 
L. Bentley (2009). "TFIIH-associated Cdk7 kinase functions in phosphorylation 
of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination 
by RNA polymerase II." Mol Cell Biol 29(20): 5455-5464. 
Gudipati, R. K., T. Villa, J. Boulay and D. Libri (2008). "Phosphorylation of the RNA 
polymerase II C-terminal domain dictates transcription termination choice." Nat 
Struct Mol Biol 15(8): 786-794. 
Hampsey, M. and D. Reinberg (2003). "Tails of intrigue: phosphorylation of RNA 
polymerase II mediates histone methylation." Cell 113(4): 429-432. 
Hausmann, S., H. Erdjument-Bromage and S. Shuman (2004). "Schizosaccharomyces 
pombe carboxyl-terminal domain (CTD) phosphatase Fcp1: distributive 
mechanism, minimal CTD substrate, and active site mapping." J Biol Chem 
279(12): 10892-10900. 
Hengartner, C. J., V. E. Myer, S. M. Liao, C. J. Wilson, S. S. Koh and R. A. Young 
(1998). "Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-
dependent kinases." Mol Cell 2(1): 43-53. 
Hollingworth, D., C. G. Noble, I. A. Taylor and A. Ramos (2006). "RNA polymerase II 
CTD phosphopeptides compete with RNA for the interaction with Pcf11." RNA 
12(4): 555-560. 
Huang, K., K. D. Johnson, A. G. Petcherski, T. Vandergon, E. A. Mosser, N. G. 
Copeland, N. A. Jenkins, J. Kimble and E. H. Bresnick (2000). "A HECT domain 
ubiquitin ligase closely related to the mammalian protein WWP1 is essential for 
Caenorhabditis elegans embryogenesis." Gene 252(1-2): 137-145. 
Jager, M., Y. Zhang, J. Bieschke, H. Nguyen, M. Dendle, M. E. Bowman, J. P. Noel, M. 
Gruebele and J. W. Kelly (2006). "Structure-function-folding relationship in a 
WW domain." Proc Natl Acad Sci U S A 103(28): 10648-10653. 
Kamenski, T., S. Heilmeier, A. Meinhart and P. Cramer (2004). "Structure and 
mechanism of RNA polymerase II CTD phosphatases." Mol Cell 15(3): 399-407. 
 29 
Kimura, M., H. Suzuki and A. Ishihama (2002). "Formation of a carboxy-terminal 
domain phosphatase (Fcp1)/TFIIF/RNA polymerase II (pol II) complex in 
Schizosaccharomyces pombe involves direct interaction between Fcp1 and the 
Rpb4 subunit of pol II." Mol Cell Biol 22(5): 1577-1588. 
Kobor, M. S., J. Archambault, W. Lester, F. C. Holstege, O. Gileadi, et al. (1999). "An 
unusual eukaryotic protein phosphatase required for transcription by RNA 
polymerase II and CTD dephosphorylation in S. cerevisiae." Mol Cell 4(1): 55-62. 
Komuro, A., M. Saeki and S. Kato (1999). "Npw38, a novel nuclear protein possessing a 
WW domain capable of activating basal transcription." Nucleic Acids Res 27(9): 
1957-1965. 
Kornberg, R. D. and Y. Lorch (1999). "Twenty-five years of the nucleosome, 
fundamental particle of the eukaryote chromosome." Cell 98(3): 285-294. 
Kouzarides, T. (2007). "Chromatin modifications and their function." Cell 128(4): 693-
705. 
Kowalski, J. A., K. Liu and J. W. Kelly (2002). "NMR solution structure of the isolated 
Apo Pin1 WW domain: comparison to the x-ray crystal structures of Pin1." 
Biopolymers 63(2): 111-121. 
Krogan, N. J., M. Kim, A. Tong, A. Golshani, G. Cagney, et al. (2003). "Methylation of 
histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional 
elongation by RNA polymerase II." Mol Cell Biol 23(12): 4207-4218. 
Li, M., H. P. Phatnani, Z. Guan, H. Sage, A. L. Greenleaf and P. Zhou (2005). "Solution 
structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction 
with the hyperphosphorylated C-terminal domain of Rpb1." Proc Natl Acad Sci U 
S A 102(49): 17636-17641. 
Lolli, G., E. D. Lowe, N. R. Brown and L. N. Johnson (2004). "The crystal structure of 
human CDK7 and its protein recognition properties." Structure 12(11): 2067-
2079. 
 30 
Lu, H., L. Zawel, L. Fisher, J. M. Egly and D. Reinberg (1992). "Human general 
transcription factor IIH phosphorylates the C-terminal domain of RNA 
polymerase II." Nature 358(6388): 641-645. 
Lu, K. P. (2004). "Pinning down cell signaling, cancer and Alzheimer's disease." Trends 
Biochem Sci 29(4): 200-209. 
Lu, K. P., S. D. Hanes and T. Hunter (1996). "A human peptidyl-prolyl isomerase 
essential for regulation of mitosis." Nature 380(6574): 544-547. 
Lu, P. J., G. Wulf, X. Z. Zhou, P. Davies and K. P. Lu (1999). "The prolyl isomerase 
Pin1 restores the function of Alzheimer-associated phosphorylated tau protein." 
Nature 399(6738): 784-788. 
Lu, P. J., X. Z. Zhou, Y. C. Liou, J. P. Noel and K. P. Lu (2002). "Critical role of WW 
domain phosphorylation in regulating phosphoserine binding activity and Pin1 
function." J Biol Chem 277(4): 2381-2384. 
Lu, P. J., X. Z. Zhou, M. Shen and K. P. Lu (1999). "Function of WW domains as 
phosphoserine- or phosphothreonine-binding modules." Science 283(5406): 1325-
1328. 
Macias, M. J., M. Hyvonen, E. Baraldi, J. Schultz, M. Sudol, M. Saraste and H. 
Oschkinat (1996). "Structure of the WW domain of a kinase-associated protein 
complexed with a proline-rich peptide." Nature 382(6592): 646-649. 
Meinhart, A. and P. Cramer (2004). "Recognition of RNA polymerase II carboxy-
terminal domain by 3'-RNA-processing factors." Nature 430(6996): 223-226. 
Morris, D. P. and A. L. Greenleaf (2000). "The splicing factor, Prp40, binds the 
phosphorylated carboxyl-terminal domain of RNA polymerase II." J Biol Chem 
275(51): 39935-39943. 
Morris, D. P., H. P. Phatnani and A. L. Greenleaf (1999). "Phospho-carboxyl-terminal 
domain binding and the role of a prolyl isomerase in pre-mRNA 3'-End 
formation." J Biol Chem 274(44): 31583-31587. 
 31 
Murphy, J. M., D. F. Hansen, S. Wiesner, D. R. Muhandiram, M. Borg, et al. (2009). 
"Structural studies of FF domains of the transcription factor CA150 provide 
insights into the organization of FF domain tandem arrays." J Mol Biol 393(2): 
409-424. 
Myers, J. K., D. P. Morris, A. L. Greenleaf and T. G. Oas (2001). "Phosphorylation of 
RNA polymerase II CTD fragments results in tight binding to the WW domain 
from the yeast prolyl isomerase Ess1." Biochemistry 40(29): 8479-8486. 
Ng, H. H., F. Robert, R. A. Young and K. Struhl (2003). "Targeted recruitment of Set1 
histone methylase by elongating Pol II provides a localized mark and memory of 
recent transcriptional activity." Mol Cell 11(3): 709-719. 
Noble, C. G., D. Hollingworth, S. R. Martin, V. Ennis-Adeniran, S. J. Smerdon, G. Kelly, 
I. A. Taylor and A. Ramos (2005). "Key features of the interaction between Pcf11 
CID and RNA polymerase II CTD." Nat Struct Mol Biol 12(2): 144-151. 
Palancade, B., N. F. Marshall, A. Tremeau-Bravard, O. Bensaude, M. E. Dahmus and M. 
F. Dubois (2004). "Dephosphorylation of RNA polymerase II by CTD-
phosphatase FCP1 is inhibited by phospho-CTD associating proteins." J Mol Biol 
335(2): 415-424. 
Ranganathan, R., K. P. Lu, T. Hunter and J. P. Noel (1997). "Structural and functional 
analysis of the mitotic rotamase Pin1 suggests substrate recognition is 
phosphorylation dependent." Cell 89(6): 875-886. 
Rondon, A. G., H. E. Mischo and N. J. Proudfoot (2008). "Terminating transcription in 
yeast: whether to be a 'nerd' or a 'rat'." Nat Struct Mol Biol 15(8): 775-776. 
Shim, E. Y., A. K. Walker, Y. Shi and T. K. Blackwell (2002). "CDK-9/cyclin T (P-
TEFb) is required in two postinitiation pathways for transcription in the C. 
elegans embryo." Genes Dev 16(16): 2135-2146. 
Strahl, B. D. and C. D. Allis (2000). "The language of covalent histone modifications." 
Nature 403(6765): 41-45. 
 32 
Sudol, M. and T. Hunter (2000). "NeW wrinkles for an old domain." Cell 103(7): 1001-
1004. 
Sun, Z. W. and M. Hampsey (1996). "Synthetic enhancement of a TFIIB defect by a 
mutation in SSU72, an essential yeast gene encoding a novel protein that affects 
transcription start site selection in vivo." Mol Cell Biol 16(4): 1557-1566. 
Trigon, S., H. Serizawa, J. W. Conaway, R. C. Conaway, S. P. Jackson and M. Morange 
(1998). "Characterization of the residues phosphorylated in vitro by different C-
terminal domain kinases." J Biol Chem 273(12): 6769-6775. 
Vasiljeva, L., M. Kim, H. Mutschler, S. Buratowski and A. Meinhart (2008). "The Nrd1-
Nab3-Sen1 termination complex interacts with the Ser5-phosphorylated RNA 
polymerase II C-terminal domain." Nat Struct Mol Biol 15(8): 795-804. 
Verdecia, M. A., M. E. Bowman, K. P. Lu, T. Hunter and J. P. Noel (2000). "Structural 
basis for phosphoserine-proline recognition by group IV WW domains." Nat 
Struct Biol 7(8): 639-643. 
Vojnic, E., B. Simon, B. D. Strahl, M. Sattler and P. Cramer (2006). "Structure and 
carboxyl-terminal domain (CTD) binding of the Set2 SRI domain that couples 
histone H3 Lys36 methylation to transcription." J Biol Chem 281(1): 13-15. 
West, M. L. and J. L. Corden (1995). "Construction and analysis of yeast RNA 
polymerase II CTD deletion and substitution mutations." Genetics 140(4): 1223-
1233. 
Wu, X., A. Chang, M. Sudol and S. D. Hanes (2001). "Genetic interactions between the 
ESS1 prolyl-isomerase and the RSP5 ubiquitin ligase reveal opposing effects on 
RNA polymerase II function." Curr Genet 40(4): 234-242. 
Wu, X., C. B. Wilcox, G. Devasahayam, R. L. Hackett, M. Arevalo-Rodriguez, M. E. 
Cardenas, J. Heitman and S. D. Hanes (2000). "The Ess1 prolyl isomerase is 
linked to chromatin remodeling complexes and the general transcription 
machinery." Embo J 19(14): 3727-3738. 
 33 
Xiao, T., H. Hall, K. O. Kizer, Y. Shibata, M. C. Hall, C. H. Borchers and B. D. Strahl 
(2003). "Phosphorylation of RNA polymerase II CTD regulates H3 methylation in 
yeast." Genes Dev 17(5): 654-663. 
Xu, Y. X., Y. Hirose, X. Z. Zhou, K. P. Lu and J. L. Manley (2003). "Pin1 modulates the 
structure and function of human RNA polymerase II." Genes Dev 17(22): 2765-
2776. 
Yaffe, M. B., M. Schutkowski, M. Shen, X. Z. Zhou, P. T. Stukenberg, et al. (1997). 
"Sequence-specific and phosphorylation-dependent proline isomerization: a 
potential mitotic regulatory mechanism." Science 278(5345): 1957-1960. 
Yeo, M., S. K. Lee, B. Lee, E. C. Ruiz, S. L. Pfaff and G. N. Gill (2005). "Small CTD 
phosphatases function in silencing neuronal gene expression." Science 307(5709): 
596-600. 
Yeo, M., P. S. Lin, M. E. Dahmus and G. N. Gill (2003). "A novel RNA polymerase II C-
terminal domain phosphatase that preferentially dephosphorylates serine 5." J 
Biol Chem 278(28): 26078-26085. 
Zhang, M., J. Liu, Y. Kim, J. E. Dixon, S. L. Pfaff, G. N. Gill, J. P. Noel and Y. Zhang 
(2010). "Structural and functional analysis of the phosphoryl transfer reaction 
mediated by the human small C-terminal domain phosphatase, Scp1." Protein Sci 
19(5): 974 - 986. 
Zhang, Y., S. Daum, D. Wildemann, X. Z. Zhou, M. A. Verdecia, et al. (2007). 
"Structural basis for high-affinity peptide inhibition of human Pin1." ACS Chem 
Biol 2(5): 320-328. 
Zhang, Y., Y. Kim, N. Genoud, J. Gao, J. W. Kelly, S. L. Pfaff, G. N. Gill, J. E. Dixon 
and J. P. Noel (2006). "Determinants for dephosphorylation of the RNA 
polymerase II C-terminal domain by Scp1." Mol Cell 24(5): 759-770. 
Zhang, Z., J. Fu and D. S. Gilmour (2005). "CTD-dependent dismantling of the RNA 
polymerase II elongation complex by the pre-mRNA 3'-end processing factor, 
Pcf11." Genes Dev 19(13): 1572-1580. 
 34 
Zhou, M., M. A. Halanski, M. F. Radonovich, F. Kashanchi, J. Peng, D. H. Price and J. 
N. Brady (2000). "Tat modifies the activity of CDK9 to phosphorylate serine 5 of 
the RNA polymerase II carboxyl-terminal domain during human 






SMALL C-TERMINAL DOMAIN PHOSPHATASE (SCP) 
The unstructured C-terminal domain (CTD) of eukaryotic RNA polymerase II 
dynamically regulates the process of transcription by recruiting different factors to the 
nascent mRNA through its multiple phosphorylation patterns. A newly discovered class 
of phosphatases, the human small C-terminal domain phosphatases (Scps), specifically 
dephosphorylate phosphorylated Ser5 (phospho.Ser5) of the tandem heptad repeats of the 
CTD of RNA polymerase II. Scps also function as transcription regulators that 
epigenetically silence the expression of specific neuronal genes. Inactivation of Scps 
leads to neuronal stem cell differentiation. Therefore, Scps are a group of important 
enzymes not only as regulators of the dynamic transcription cycles, but also as potential 
targets for the treatment of neurodegenerative diseases. This section will reveal to the 
readers the detailed stories about this group of enzymes (focusing on Scp1), from their 
catalytic mechanism, to the selective inhibition of these enzymes, to the effort on 
unveiling how these enzymes read the ‘CTD code’. 
Chapter 3:  Structural and Functional Analysis of the Phosphoryl 
Transfer Reaction Mediated by Scp1 
INTRODUCTION 
The CTD of RNA polymerase II is a unique structure that not only temporally and 
spatially modulates the progression of RNA polymerase II through the transcription 
cycle, but also associates mRNA transcription to mRNA processing, DNA repair and 
other cellular processes (Egloff et al. 2008). The biological functions of the CTD are 
performed through controlling the recruitment of regulatory factors in accordance with 
the dynamic modifications and conformation changes of the CTD (Meinhart et al. 2005), 
including phosphorylation, isomerization, and possibly glycosylation (Egloff et al. 2008). 
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The CTD largely consists of tandem heptad repeats with a consensus sequence 
Tyr1Ser2Pro3Thr4Ser5Pro6Ser7 where the phosphorylation of Ser2, Ser5 and Ser7 has been 
shown to have important regulatory effects on the function of RNA polymerase II 
(Meinhart et al. 2005; Chapman et al. 2007; Egloff et al. 2007). The enzymes responsible 
for the phosphorylation and dephosphorylation of these residues therefore play essential 
roles in the regulation of transcription and related processes. 
The transcription factor IIF (TFIIF)-interacting C-terminal domain phosphatase 1 
(Fcp1) is the first discovered CTD-specific phosphatase that preferentially 
dephosphorylates Ser2 (Chambers et al. 1994; Cho et al. 2001) in eukaryotes. Fcp1 has 
been shown to regulate the recycling of RNA polymerase II by dephosphorylating Ser2 
after each round of transcription (Cho et al. 1999). More recently, a family of small CTD 
phosphatases (Scps) with activities preferential for phosphoryl-Ser5 (phospho.Ser5) was 
identified (Yeo et al. 2003; Yeo et al. 2005). This family includes three highly similar 
proteins designated Scp1, Scp2 and Scp3. They share more than 90% similarity at the 
catalytic domain and have essentially the same activity to dephosphorylate phospho.Ser5. 
In humans, Scp1 has ~20% identity with the catalytic domain (FCPH domain) of 
Fcp1 but lacks the C-terminal breast cancer protein related C-terminal domain (BRCT) 
which is associated with CTD recognition by Fcp1. Scps show a strong preference 
towards Ser5 over Ser2 by 70-fold (Zhang et al. 2006). The first clue to the specificity of 
Scps was elucidated when the structures of Scp1 bound to the CTD peptides were 
determined (Zhang et al. 2006). These structures revealed a unique mode for CTD 
recognition and provided a structural explanation for the preferential binding and 
turnover of phospho.Ser5 of the CTD. Consistent with the known specificity of Scp1 
towards phospho.Ser5 instead of phospho.Ser2, in the complex structure the phospho.Ser5 
is bound to the active site whereas phospho.Ser2 flips out of the active site, making no 
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direct interaction with the protein. Notably, Scp1 shows remarkable specificity toward 
the trans peptide-bond configuration of the two prolines in the CTD repeat which can 
adopt both cis and trans configurations. Such configuration switching is known to 
modulate the structure of the CTD and its accessibility to kinases and/or phosphatases 
(Morris et al. 1999; Verdecia et al. 2000). Computational docking shows that if a similar 
active site conformation is adopted, the peptide with cis Pro will result in an unfavorable 
steric clash with the protein. However, it has yet to be established if Scps can undergo a 
dramatic conformational change to accommodate cis Pro. 
Unlike kinases that evolved from the same ancestor, the protein phosphatases 
derived from separate origins which results in different structures and reaction 
mechanisms (Tonks 2006). Protein tyrosine phosphatases mediate the phosphoryl transfer 
via a phosphoryl-protein intermediate at a conserved Cys residue at the active site (Zhang 
2003). On the other hand, protein serine/threonine (Ser/Thr) phosphatases normally 
require metal ions for their associated reactions. The Ser/Thr phosphatase family is 
further divided into phosphoprotein phosphatase (PPP) and Mg2+- or Mn2+-dependent 
protein phosphatase (PPM) families with different metal requirements (Cohen 1997; 
Barford et al. 1998). Nonetheless, in both cases, the dephosphorylation reaction occurs in 
a single step in which a water molecule activated by metal ions targets the leaving 
phosphate group (Shi 2009). One of the major distinctions between tyrosine phosphatases 
and Ser/Thr phosphatases is the involvement of metal ions (Ser/Thr phosphatases) and 
the generation of phosphoryl intermediate (tyrosine phosphatases). Therefore, when a 
group of novel human CTD phosphatases (Fcp/Scp phosphatases) were identified, they 
were classified as the PP2C subfamily of the PPM Ser/Thr phosphatase family 
(Chambers et al. 1996; Yeo et al. 2003). Like other PP2C phosphatases, Fcp/Scp 
phosphatases are Mg2+-dependent enzymes with multiple highly conserved aspartates. 
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However, when the Scp structure was determined (Kamenski et al. 2004), it exhibited 
several fundamental distinctions from other PP2C members. First, it lacks the di-metal 
center which is present in other PP2C Ser/Thr phosphatases but has a single Mg2+ ion 
bound at the active site (Figure 3-1). Moreover, the four strictly conserved aspartates are 
arranged in a different topology from PP2C active sites.   
Figure 3-1: Ribbon diagram of metal centers in human protein phosphatase 2C (1A6Q) 
and human Scp1 (2ghq).6 
Based on the structure-based sequence alignment, Scp is similar to the HAD 
superfamily proteins, the majority of which are involved in phosphoryl transfer (Allen et 
al. 2004). Indeed, with little primary sequence identity, the active site of Scp 
superimposes perfectly with that of other HAD members (Wang et al. 2001; Lahiri et al. 
2003; Kamenski et al. 2004). Even the Mg2+ ion position and its coordinating water 
molecules are conserved (Zhang et al. 2006). This suggests that Scp is a unique family of 
Ser/Thr phosphatases that mediates phosphoryl transfer through the generation of a 
phosphoryl-aspartate using its DXDX(T/V) signature motif, a mechanism conserved in 
                                                 
6 (a) Di-metal ion center of PP2C. Invariant metal-coordinating residues (yellow) and phosphate group 
(red) are shown in stick, and the two catalytic essential Mn2+ ions are shown in cyan sphere. (b) Single-
metal ion center of Scp1. Key residues at the active site are shown in yellow stick, and the essential Mg2+ 
ion is shown in purple sphere. The substrate, phosphorylated CTD peptide, is shown in white stick. 
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the HAD family. Using BeF3
- as a phosphoryl analogue, the first Asp of the motif was 
identified to be the nucleophile that undergoes phosphorylation leading to a phosphoryl-
aspartate intermediate. This high-energy mixed anhydride is subsequently hydrolyzed to 
regenerate the enzyme (Allen et al. 2004). Although this proposed mechanism is well 
accepted, the phosphoryl intermediate was never directly visualized in Fcp/Scp family. 
Considering the uniqueness of Fcp/Scp phosphatases in their phosphoryl reaction 
mechanism as a Ser/Thr phosphatase, we sought to isolate the phosphoryl intermediate 
combining mutagenesis and X-ray crystallography. We extend our previous structural 
and functional investigations to further probe the role of key residues in the 
dephosphorylation reaction. Steady-state kinetic analysis of a variety of Scp1 mutants 
verified the Mg2+-coordinating function of Asp206, a conserved residue in the HAD 
superfamily whose role was not highlighted before. We have successfully captured the 
phosphoryl-aspartate intermediate in the crystal structure of Scp1D206A mutant soaked 
with pNPP, providing evidence for the proposed two-step mechanism. In this study, we 
were able to obtain the snapshots of Scp protein at each stage of the phosphoryl-transfer 
reaction which will be really valuable for the structure-function study of Fcp/Scp 
phosphatases. 
RESULTS AND DISCUSSION 
Design of mutants based on proposed phosphoryl transfer mechanism  
Based on the structures of Scp1, a two-step reaction mechanism for the 
dephosphorylation reaction catalyzed by Scp1 was proposed (Zhang et al. 2006). In this 
proposed mechanism (Figure 3-2a), the Asp96 [the first Asp in the DXDX(T/V) 
signature motif] acts as the attacking nucleophile in the first step of the reaction where 
the phosphoryl group on phospho.Ser5 is transferred to Asp96, forming a phosphoryl-
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carboxyl mixed anhydride, which is subsequently hydrolyzed in the second step to 
release the phosphate and regenerate Asp96. Phosphoryl analogues have been used to 
understand the reaction mechanism (Kamenski et al. 2004). Most recently, a study 
conducted on Schizosaccharomyces pombe Fcp1 captured the mimic structures of the 
phosphoryl-aspartate intermediate and the transition state of the hydrolysis step using 
BeF3
- and AlF4
- respectively (Ghosh et al. 2008). In the Fcp1 structure, a water molecule 
occupies the position close to the Asp172 (corresponding to Asp98 in human Scp1) and 
can potentially be activated by Asp172 side chain for the breakdown of the phosphoryl-
intermediate. This observation is consistent with the structural studies on phosphoserine 
phosphatase (PSP) (Wang et al. 2002). Based on the similarity between Fcp1 and Scp1, it 
is likely that Asp98 functions as the general acid to protonate the leaving group and as the 
general base to activate a water molecule in the first and second steps, respectively.  
However, structural or biochemical data that directly test this model in Scp1 are lacking. 
One of the most efficient ways to understand the catalytic mechanism of an 
enzyme is to capture the intermediate of the reaction. It has been shown in an earlier 
study that a transient phosphoryl-cysteine intermediate was captured in the protein 
tyrosine phosphatase 1B crystal structure by generating an active site mutation at Gln262 
to Ala (Pannifer et al. 1998). However, although the two-step mechanism of the 
dephosphorylation reaction (Figure 3-2a) by the HAD superfamily enzymes is generally 
accepted (Allen et al. 2004), the phosphoryl-aspartate intermediate has rarely been shown 
structurally (Lahiri et al. 2002). In theory, there are two scenarios where the phosphoryl-
aspartate intermediate may be captured in crystal structure. First, if the general acid that 
protonates the product (in the first step, Figure 3-2a) is a different residue from the 
general base that catalyzes the hydrolysis of the phosphoryl-aspartate intermediate (the 
second step, Figure 3-2a) then mutation of the latter residue would result in the 
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accumulation of the intermediate. Second, if the general acid and the general base are the 
same residue, but the mutation of an auxiliary residue (e.g. a Mg2+-coordinating residue) 
slows down the rate of both the first and the second reactions, the overall reaction rate 
might be low enough so that the added substrate is not completely consumed during the 
process of crystallization. In this case if the rate of the second step (k2, Figure 3-2a) is 







) should exist as the phosphoryl-aspartate intermediate. 
With this reasoning in mind, we designed a series of Scp1 mutants where each of 
the acidic residues (namely, Asp98, Asp99 and Asp206) was mutated to either the 
isosteric neutral residue (i.e. Asn) or Ala, examined these mutants with biochemical 




Figure 3-2: Proposed mechanism of phospho.Ser5 dephosphorylation catalyzed by 
Scp1.7 
                                                 
7 (a) Proposed mechanism of phospho.Ser5 dephosphorylation catalyzed by Scp1. At early steady-state, the 
concentration of product has not accumulated to a significant level so that the reverse reaction of the first 
step can be ignored. (b) Stereo diagram of the CTD-bound active site of Scp1D96N. The structure of 
human Scp1D96N in complex with a CTD heptad repeat peptide phosphorylated at Ser5 shown as a stereo 
pair of ribbon diagram. The active site residues are depicted as color-coded bonds. The three residues 
serving as candidate general bases for hydrolysis of the phosphoryl-Asp96 intermediate are highlighted 
with cyan colored bonds. 
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Phosphatase activity assays for Scp1 mutants 
We used two complementary methods to measure the general dephosphorylation 
activity of Scp1 mutants: a colorimetric assay with pNPP as the substrate and a 
fluorescent assay using 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) as the 
substrate. The pNPP assay is highly robust but shows a strong background absorbance, 
resulting in insensitivity with an enzyme with low activity. On the other hand, the 
fluorescence-based DiFMUP assay is highly responsive towards dephosphorylation and 
can detect very low phosphatase activity. However, high concentrations of DiFMUP 
appeared to non-specifically inhibit the activities of all tested variants of Scp1. The 
inhibitory effect was evident at concentrations of DiFMUP around 500 µM and was 
nearly complete at higher concentrations of DiFMUP (>5 mM). For this reason, the 
highest concentration of DiFMUP used in our assay was 150 µM which is below the Km 
of all active Scp1 variants, making the measurement of Km and kcat unfeasible. 
Nonetheless, the kcat/Km could still be measured in DiFMUP assays and were used to 
compare relative activities of Scp1 variants. Despite being less sensitive, the pNPP assay 
allowed high concentrations of substrate (up to 30 mM pNPP) and, when necessary, 
enabled us to obtain the kcat and Km for Scp1 variants toward pNPP. Using the two assays, 
significant information on the catalytic activity of these Scp1 variants was obtained. 
As expected, the mutation of the active site nucleophile Asp96 to Asn (D96N) or 
Ala (D96A) abolished all measurable activity in both assays. Interestingly, although 
Asp98 was proposed to act as a general acid to protonate the leaving group of the first 
phosphoryl transfer and subsequently deprotonate a water to accelerate hydrolysis of the 
anhydride (Kamenski et al. 2004; Zhang et al. 2006), mutation of Asp98 to Asn (D98N) 
retained 30% activity of the wildtype Scp1 (DiFMUP assay data, Table 3-1). Even a 
D98A mutant showed 10% activity of the wildtype Scp1 (both assays, Table 3-1). The 
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kcat of D98A using pNPP as the substrate was as high as 0.5 s
-1. This high kcat is 








=         [1]  
Or in other words, k2 must of necessity be greater than kcat. Therefore, the first-order rate 
constant for the dephosphorylation of D98A mutant (k2) must be greater than 0.5 s
-1, 
which is at least 4 orders of magnitude higher than the reported uncatalyzed hydrolysis of 
phosphoryl-aspartate mixed anhydrate [10-4 s-1, (Allen et al. 2004)]. These results argue 
against the proposed function of Asp98 as the only possible general acid/base in catalysis, 
suggesting that complementarity by another active site residue may be applied in Scp-
mediated phosphate transfer. 
Similarly, mutations of Glu99 to Gln or Ala did not abolish phosphatase activity, 
resulting in 10% and 5% activity compared to wildtype, respectively. The mutation of 
Asp206 to Asn resulted in greatly reduced stability and solubility of the protein. The 
corresponding mutation of Asp to Asn is also reported to be very disruptive for Fcp1 
(Hausmann et al. 2003), possibly due to the misfolding of the protein induced by the 
disruption of the salt bridge between this Asp and active site Lys. Therefore, alanine 
mutation was tested to investigate the functional role of D206. Under the standard assay 
condition with 20 mM MgCl2, the activity of D206A mutant was too low to be reliably 
detected in both assays. The crystal structure of Scp1 (Figure 3-2b) shows that an active 
site Mg2+ is coordinated by a water molecule which is further positioned by Asp206. 
Such secondary stabilization of metal ion binding via water molecules might be essential 
for the effective catalysis. Indeed, this role of Mg2+-coordination by residues 
corresponding to D206 is also observed in many other HAD family proteins in three-
dimensional structure (see structural alignment later). Consistent with these structural 
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observations, when the MgCl2 concentration was increased to 50 mM, the D206A mutant 
displayed a well-detectable activity toward DiFMUP. The kcat/Km was 0.2 mM
-1min-1 
(~2% of the wildtype activity measured at 20 mM MgCl2).  
 
 DiFMUP assay pNPP assay 
 kcat/Km (mM
-1min-1) kcat (s
-1) Km (mM) kcat/Km (mM
-1s-1) 
Wildtype 10.3 ± 0.8 2.5 ± 0.1 3.6 ± 0.8 0.7 ± 0.2 
D96N N.A.8 N.A.8 N.A.8 N.A.8 
D96A N.A.8 N.A.8 N.A.8 N.A.8 
D98N 3 ± 1 N.A.9 N.A.9 N.A.9 
D98A 0.8 ± 0.2 0.50 ± 0.02 7.3 ± 0.8 0.068 ± 0.008 
E99Q 1.14 ± 0.09 2.0 ± 0.3 8 ± 4 0.2 ± 0.1 
E99A 0.5 ± 0.1 0.005 ± 0.001 N.A.10 N.A.10 
D206A11 0.23 ± 0.04 0.022 ± 0.005 8 ± 4 0.002 ± 0.001 
Table 3-1: Steady-state parameters of Scp1 variants tested by DiFMUP and pNPP 
assays. 
To further characterize the Mg2+-dependence of D206A mutant, we tested the 
catalytic activity of wildtype Scp1 and the D206A mutant at various MgCl2 
concentrations (Figure 3-3). While the apparent Kd of wildtype Scp1 with Mg
2+ was 1.3 
                                                 
8 Signal below detection limit.  
9 Although D98N showed strong activity to pNPP, the activity of this mutant appeared unstable so that 
during the time course required for pNPP assay the enzyme did not maintain constant activity, leading to 
uninterpretable data. 
10 The Km of E99A mutant is greatly increased, and thus can not be accurately determined from the rate-
vs-pNPP concentration curve. 
11 Both DiFMUP and pNPP assay were performed with 20 mM Mg2+, however, no signal can be detected 
for D206A mutant under this condition. Therefore, the data for D206A were obtained under 50 mM Mg2+ 
condition. 
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± 0.9 mM, that of the D206A mutant was at least 100-fold higher. These results indicate 
that Asp206 is critical during catalysis at least in part by coordinating the catalytic Mg2+. 
 
Figure 3-3: Mg2+-dependence of enzyme activity of wildtype Scp1 and Scp1D206A 
mutant. 
Phosphoryl intermediate of Scp1 obtained by incubating Scp1D206A mutant with 
pNPP at low Mg
2+
 concentration 
Based on the kinetic characterization above, we crystallized D98A, E99A and 
D206A and soaked the crystals in the buffer containing a high concentration of pNPP. X-
ray diffraction data were collected for each mutant at resolutions from 2.35-2.45 Å 
(Table 3-2). In the structure of the Scp1D98A mutant, a hydrogen bond originally 
observed between the side chain of Asp98 and that of Tyr158 found both in the apo 
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protein structure (Figure 3-4) and our previous complex structures (Figure 3-5a) is 
interrupted due to mutation of Asp98. This hydrogen bond appears to anchor Tyr158 to 
facilitate the formation of part of the CTD binding groove (Zhang et al. 2006). Without 
this hydrogen bond anchoring the side chain of Tyr158 by Asp98 side chain, an 
alternative conformation of Tyr is adopted (Figure 3-5b), which places the phenolic side 
chain of Tyr in the hydrophobic pocket previously observed to specifically sequester Pro3 
of the CTD repeat sequence (Figure 3-5c). This hydrophobic pocket prefers binding to 
hydrophobic molecules, and the adoption of Pro3 of the CTD repeat is essential for CTD 
recognition by Scp1. The structure of Scp1E99A exhibits an identical metal center with 
wildtype Scp1 and Scp1D96N structures (Figure 3-6), with the only difference being the 
coexistence of both conformations of Tyr158 due to a minor change of the Asp98 
position. Apparently, the orientation of the Tyr158 is directly affected by its hydrogen 
bonding to Asp98 carboxyl side chain. 
 
Figure 3-4: Ribbon diagram showing the salt bridge between Asp98 and Tyr158 in Scp1 
apo protein structure. 
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 Scp1D206A soaked 













Data collection    
Space group C2 C2 C2 
Cell dimensions    
      a, b, c (Å) 124.7, 78.2, 62.6 125.5, 77.3, 63.1 124.8, 79.0, 62.9 
      α, β, γ (°) 90.0, 112.3, 90.0 90.0, 112.5, 90.0 90.0, 112.8, 90.0 
Resolution (Å) 49.1–2.35 (2.43–2.35) 48.6–2.45(2.54–2.45) 48–2.30 (2.38–2.30) 
No. of 
observation 
39564 32699 39941 
No. of unique 
reflections 
23379 20421 24660 
Rsym or Rmerge (%) 7.1 (20.4) 7.5 (22.7) 7.2 (20.5) 
I/σ(I) 16.4 (2.6) 13.4 (2.1) 17.5 (3.4) 
Completeness 
(%) 
91.3 (59.1) 90.7 (53.2) 90.2 (57.2) 
Redundancy 2.4 (1.7) 3.3 (2.1) 3.4 (2.6) 
    
Refinement    
Resolution (Å) 49.1–2.35 48.6–2.45 32.2–2.35 
No. reflections 
(test set) 
23286 (1109) 17693 (864) 21099 (1131) 
Rwork / Rfree (%) 19.5(25.9)/24.5(34.5) 20.4(25.6)/25.4(37.7) 19.2(24.0)/23.1(30.6) 
No. of atoms    
      Protein 2930 2908 2928 
      ion 2 12 2 
      Water 95 32 99 
B-factors (Å2)    
      Protein 36.2 37.8 37.4 
      Mg2+ 20.5 39.3 24 
      Water 37.2 38.2 39.1 
Table 3-2: Data collection and refinement statistics.12 
 
 
                                                 
12 Highest resolution shell is shown in parenthesis. Rfree is calculated with 5% of the data randomly 
omitted from refinement. 
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(Table 3-2 cont.) 
R.m.s deviations    
Bond lengths (Å) 0.013 0.014 0.011 
Bond angles (°) 1.48 1.60 1.36 
Ramachandran 
plot (%) 
   
Most favored 87.8 84.4 90.5 
Additionally 
allowed 
11.3 15.3 9.2 
Generally allowed 0.9 0.3 0.3 
 
Figure 3-5: Two different conformations of Tyr158 observed in Scp1D96N structure (a) 
and Scp1D98A structure (b).13 
 
                                                 
13 In (a), the side chain of Tyr158 forms a hydrogen bond (yellow dashed line) with the side chain of 
Asp98 which is lost in (b). (c) Stereo diagram of superimposition of Scp1D98A structure with Scp1D96N-
CTD complex (PDB code: 2ghq). The CTD peptide is shown in yellow stick. 
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Figure 3-6: Superimposition of Scp1E99A (magenta) and D96N (cyan) active site 
structures.14 
Unlike D98A and E99A structures, the Scp1D206A mutant exhibited strong 
positive electron density directly contiguous with the electron density associated with the 
Asp96 residue. The shape and high signal to noise ratio of the contiguous density is 
consistent with a covalently trapped phosphate group, which was built and refined as a 
phosphoryl-Asp96 intermediate (Figure 3-7a, b). The remaining parts of the overall 
Scp1D206A structure are virtually identical to the wildtype and D96N Scp1 structures. 
Additional density resided in the Pro3 binding pocket that was refined well as a part of 
PEG molecule in one of the two Scp1D206A monomers in the asymmetric unit. This is 
consistent with previous observation that this pocket highly favors hydrophobic 
molecules and might non-specifically bind to chemical molecules in crystallization 
solution (Kamenski et al. 2004).  
 
                                                 
14 The structure of E99A mutant exhibits an identical metal center with that of D96N. Notably, the Tyr158 
can adopt two conformations as discussed in the paper due to the minor change of Asp98 position. 
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Figure 3-7: Structural studies of Scp1D206A.15 
Apparently, in the crystalline environment of the Scp1D206A mutant, the high 
energy phosphoryl-enzyme intermediate bound to Asp96 reaches appreciable levels and 
remains stable over time to allow visualization by protein X-ray crystallography. Based 
on the peak height from initial Fo-Fc electron density maps as well as thermal factors 
from active sites, we estimated that the occupancy of the phosphate group covalently 
                                                 
15 (a) Phosphorylation of Asp96. The mutation of Asp206 (labeled in red) stabilizes the trapped 
phosphoryl-aspartate intermediate of the enzyme. (b) The hydrogen bonding formed between phosphate 
group and the enzyme. (c) Superimposition of phosphate-trapping Scp1D206A (light blue) with Scp1 
bound with BeF3
-
 (1ta0) (lime). The water molecules are colored red and Mg
2+ ion colored magenta for the 
former structure, whereas water as white and Mg2+ as orange for the latter. (d) Superimposition of 
Scp1D206A soaked in substrate pNPP at different Mg2+ concentrations. The active site residues are shown 
in stick. The Asp96 covalently linked to phosphate group is shown in yellow, and the phosphoryl-free 
Asp96 is shown in green. 
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attached to Asp96 reached approximately 50%. In the crystalline environment of the 
Scp1D206A mutant, the electron density of Mg2+ (Figure 3-8) is significantly weaker 
than that obtained in the Scp1D96N-CTD peptide complex structure, suggesting the Mg2+ 
occupancy is not 100% (refined as 50% occupancy with B factor around 20 Å2). This is 
again consistent with the kinetic study that the binding affinity between Mg2+ and 
Scp1D206A is much lower. Therefore, using lower Mg2+ concentration in the 
crystallization mother liquor could be one of the major reasons why we captured this 
phosphoryl-enzyme intermediate in Scp1D206A crystal. The crystallization state also 
sheltered the phosphoryl intermediate from bulk water in the D206A mutant and slowed 
down the hydrolysis of phosphoryl-Asp96. 
 
Figure 3-8: Fo-Fc electron-density map (green) of Mg
2+ ion with a sigma cutoff of 8σ. 
A previously reported structure of BeF3
- in complex with Scp1 suggested the 
existence of a Scp1 phosphoryl-enzyme intermediate (Kamenski et al. 2004). Because of 
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the presumed chemical instability of phosphoryl-aspartate intermediates of HAD family 
proteins, BeF3
- has been used as a phosphate mimic (Cho et al. 2001). By comparing the 
structure of our trapped phosphoryl-aspartate intermediate and that of BeF3
- bound to 
Scp1 (PDB code: 1ta0), we conclude that the complex structure encompassing BeF3
- 
bound to Asp96 is a reasonably acceptable mimic for the covalent phosphoryl-aspartate 
intermediate (Figure 3-7c). 
Product-trapping structure of Scp1 obtained by incubating Scp1D206A mutant with 
pNPP at high Mg
2+
 concentration and high pH 
Based on the proposed mechanism that a general base is involved in the second 
step and our kinetic data, we hypothesized that increased Mg2+ availability and higher pH 
would facilitate the hydrolysis of the phosphoryl-aspartate. To evaluate these effects on 
the activity of Scp1D206A crystallographically, we used the same Scp1D206A crystal 
form but soaked the samples in 25 mM pNPP with 0.2 M MgCl2 at slightly higher pH 
(pH 6.5–7.0). Clear and unmistakable electron density indicates a bound phosphate group 
in the Scp1D206A active site. However, unlike the electron density associated with 
phosphate for the low Mg2+ soaked crystals, this electron density clearly showed a 
complete loss in covalent attachment to the enzyme (Figure 3-7d). The phosphate group 
in the structure was refined to 100% occupancy with the same thermal factors as the 
surrounding protein residues. The position of the phosphate group moves by 
approximately 1.2 Å away from its original position in the low Mg2+ complex while the 
side chain of the Asp96 nucleophile rotates away from the phosphate (Figure 3-7d). 
Together with previously reported structures, these newly determined Scp1 crystal 
structures provide static snapshots along the reaction pathway catalyzed by Scp1 (Figure 
3-9). Our complex structure of Scp1D96N with CTD phosphoryl-peptide presents the 
pre-reaction binding mode. The D206A structure soaked with pNPP at low Mg2+ 
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concentration is the capture of phosphoryl intermediate, whereas the same mutant at high 
Mg2+ concentration is a product trapped image with inorganic phosphate group at the 
active site. 
 
Figure 3-9: Snapshots of dephosphorylation reaction of human Scp1.16 
Capture of phosphoryl intermediate for HAD superfamily 
The formation of phosphoryl-enzyme intermediates is a crucial component of 
various enzymatic mechanisms involving phosphoryl transfer (Pannifer et al. 1998). Even 
though phosphoryl-aspartate is not very stable, it has been captured in other proteins 
containing a DXDX motif (Allen et al. 2004; Diaz et al. 2008), mostly using phosphoryl 
analogues. In addition to the direct visualization of phosphoryl intermediate in our X-ray 
structure for Scp1, β-phosphoglucomutase (β-PGM) is found to be phosphorylated at the 
active site aspartate (Asp8) in the crystalline state (PDB code: 1lvh) (Lahiri et al. 2002). 
β-PGM is a subclass I HAD family protein, which catalyzes the transfer of a phosphate 
group between the 1 and the 6 position of the cyclic glucose ring. As the enzyme needs to 
                                                 
16 This is the presumed model for the reaction catalyzed by Scp1 in substrate recognition (a), phosphoryl 
transfer (b), and phosphate release (c) stages. In order to capture them in crystallization state, certain 
residues were mutated (see below). Scp1 is shown in ribbon diagram in light blue, and Asp96, Asp98 and 
Asp206 residues are shown in stick in yellow. Mg2+ ion and the two water molecules are shown in sphere in 
magenta and orange, respectively. (a) Scp1 bound to phosphorylated CTD (carbon chain shown in white). 
Asp96 was mutated to Asn to capture this complex structure. (b) Phosphate group of phospho.Ser5 is 
transferred to Asp96 and generates the phosphoryl-aspartate intermediate. Asp206 was mutated to Ala in 
this structure. (c) Hydrolysis of the phosphoryl-aspartate intermediate and release of phosphate group from 
Asp96 side chain. Again, Asp206 was mutated to Ala in this structure. 
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transfer the phosphate group from position 1 on the hexose to position 6, the phosphoryl-
enzyme intermediate is sufficiently stable to allow reorientation of the acceptor in the 
active site while preventing water-mediated loss of phosphate. Other phosphoryl-




-) were used to mimic the different stages of phosphoryl transfer. For instance, 
in Ca2+-ATPase, the ATP-dependent phosphorylation of its catalytic Asp is a critical step 
in transducing chemical energy into conformational energy for Ca2+ ion transport 
(Toyoshima et al. 2004; Toyoshima et al. 2007). Subsequent to ATP-dependent 
phosphorylation of the ATPase, the dephosphorylation reaction of the phosphoryl-
enzyme intermediate triggers a conformational change that closes the lumenal gate of the 
Ca2+ channel though the movement of a domain capping the transmembrane portal 
(Toyoshima et al. 2004; Toyoshima et al. 2007). Furthermore, the phosphoryl-aspartate 
intermediate was observed in Schizosaccharomyces pombe Fcp1 structure with BeF3
- 
mimicking the phosphate group (PDB code: 3ef0) (Ghosh et al. 2008). In the crystal 
structure, a covalent bond was clearly observed between the BeF3
- and Asp170 of Fcp1 
(the first Asp in the DXDX motif). Human eyes absent (Eya) proteins, which also belong 
to the HAD family, play dual roles as a protein tyrosine phosphatase and a transcription 
factor in organ formation during development. Again, using phosphate analog BeF3
- and 
AlF3, a phosphoryl-aspartate intermediate and a transition sate of phosphoryl-enzyme 
were captured in the catalytic domain of Eya2 phosphatase, respectively (Jung et al. 
2010). Additionally, phosphoryl-aspartate intermediates have been detected by 
radioactivity measurements in DNA 3’ phosphatase Tpp1 (Deshpande et al. 2004), and in 
a recent study, Ca2+ ions were shown to have an inhibitory effect and induce the 
accumulation of a phosphoryl-aspartate intermediate detected by mass spectrometry in 
histidinol phosphate phosphatase (Rangarajan et al. 2006). 
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Conservation of D206 in HAD family 
While most HAD family proteins vary considerably in primary sequence, they all 
share the DXDX(T/V) motif (motif I) (Asp96 and Asp98 in human Scp1) as well as two 
other motifs at similar positions in their 3D structures (Figure 3-10a). Motif II is a single 
residue, either Thr (Thr152 in human Scp1) or Ser, which hydrogen bonds through its 
side chain with the phosphate moiety of the substrate. These two motifs are highly 
conserved and easily identified using structure-based alignment. Motif III is a DD or DN 
pair with a Lys residue located a short distance away on the N-terminal side of the acidic 
pair. The first Asp of the DD (DN) pair (Asp206 in human Scp1) aligns a water molecule 
which coordinates the catalytic Mg2+ ion in the active site. This residue also forms a salt 
bridge to the side chain amino group of the upstream Lys (Lys190 in human Scp1) 
residue, which in turn forms a second intermolecular bridge to the phosphate moiety of 
the substrate. The second Asp or Asn (Asn207 in human Scp1) forms an axial 
coordination bond with the octahedrally coordinated Mg2+ ion (Figure 3-2b). 
Interestingly, the conservation of the second of the acidic stretch (Asn207) extends 
throughout HAD family whereas Asp206 is found to be replaced by Gly in a lot of HAD 
proteins (protein serine phosphatase, P-type ATPase, phosphomannomutase, histidinol 
phosphate phosphatase, sucrose phosphatase). This is very puzzling at first since our 
kinetic study strongly supports an essential structural function of Asp206 (or 
corresponding residues) in ion coordination and possibly a functional role in catalysis due 
to its mutation leads to capture of phosphoryl intermediate. A more careful examination 
of structure-based alignment shows that in HAD proteins where the first Asp of Motif III 
is replaced by Gly, the position corresponding to the side chain of Asp206 in Scp1 is 
always occupied by an Asp side chain extended from an amino acid 4~5 residue 
downstream of the second residue of Motif III (Figure 3-10b). Therefore, Asp206 side 
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chain function is conserved spatially with similar functions: Mg2+ coordination and salt 
bridging to Lys (Table 3-3). 
 
Figure 3-10: Structural alignment of HAD family members.17 
                                                 
17 (a) Structural alignment of alpha-carbon backbone of Scp1 (yellow, 2ght), PSP (green, 1l7m), β-PGM 
(cyan, 1lvh), PMM (magenta, 2fuc), P-Type ATPase (pink, 2zbd) and Eya2 (gray, 3geb). Red sphere is the 
Mg2+ in Scp1, indicating the active site. For visual clarity, only the conserved portion is shown in each 
structure (Scp1: show residue 89-222 without residue 104-130; PSP: show residue 4-184 without residue 
19-73 and 120-137; β-PGM: show residue 1-188 without residue 15-91; PMM: show residue 12-240 
without residue 82-190; P-Type ATPase: show residue 346-719 without residue 359-602 and 641-673; 
Eya2: show residue 268-519 without 281-424). (b) Structural alignment of the active site of human Scp1 
(light pink, 2ght) and MjPSP (white, 1l7m). The Asp206 in Scp1 and corresponding residue Asp171 in 
MjPSP are shown in stick. The water molecule hydrogen-bonding with Asp206 (or Asp171) is shown in 
pale green, and Mg2+ is shown in red. Hydrogen bonds are indicated by yellow dashed lines. 
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   Motif I Motif II Motif III 
Pseudomonas sp. YL 
HAD 
1jud 14 D10 Y12 S118 T175 K151 S176 
Schizosaccharomyces 
pombe Fcp1 
3ef0 24 D170 D172 T243 D297 K280 D298 
Lactococcus lactis β-
PGM 
1lvh 14 D8 D10 S114 E169 K145 D170 
T4 polynucleotide 
kinase 




2i54 12 D10 D12 S46 D215 K188 D207 





1l7m 10 D11 D13 S99 D171 K144 D167 
Human PSP 1l8l 15 D20 D22 S109 D183 K158 D179 
Oryctolagus cuniculus 
P-Type ATPase 








1tj3 15 D9 D11 T41 D190 K163 D186 
Escherichia coli NagD 2c4n 14 D9 D11 T42 D206 K176 D201 
Escherichia coli Class B 
acid phosphatase 
(AphA) 
2b82 12 D44 D46 T112 D171 K152 D167 
Human eyes absent 
phosphatase 2 (Eya2) 
3geb 13 D274 D276 T448 E506 K480 D502 
Table 3-3: Conserved residues in the HAD family in comparison to Scp1. 
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Possible additional role of D206 in catalysis 
Our studies have established that even though the coordination of Mg2+ by D206 
is mediated through a water molecule, its mutation can reduce Mg2+ binding by at least 
100-fold. When considering the reaction mechanism of phosphoryl transfer reaction, the 
most logical candidate for general acid/based is Asp98. As shown in a recent paper about 
a Scp family member, Schizosaccharomyces pombe Fcp1, a water molecule is occupying 
at an ideal position to be activated by Asp98 and nucleophically attacks phosphorus 
(Ghosh et al. 2008). Interestingly, our mutants of Asp98 still retain a significant 
percentage of phosphoryl activity, which prompted us to speculate if alternative general 
acid/base might exist especially when Asp98 is replaced. Considering the conservation of 
Asp206 throughout HAD family and our capture of phosphoryl intermediate upon 
mutation, it is possible that this residue may also play a catalytic role. With our current 
experimental method, Mg2+ concentration higher than 100 mM causes precipitation of the 
protein, therefore it is hard to determine whether saturating concentration of Mg2+ would 
fully rescue the activity of D206A mutant. However, it would be interesting to investigate 
the structural and functional roles of this residue in other HAD family. For example, it 
was reported that mutation at this residue in P-type ATPase (Asp707) totally abolishes its 
activity (McIntosh et al. 2004). 
In summary, our current study provided definitive evidence for the existence of 
the phosphoryl-aspartate intermediate in the reaction catalyzed by Fcp/Scp phosphatase 
family. We identified Asp206 as a key residue for catalysis and metal binding, whose 
mutation can result in product trapping. Our results strongly suggest that Asp206 and its 
equivalent residues in other HAD family members play a structural and possible 
mechanistic role through divalent cation coordination. We believe these results will direct 
future studies on the mechanism of Scp1 and other HAD family enzymes. 
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MATERIALS AND METHODS 
Cloning, mutagenesis and purification 
Wildtype human Scp1, residues 77-256, was sub-cloned and expressed in E.coli 
BL21(DE3) strain using pHIS8 vector encoding a thrombin cleavable N-terminal octa-
histidine tag (Jez et al. 2000). Mutant genes were generated using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene, CA). The expression of Scp1 wildtype or mutants 
was induced in E.coli at low temperature (16°C) with 250 µM IPTG and allowed to 
accumulate to high levels overnight. Cells were harvested and re-suspended in 0.5 M 
NaCl, 15 mM imidazole, 50 mM Tris-HCl pH 8.0, 10% (v/v) glycerol and 0.1% (v/v) 
Triton X-100. After sonication, cell debris was removed by centrifugation. The 
supernatant was loaded onto a Ni2+-NTA affinity column, washed extensively with 
sonication buffer and then with sonication buffer minus Triton X-100. Nearly 
homogeneous Scp1 was eluted with sonication buffer minus Triton X-100 but including 
150 mM imidazole. Eluted protein was dialyzed into 20 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 5 mM β-mercaptoethanol and stored at a concentration of 2 mg/ml at 4 °C. 
Samples for protein x-ray crystallography were subjected to thrombin processing to 
remove the octa-histidine tag followed by size exclusion chromatography for final 
cleanup. These samples were stored in 20 mM HEPES-Na+ pH 7.5, 100 mM NaCl, 3 mM 
dithiothreitol at a concentration of 12-16 mg/ml at -80 °C. 
pNPP assay 
The steady-state parameters of D98A/N, E99Q/A, and D206A were measured 
using pNPP as a substrate. The reaction mixtures contained 50 mM Tris-acetate pH 5.5, 
20 or 50 mM MgCl2, 0.5–50 mM of pNPP, and suitable amount of mutant proteins. The 
reactions were incubated at 37 °C for 15 mins and then quenched by adding 80 µl of 0.25 
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N NaOH. Release of pNP was determined by measuring absorbance at 410 nm. The 
absorbance was converted to product concentration by a pNP standard curve. The data 
were analyzed by nonlinear regression performed in Matlab (The MathWorks, Inc., MA). 
The Mg2+ dependence of wildtype Scp1 or Scp1D206A was measured by the same assay 
at constant substrate concentration with 0–100 mM Mg2+. 
DiFMUP assay 
DiFMUP (Invitrogen, CA) was dissolved in 100% DMSO to make 100 mM stock.  
Before each measurement, the DiFMUP was freshly diluted in 1× reaction buffer 
containing 50 mM Tris-acetate pH 5.5, 20 mM MgCl2 to desired concentrations. The 
substrate mixture and protein mixture were pre-incubated at 37 °C for 10 mins prior to 
mixing. The final reaction mixture contained 0–150 µM of DiFMUP and wildtype Scp1 
or Scp1 mutants. The generation of the fluorescent DiFMU was monitored continuously 
at excitation/emission maxima ~358/450 nm for 2 hrs. The data were analyzed by the 
same method as described for pNPP assay. 
Crystallization and structure determination  
Scp1 mutants were crystallized in 0.5–0.8 M ammonium sulfate, 100 mM 
HEPES-Na+ pH 7.0, with 0.2 M lithium sulfate. Crystals were then transferred to a 
stabilizer consisting of 100 mM sodium citrate, pH 5.5 (or MES-Na+, pH 6.5), 30% (w/v) 
PEG 8000, 5-25 mM pNPP and 10 mM MgCl2 or 0.2 M MgCl2. The pH of the crystal 
stabilizer drop was retested and confirmed using pH paper. After soaking for 24 hrs, 
crystals were transferred to a cryo-protecting stabilizer containing 30% (v/v) glycerol, 
30% (w/v) PEG8000 and 100 mM of the respective buffer of the original stabilizer. After 
a brief period of equilibration, crystals were frozen in nylon loops in liquid nitrogen and 
stored in liquid nitrogen prior to data collection. Data were collected at 100 K on beam-
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line 8.2.2 of the Advanced Light Source (ALS). Diffraction data were processed with 
HKL2000 (Otwinowski et al. 1997). The data collection statistics are summarized in 
Table 3-2. 
The crystal structures of Scp1 mutants were determined by molecular replacement 
(MR) using the Scp1D96N structure as a search model (PDB code: 2ghq) using the 
program AmoRe (Navaza 1994) available in the CCP4 software package (CCP4 1994). 
MR solutions were refined using CNS (Brunger et al. 1998) and REFMAC, reserving 5% 
of the measured and reduced structure factor amplitudes as an unbiased test set for cross 
validation (Rfree) (Brunger 1992). SigmaA-weighted electron density maps (2Fo-Fc and 
Fo-Fc) were calculated after each cycle of refinement and carefully inspected to guide 
model rebuilding using O (Jones et al. 1991). The final models were evaluated by 
PROCHECK (Laskowski et al. 1993). 
ACCESSION NUMBERS 
Coordinates for structural studies in the paper have been deposited in the Protein 
Data Bank with human Scp1 D206A phosphoryl-Asp structure as 3L0B, D206A product 
trapped structure as 3L0C and D98A mutant as 3L0Y. 
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Chapter 4:  Selective Inactivation of Scp1 by a Small Molecule 
Inhibitor 
INTRODUCTION 
The CTD specific kinases and phosphatases function as house-keeping regulatory 
factors for global transcription (Majello et al. 2001). Recently, it has been shown that 
certain CTD regulatory factors can also epigenetically modulate the expression level of a 
specific group of genes (Li et al. 2005; Yeo et al. 2005; Zhang et al. 2010). As an 
example, a newly discovered class of phosphatases, the human small C-terminal domain 
phosphatases (Scps), specifically dephosphorylates phosphorylated Ser5 (phospho.Ser5) 
of the tandem heptad repeats of the CTD (Yeo et al. 2003). Interestingly, Scps have also 
been shown to epigenetically silence the expression of a specific set of neuronal genes in 
neuronal stem cells and non-neuronal cells by acting as co-repressors in REST/NRSF 
complex (Yeo et al. 2005). Inhibition of Scps in P19 stem cells by the dominant negative 
mutants (which retain the overall structure but have abolished phosphatase activity) or 
microRNA miR-124 (which directly targets the untranslated region of Scp genes and 
suppresses their expression) allows neuronal gene expression and induces neuronal 
differentiation (Yeo et al. 2005; Visvanathan et al. 2007). Given the demonstrated role of 
Scps in limiting inappropriate expression of neuronal specific genes in pluripotent cells 
and the fact that their down-regulation leads to neuronal differentiation, Scps serve as 
promising new targets for small molecule inhibitors to regulate neuronal stem cell 
development and to promote neuronal differentiation. 
However, one of the greatest challenges associated with phosphatase inhibitor 
identification is the cross inhibition of other phosphatases due to poor selectivity (Yu et 
al. 2007), which usually stems from small, uncharacteristic active sites of phosphatases. 
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For Scp inhibitors, selectivity is of great concern as two close family members in the 
Scp/Fcp family, Fcp1 (Cho et al. 1999) and Dullard (Kim et al. 2007), play essential roles 
in cell survival as well as proper development (Chambers et al. 1994; Archambault et al. 
1997; Kim et al. 2007).  
The crystal structures of Scp/Fcp family members Fcp1 and Scp1 were initially 
solved by Ghosh et al. (Ghosh et al. 2008) and Kamenski et al. (Kamenski et al. 2004). 
Unlike the traditional cysteine-based or dimetal-dependent phosphatases, the Scp/Fcp 
family members belong to a unique family of phosphatases that rely on the DXDX(T/V) 
motif and Mg2+ to catalyze the phosphoryl-transfer (Yeo et al. 2003; Kim et al. 2007), as 
found in the haloacid dehydrogenase (HAD) superfamily (Allen et al. 2004). In fact, the 
overall core fold of Scps resembles the core domains of other HAD family members, 
despite low sequence similarity (see Chapter 3) (Zhang et al. 2010). 
The HAD superfamily can be further divided into three subfamilies (Figure 4-1) 
according to the presence and the location of a second domain known as the “cap 
domain” (Morais et al. 2000; Zhang et al. 2002). Both type I and II subfamily members 
utilize the cap domain to shield the active site from bulk solvent and to achieve substrate 
recognition (Allen et al. 2004). The type III HAD superfamily, including the Scp/Fcp 
family, do not have a cap domain, requiring specificity achieved through alternative 
strategies, such as recruitment of other regulatory proteins. This feature poses an 
additional challenge for inhibitor design. In fact, no specific inhibitors have been reported 
to date for type III HAD family members. 
The complex structure of Scp1 bound to its substrate peptide has previously been 
solved (Zhang et al. 2006), and the snapshots of the phosphoryl-transfer reaction at each 
step and the formation of the phospho-aspartyl intermediate were captured using X-ray 
crystallography and the reaction mechanism of Scps was established (Zhang et al. 2010). 
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These crystallographic and biochemical studies not only provided insights into the 
catalytic mechanism of Scp/Fcp, but also hinted a novel strategy of specific recognition 
of substrates by Scps. The complex structure of Scp1 bound to its substrate peptide 
revealed a hydrophobic binding pocket which is specific for Scps, suggesting that a 
specific Scp inhibitor might be obtained through targeting this pocket (Zhang et al. 2006). 
In the present study, we exploited this possibility and identified rabeprazole as the first 
reported lead compound for Scp inhibition (Ki = 5 ± 1 µM). This small molecule shows 
no inhibition towards Fcp1 or Dullard, nor towards bacteriophage lambda Ser/Thr 
phosphoprotein phosphatase (λPPase). This extraordinary selectivity can be explained 
through analysis of our high resolution structure of Scp1 complexed with the compound, 
which shows, as expected, the compound binds specifically to the unique hydrophobic 
binding pocket of Scps. The structure highlights the chemical functional groups that 
make essential contributions to binding. To the best of our knowledge, this is the first 




Figure 4-1: Representative family members of HAD super family.18 
                                                 
18 (a) Type I family member β-phosphoglucomutase (PDB code: 1o08), (b) Type II family member 
phosphatase TM0651 (PDB code: 1nf2), (c) Type III family member Scp1 (PDB code: 2ght). The 
conserved core domain is colored in lime, and the portion that does not align structurally is colored in gray.  
Mg2+ is shown in violet to indicate the active site. 
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RESULTS AND DISCUSSION 
Human Scps as target for inhibitor identification 
Phosphatases have historically proven to be difficult targets for inhibitor design. 
The difficulty stems from three major challenges in inhibitor design: (1) affinity: the 
binding pockets of phosphatases tend to be small, and therefore limit potential molecular 
interactions; (2) specificity: the substrate-specificities of phosphatases tend to overlap, 
creating possibilities for cross inhibition; (3) permeability: the mimicry of the charged 
phosphate group, which is key to recognition by phosphatases, often prevents the 
compounds from penetrating cell membranes. Owing to these difficulties, one of the best 
phosphatases inhibitors, I-C11, inhibits its target lymphoid-specific tyrosine phosphatase 
(Lyp) with a Ki of 2.9 ± 0.5 µM and shows some degree of promiscuity (Yu et al. 2007). 
With hundreds of Ser/Thr PPases and protein tyrosine phosphatases identified, the 
specific inhibitors reported are very limited. The most potent inhibitor for any 
phosphatase is a small molecule reported recently which targets T cell protein tyrosine 
phosphatase with a Ki of 4.3 ± 0.2 nM and a minor degree of cross inhibition (Zhang et 
al. 2009). 
The newly discovered Scps might prove to be viable targets for inhibitor design. 
First, the structure of Scp1 bound to its natural substrate phosphorylated CTD peptide 
reveals a spacious substrate-binding area compared to that of other phosphatases (Figure 
4-2a). Most notably, there is a hydrophobic pocket unique to Scps that specifically 
recognizes the Pro3 of the CTD and is about 7 Å away from the active site where the 
phosphate group binds (Figure 4-2a). Compounds that target this hydrophobic pocket are 
expected to have high binding affinities due to ample opportunities of making molecular 
contacts. Secondly, cross inhibition of close family members might be prevented by 
targeting this hydrophobic pocket since it is unique to Scps. The hydrophobic pocket is 
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located between the three-stranded β sheet insertion domain and the core domain. Many 
of the hydrophobic residues lining a part of the hydrophobic pocket are from the insertion 
domain which is unique to the Scp/Fcp family and is highly diversified within Scp/Fcp 
family members (Figure 4-2b). There is no sequence similarity between Scp, Fcp, 
Dullard and other family members in the insertion domain (Figure 4-2c). Finally, the 
affinity provided by binding to the hydrophobic pocket might mitigate the necessity of 
having a charged moiety to mimic phosphate, making the prospect compound more 
membrane-permeable. By considering these unique advantages of Scps, we reasoned that 
Scps might be feasible targets for selective and high affinity inhibitor design. 
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Figure 4-2: The hydrophobic binding pocket is unique to Scps.19 
                                                 
19 (a) The complex structure of Scp1 and a CTD-derived peptide (PDB code: 2ght). The active site 
DXDXT motif is shaded with pink color and the hydrophobic pocket residues are shaded with blue color. 
(b) Domain construct of human CTD phosphatases Scp1 (NCBI accession number: AAH12977), Scp2 
(AAH65920), Scp3 (NP_005799), Dullard (AAH09295), Fcp1 (AAC64549) and S. pombe Fcp1 
(NP_594768). Each domain is represented by a colored block. The catalytic domain is colored in light blue. 
The insertion domain, which is partially conserved, is colored in yellow. (c) The zoom-in figure of the 
insertion domain alignment. The upper panel shows the secondary structure of human Scp1 insertion 
domain, and the lower panel shows the secondary structure of S. pombe Fcp1 insertion domain. α indicates 
α helix, β indicates β sheet, and η indicates 310 helix. 
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Identification of Scp inhibitors 
Scps include three highly similar homologous family members in the human: 
Scp1, Scp2, and Scp3 (Yeo et al. 2003). Since no differences are found in the catalytic 
activities or biological functions of Scp1–3, they are thought to be functionally redundant 
(Yeo et al. 2005). Our structural studies of Scp1, 2 and 3 show little overall structural 
difference and no observable difference at the active site (Zhang Y, unpublished data). 
Furthermore, they display identical kinetic characteristics against para-nitrophenyl 
phosphate (pNPP) and phosphorylated CTD peptide (Kim Y and Dixon JE, personal 
communication). Therefore, we chose the best-characterized family member, Scp1, in the 
following studies. 
In order to identify the inhibitors for Scps, we screened a pilot library of the NIH 
clinical collection (~400 compounds) and spectrum collection (2000 compounds) for 
their ability to impede phosphatase activity of Scp1. The screening assay was performed 
using pNPP as the substrate at a concentration comparable to its Km (~6 mM). It was 
confirmed that Scp1 was stable under the assay conditions and can tolerate up to 10% 
DMSO. A Z’ factor of 0.87 was obtained using the optimized screening protocol.  
Thirty-nine compounds showed greater than 70% inhibition when screened at a 50 µM 
inhibitor concentration.   
To eliminate the false positives, we compared our initial hits with the 
collaborative drug discovery database (CDD) and identified eight compounds that are 
sufficiently soluble and less likely to be false positives. To further confirm the inhibitory 
effect of the compounds, we used a secondary assay to monitor phosphatase activity, 
where the CTD-derived phosphorylated peptide 
(Sa5Pa6Sa7Yb1Sb2Pb3Tb4Sb5Pb6Sb7Yc1Sc2Pc3Tc4phospho.Sc5Pc6Sc7) was used as the substrate 
and malachite green reagent was used to capture the released phosphate, and in doing so 
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produce a colorimetric signal. Five of the eight compounds showed inhibition for Scp1 
when using the natural substrate in the assay. Rabeprazole (Figure 4-3a), which showed 
the strongest inhibition, was further characterized to exhibit an IC50 of 4 ± 0.7 µM in the 
pNPP assay and 9 ± 3 µM in the malachite green assay, where the concentration of pNPP 
and phosphorylated peptide were 6 mM and 30 µM, respectively, close to their respective 
Km values (Figure 4-3b). To eliminate the possibility that the inhibitory effect of the 
compound was caused by protein denaturation, the thermal stability of Scp1 in the 
absence or presence of rabeprazole was tested in differential scanning fluorimetry assay 
(Niesen et al. 2007). Under the measurement condition, the melting temperature of Scp1 
is 57.8 °C and 59.1 °C in the absence and presence of the compound, respectively. This 
result excludes protein destabilization as the mechanism for the observed inhibitory effect 
of rabeprazole on Scp1 (Figure 4-4). 
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Figure 4-3: Inhibition of Scp1 by rabeprazole.20 
                                                 
20 (a) Structure of rabeprazole. The benzimidazole ring is in black. The methyl pyridine ring and methyl 
sulfinyl groups are in red. The methoxypropoxy tail is in blue. (b) Concentration-response of rabeprazole 
inhibition towards Scp1 tested by the pNPP assay and the malachite green assay. IC50 values were derived 
by fitting the data to the equation (1) in Materials and Methods. (c) Steady-state kinetics of Scp1 in the 
presence (blue) and absence (red) of rabeprazole. Inhibition constants were derived by fitting the data to 
equation (2) in Materials and Methods. 
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Figure 4-4: Melting curves measured by differential scanning fluorimetry (DSF).21 
In order to probe the mechanism of inhibition, the steady-state kinetics using both 
the pNPP and malachite green assays were determined. Kinetic analysis revealed that the 
compound is a mixed inhibitor for Scp1 against pNPP. The inhibition constants Ki and 
Ki’ of the compound was determined to be 5 ± 2 µM and 10 ± 2 µM using pNPP as the 
substrate. Interestingly, when the CTD-derived phosphorylated peptide was used as the 
substrate, rabeprazole exhibited characteristics of a competitive inhibitor: while the Ki 
was determined to be 5 ± 1 µM, the Ki’ was at least ten times higher than Ki, and could 
not be precisely determined (Figure 4-3c). Rabeprazole very likely directly competes 
with the natural substrate CTD peptide in binding to Scp1. 
                                                 
21 The samples are Scp1 only at 20 µM final concentration (a), Scp1 with 1% DMSO (b), Scp1 with 
rabeprazole at 100 µM final concentration plus 1% DMSO (c), and Scp1 with 17-mer peptide at 1mM final 
concentration (d). Each measurement was done in duplicates. 
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Complex structure of Scp1 and rabeprazole 
To understand the inhibition mechanism of rabeprazole at the molecular level, we 
attempted to obtain the structure of Scp1 and rabeprazole by X-ray crystallography. 
Unfortunately, crystals derived from the published conditions proved to be too fragile 
upon compound soaking. We therefore identified new crystallization conditions for 
wildtype Scp1 which yielded Scp1 crystals in much higher quality (see Materials and 
Methods). Unlike the original conditions, with high concentration of ammonium sulfate 
as precipitant, the crystals grown from the new polyethylene glycol (PEG)-based 
conditions are much more durable upon compound soaking. The complex structures were 
obtained by soaking the Scp1 crystals in buffer containing 0.1–1 mM rabeprazole and 
incubating for various amounts of time at 25 ºC. After optimization of soaking 
conditions, the crystals soaked in ~0.5 mM rabeprazole for 2–3 hr were used in X-ray 
data collection with good diffraction quality (Table 4-1).   
In all the data collected from multiple crystals, a strong area of electron density 
was observed at the hydrophobic pocket for recognition of the Pro3 of CTD substrate 
(Figure 4-5a). The final structure of the Scp1-rabeprazole complex was refined to 2.35 Å 
with the protein portion of the structure highly identical to apo Scp1 (Figure 4-6). 
Between the two molecules in each asymmetric unit, molecule A shows strong and 
consistent positive density at the active site, indicating effective compound binding. In 
comparison to molecule A, the density at the active site of molecule B is much weaker. 
Our subsequent discussion of protein and ligand interaction focuses on molecule A in 





Data collection Scp1-rabeprazole complex 
Space group C2 
Cell dimensions:           a, b, c (Å) 125.5, 78.3, 62.7 
                     α, β, γ (°) 90.0, 111.9, 90.0 
Resolution (Å) 50–2.35 (2.39–2.35) 
No. of unique reflections 21285 
Rsym or Rmerge (%) 10.0 (39.7) 
I/σ(I) 11.4 (1.6) 
Completeness (%) 90.2 (47.3) 
Redundancy 3.1 (2.2) 
Refinement  
Resolution (Å) 64.95-2.35 
No. of reflections (test set) 20188 (1097) 
Rwork / Rfree (%) 20.7/26.5 
No. of atoms:              Protein 2928 
                         Ion 2 
                         Ligand 25 
                         Water 112 
B-factors (Å2):              Protein 32.0 
                          Mg2+ 28.0 
                          Ligand 52.5 
                          Water 34.6 
R.m.s deviations:   Bond lengths (Å) 0.020 
                 Bond angles (°) 1.977 
Ramachandran plot (%): Most favored 85.7 
               Additionally allowed 13.7 
                 Generally allowed 0.3 
Table 4-1: Crystallographic data statistics.22 
                                                 
22 Highest resolution shell is shown in parenthesis. Rfree is calculated with 5% of the data omitted. 
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Figure 4-5: Complex structure of Scp1 and rabeprazole.23 
                                                 
23 (a) Structure of rabeprazole bound to Scp1 with the blue SIGMAA-weighted 2Fo-Fc electron-density 
map contoured at 1σ shown in stereo. (b) Surface representation of rabeprazole bound to the hydrophobic 
pocket of Scp1. (c) Superimposition of Scp1-rabperazole complex and Scp1-CTD peptide complex (PDB 
code: 2ght). The protein portion is identical. The hydrophobic pocket residues are shown in stick in cyan. 
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Figure 4-6: The SIGMAA-weighted Fo-Fc electron density map of Scp1 contoured at 
1.7σ. 
The total buried contact area of Scp1 upon rabeprazole binding is about 279 Å2. 
The shape complementarily (Sc) value is calculated to be 0.54 which indicates a good 
shape complementarity between the protein and ligand surfaces (an Sc value of 1 reflects 
a perfect fit). The most distinguishing characteristic of the compound binding is the site 
of interaction of the methyl pyridine ring at the hydrophobic pocket surrounded by 
Tyr158, Phe106, Val118, Ile120, Val127 and Leu155 (Figure 4-5b, c). The distances 
between the methyl pyridine ring and surrounding key residues are within 3.5–4.5 Å. The 
binding to this hydrophobic pocket is noteworthy as this “insertion domain” is unique for 
Scps and is believed to be the major structural element for the specific recognition of Pro3 
of the CTD (Zhang et al. 2006). Since the compound binds to the hydrophobic pocket of 
Scp1, it is likely to prevent Pro3 of the substrate from binding to the protein, explaining 
why the compound resembled a competitive inhibitor to Scp1 when the peptide was used 
as the substrate (Figure 4-5c). To further validate the binding mode of rabeprazole 
binding to Scp1, mutagenesis study around the hydrophobic binding pocket was 
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performed. Four mutants, including F106E, V127A, K157A and L155A, were tested by 
the pNPP assay. The IC50 of rabeprazole when tested against each mutant was derived 
from the concentration-response curve (Figure 4-7). It is clearly shown that F106E 
mutant increased IC50 by at least ten fold. The other mutants, V127A, K157A and 
L155A, all have moderately increased IC50, indicating some degree of loss of inhibition. 
The mutagenesis results show that the hydrophobic residues in the insertion domain are 
very important for inhibition of Scp1 by rabeprazole. 
The interaction of the sulfoxide group of rabeprazole and Tyr158 side chain 
resembles a cation-π interaction where the electron-rich π cloud of the phenyl ring of 
Tyr158 interacts with the partially positively charged sulfur of rabeprazole. Cation-π 
interactions are not uncommon in protein-inhibitor interactions and have been recognized 
as an important noncovalent interaction in structural biology (Dougherty 1996; Scrutton 
et al. 1996; Ma et al. 1997; Gallivan et al. 1999). For instance, the horse liver alcohol 
dehydrogenase is bound by its inhibitor sulfoxides through a cation-π interaction between 
the inhibitor and the benzene ring of Phe93 of the enzyme (Cho et al. 1997). In our 
structure, the sulfur atom locates directly over the phenyl ring of Tyr158. The distance 
between the sulfur atom and the center of phenyl ring is about 4 Å, which is within the 
range of typical distance for “amino-aromatic” interactions (Burley et al. 1986). Indeed, 
when we eliminated this cation-π interaction by mutating Tyr158 to Ala, a loss of 







Figure 4-7: Inhibition assay of Scp1 mutants.24 
It is likely that not all functional groups of rabeprazole contribute to Scp1 binding. 
Unlike pyridine ring and sulfoxide, the benzimidazole ring showed little if any electron 
                                                 
24 (a) Steady-state kinetics of Y158A, F106E, V127A, K157A and L155A tested by the pNPP assay. (b) 
Concentration response of rabeprazole inhibition towards Y158A, F106E, V127A, K157A and L155A 
determined by the pNPP assay. 
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density which suggests that this portion is flexible in our structure. Accordingly, the 
refinement of this part of the structure presents a higher thermal factor than the active site 
residues, thus we rebuilt our model with the benzimidazole ring as 50% occupancy. The 
refinement puts the group in a position that extends it outward of the active site, 
contributing little to the recognition of the inhibitor. In addition, the methoxypropoxy 
“tail” portion also showed partial densities consistently in multiple crystals. Although 
there are two oxygen atoms on the “tail”, no identifiable polar interactions were observed 
in our structure. It may also form hydrophobic interactions with the pocket, and the 
distances between the “tail” and surrounding hydrophobic residues are within 4–4.4 Å. 
It should be noted that the rabeprazole used in our structural studies is a mixture 
of two enantiomers with the sulfur as the chiral center. However, only (R)-rabeprazole 
can be built into the electron density whereas the S enantiomer does not fit the density 
well (Figure 4-8). We predict that only the R enantiomer binds the protein and exerts 
inhibitory effect. 
 
Figure 4-8: Model of (S)-rabeprazole bound to Scp1.25 
                                                 
25 The distance between the main chain oxygen of Ser104 and the benzoimidazole ring is 3.3 Å. 
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Selectivity of rabeprazole 
To evaluate the specificity of rabeprazole as a Scps inhibitor, we tested its 
inhibition against other Scp/Fcp family phosphatases including Fcp1 and Dullard, whose 
inactivation usually lead to cell death or improper development (Chambers et al. 1994; 
Archambault et al. 1997; Kobor et al. 1999; Satow et al. 2002). Such tests are not only 
important to evaluate the potential value of rabeprazole in biological applications, but 
also crucial for confirming the mechanism of the inhibition. In the Scp/Fcp phosphatase 
family, all enzymes share the same signature motif DXDX(T/V) for phosphoryl transfer. 
They all belong to the HAD superfamily (also called DXDX(T/V) superfamily) type III 
subfamily which predominantly act on protein substrates (Allen et al. 2004). 
The possible off-target inhibitory effect of rabeprazole was tested on the closest 
homologues of Scps: Schizosaccharomyces pombe (S. pombe) Fcp1 (Hausmann et al. 
2003; Ghosh et al. 2008) and human Dullard.  His-tagged S. pombe Fcp1 and His-GST-
tagged Dullard were purified to homogeneity and exhibit stable phosphatase activity 
(Figure 4-9). The steady-state kinetic studies of these enzymes were performed. The Km 
for Fcp1 and Dullard were determined to be 15 ± 3 mM and 10 ± 2 mM respectively, 
comparable with previously reported values (Hausmann et al. 2003; Kim et al. 2007). The 
concentration-response of inhibition was tested for both proteins using substrate 
concentrations comparable to the Km. No inhibition was observed for either enzyme when 






Figure 4-9: Steady-state kinetics of His-tagged Fcp1 and His-GST-tagged Dullard.26 
The observed specificity of rabeprazole can be explained structurally. The major 
interactions of rabeprazole with Scp are attributed to the insertion domain which is 
unique to the Scp/Fcp family and poorly conserved among the family member (Figure 4-
2c). For example, the three-stranded β sheet insertion domain in Scp1 is accessible for 
substrate recognition, whereas in Fcp1 it exhibits a different secondary structure and is 
buried by a helical insertion domain, suggesting a different binding interface between 
Fcp1 and the CTD with phospho.Ser2 (Figure 4-10b). Even though the Dullard structure 
has yet to be determined, the secondary structure is predicted to be different from the 
three-stranded β sheet as observed in Scp1. It is highly likely that rabeprazole does not 
inhibit human Dullard due to a different insertion domain in Dullard. 
Rabeprazole also exhibits no inhibition of λPPase, a Ser/Thr PPases outside the 




                                                 
26 The red data points in both plots indicate the no enzyme control of the pNPP reaction. 
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Figure 4-10: Inhibition of Fcp1 and Dullard by rabeprazole.27 
                                                 
27 (a) Concentration-response of rabeprazole inhibition towards S. pombe Fcp1 and human Dullard tested 
by the pNPP assay. (b) Superimposition of Scp1 (white) and S. pombe Fcp1 FCPH domain (pink, PDB 
code: 3ef0). The catalytic core folds of the two proteins are similar. The three-stranded β sheet insertion 
domain of Scp1 (cyan) is accessible for substrate recognition, whereas the insertion domain of Fcp1 
(yellow) exhibits different secondary structure and is buried by an additional helical insertion domain (light 
blue). 
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We next determined if rabeprazole analogues also exhibit inhibitory effect on 
Scps (Figure 4-11). Rabeprazole sulfone, a metabolite of rabeprazole (Klotz 2000) did 
not show any inhibition in our concentration-response assay (data not shown). The 
absence of inhibition might stem from the loss of cation-π interaction between the 
sulfoxide group and Tyr158 with the extra oxygen in rabeprazole sulfone. The result 
further demonstrates that the sulfoxide group is important for the Scp1-rabeprazole 
interaction and should be kept intact. 
Rabeprazole N-oxide (Figure 4-11), a contaminate during the rabeprazole 
synthesis process (Reddy et al. 2009), also exhibited no inhibition towards Scp1. It is 
likely that the change of the methyl pyridine ring interrupts or weakens the van del Waals 
interactions originally existing between the hydrophobic pocket residues and rabeprazole. 
Likewise, lansoprazole (marketed as Prevacid in U.S., Figure 4-11) which only 
differs from rabeprazole at the tail portion, showed no inhibition, probably because the 
electrons of pyridine ring are dramatically influenced by converting the ether to the 
trifluoromethyl group. It is equally likely that the shorter tail and significant change in 
hydrophobicity disrupt important contacts. Since the pyridine ring is important in making 
hydrophobic interactions with the protein, the changed electron distribution or changed 
hydrophobicity will likely weaken the hydrophobic interactions. 
Taken together, these results not only demonstrate the excellent specificity of 
rabeprazole, but also validate our strategy of targeting the hydrophobic binding pocket 
adjacent to the active site. To the best of our knowledge, rabeprazole is the first reported 






Figure 4-11: Structures of rabeprazole analogues.28  
Considerations on the clinic application of rabeprazole 
Rabeprazole is the active ingredient of an FDA-approved antiulcer drug AcipHex 
which is used to treat gastroesophageal reflux disease (GERD). In acidic environment 
such as lumen of gastric parietal cells, rabeprazole inhibits its target H+/K+ ATPase by 
forming a covalent bond with the active site cysteine under acidic condition (pH around 
1). Rabeprazole behaves as a pro-drug for GERD and only becomes activated in highly 
acidic condition through two protonations and a subsequent spontaneous rearrangement 
to form the active sulfenamide (Figure 4-12) (Roche 2006). However, we reason that 
rabeprazole does not inhibit Scp1 through this mechanism, since no cysteines participate 
in the catalysis of Scp1 and no covalent bond between rabeprazole and Scp1 was 
                                                 
28 The differences between the analogues and rabeprazole are indicated by thick lines. 
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observed in the complex structure (crystals obtained at neutral pH). This reasoning is 
corroborated by the fact that lansoprazole, another a proton pump inhibitor that shares the 
same mechanism with rabeprazole in treating GERD, does not inhibit Scp1. 
 
Figure 4-12: Mechanism of rabeprazole sodium inhibition of Cys-based enzymes. 
Further development of inhibitors with higher binding affinity 
Based on the complex structure of Scp1 and rabeprazole, further development of 
Scps specific inhibitors with higher affinity should be attainable. The important groups of 
this lead compound contributing to the binding are the methyl pyridine ring and methyl 
sulfinyl moieties. The benzimidazole ring seems to play little positive role if not 
hindering the compound binding, therefore, its replacement by other groups should be 
desirable. In our structure, no interaction of rabeprazole with the DXDX motif was 
observed. Further optimization can be explored by keeping the methyl pyridine ring and 
methyl sulfinyl groups of rabeprazole intact but changing other portions to explore 
interactions with the active site pocket.     
In conclusion, we successfully identified the first selective lead compound for the 
inhibition of Scps in our high-throughput screening efforts. Our kinetic and structural 
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analyses further confirmed its inhibitory effect towards Scp1 but not its close family 
members, Fcp1 and Dullard. Thus, rabeprazole represents the first specific inhibitor for 
Scp/Fcp family phosphatases and also the first inhibitor for type III HAD family 
members. The complex structure of Scp1 bound with rabeprazole clearly shows the 
binding mode of the small molecule. As we expected, rabeprazole binds to the unique 
hydrophobic pocket of Scps which, in natural context, binds to Pro3 of the CTD peptide. 
Since the hydrophobic pocket is located at the insertion domain which is unique to 
Scp/Fcp family members and shows diverse sequence among those family members, 
cross inhibition of other family members is prevented. The pyridine ring and sulfoxide 
groups are essential for this compound binding to Scp1. Other groups which may not 
substantially contribute to the binding can be optimized to make more potent inhibitors. 
The present study provides a starting point for the development of new inhibitors of Scps 
that can induce neuronal stem cell differentiation, which is of great interest in both basic 
and clinical research. 
MATERIALS AND METHODS 
Materials  
pNPP was purchased from Fluka, Sigma-Aldrich. CTD peptides were purchased 
from Anaspec. SYPRO orange dye was purchased from Invitrogen. The S. pombe Fcp1 
cDNA was purchased from National BioResource Project (NBRP)-Yeast Genetic 
Resource Center (Osaka City University, Osaka, Japan). Malachite green reagent was 
purchased from BIOMOL, Enzo Life Sciences. Rabeprazole and rabeprazole analogues 
were purchased from Toronto Research Chemicals, Inc., and the identity and purity of 
each compound was confirmed by our in-house mass spec facility. 
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Cloning, protein expression and purification 
Wildtype or mutant human Scp1, residues 77–256, was sub-cloned and expressed 
in E.coli BL21(DE3) strain using pHIS8 vector encoding a thrombin cleavable N-
terminal octa-histidine tag (Jez et al. 2000). The expression of Scp1 was induced in E.coli 
at low temperature (16 °C) with 250 µM IPTG and allowed to accumulate to high levels 
overnight (16 hr). Cells were harvested and re-suspended in lysis buffer (0.5 M NaCl, 15 
mM imidazole, 50 mM Tris-HCl pH 8.0, 10% (v/v) glycerol and 0.1% (v/v) Triton X-
100). Then the cells were sonicated. After sonication, cell debris was removed by 
centrifugation. The supernatant was incubated with Ni2+-NTA affinity beads at 4 ºC for 
20 min, then loaded onto a column and washed extensively with the lysis buffer minus 
Triton X-100. Nearly homogeneous Scp1 was eluted with the lysis buffer minus Triton 
X-100 but including 150 mM imidazole. Eluted protein was dialyzed into 25 mM Tris-
HCl pH 8.0, 50 mM NaCl, 10 mM β-mercaptoethanol and stored at a concentration of 2 
mg/ml at 4 °C. Samples for protein x-ray crystallography were subjected to thrombin 
processing to remove the octa-histidine tag followed by size exclusion chromatography 
for final cleanup. These samples were stored in 20 mM Tris-HCl pH 8.0, 50 mM NaCl, 
10 mM β-mercaptoethanol at a concentration of 8–10 mg/ml at –80 °C. 
Wildtype S. pombe Fcp1, residues 148–641, was also sub-cloned into pHIS8 
vector. Wildtype human Dullard, residues 46–244, was sub-cloned into engineered 
pET28 vector encoding a 3C protease cleavable N-terminal His-GST tag. The expression 
and purification of human Dullard and yeast Fcp1 followed the same protocol as Scp1 
with minor modifications. The protein samples were stored in the buffer containing 20 
mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM β-mercaptoethanol and 10% glycerol. 
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High-throughput screening 
The high-throughput screening was performed in 384-well plates using pNPP as 
the substrate. We screened a library of NIH clinical collection (~400 compounds) and 
spectrum collection (2000 compounds) in our local high-throughput facility TI3D. The 
proteins were pre-incubated in the presence of 50 µM compounds in 0.8% DMSO at 
room temperature for 10 min. All the screening reactions (10 µl) were carried out at 
37 °C in Master Buffer (50 mM Tris-acetate pH 5.5, 10 mM MgCl2, 0.02% Triton X-100, 
0.5% DMSO) with 25 ng of Scp1, and pNPP concentration at its Km (6 mM). The 
reactions were quenched by addition of 40 µl of 0.25 N NaOH after 10 min of reaction.  
Release of pNP was determined by measuring absorbance at 410 nm. 
pNPP assay 
The activity of each phosphatase toward pNPP in the absence or presence of 
inhibitor was measured in Assay Buffer (50 mM Tris-acetate pH 5.5, 10 mM MgCl2, 
0.02% Triton X-100, 1% DMSO) with appropriate amount of protein (50 ng of Scp1 or 
Scp1 mutants, 5 µg of Dullard or Fcp1) at 37 oC in 20 µl volume. When inhibitor was 
included, protein and inhibitor were pre-incubated in Assay Buffer at room temperature 
for 10 min in 15 µl volume. After 10–15 min of reaction, the reactions were quenched by 
adding 80 µl of 0.25 N NaOH. Released pNP was quantified by measuring absorbance at 
410 nm. 
Malachite green assay 
The activity of Scp1 toward 17-mer Ser5-phosphorylated peptide 
(Sa5Pa6Sa7Yb1Sb2Pb3Tb4Sb5Pb6Sb7Yc1Sc2Pc3Tc4phospho.Sc5Pc6Sc7) in the absence or 
presence of inhibitor was measured in Assay Buffer with 5 ng of Scp1 at 37 oC in 20 µl 
volume. When inhibitor was included, protein and inhibitor were pre-incubated in Assay 
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Buffer at room temperature for 10 min in 15 µl volume. After 3 min of reaction, the 
reactions were quenched by adding 40 µl of malachite green reagent. The release of free 
inorganic phosphate was determined by measuring the absorbance at 620 nm. 
Determination of steady-state and inhibition constants 
The raw absorbance readings were exported to Excel for further processing. For 
all reactions, a corresponding mock reaction containing everything but the protein was set 
up. The absorbance reading of a mock reaction was treated as background and used to 
subtract the raw absorbance readings of the corresponding true reaction, resulting in a 
processed absorbance reading caused by the product of the reaction. In the following text 
the term ‘absorbance’ is used to refer to ‘processed absorbance reading’. When 
necessary, the absorbance was converted to concentration of product using a standard 
curve that was established beforehand. 
To determine the IC50 of rabeprazole towards Scp1 (or Scp1 mutants), the relative 
activity of enzyme were determined by dividing the absorbance at each inhibitor 
concentration by the absorbance of positive control ([I] = 0). The relationship between 









=         (1)  
where Y is relative activity of enzyme, x is the inhibitor concentration, H is hill 
coefficient. 
To determine steady-state constants (Vmax and Km) and inhibition constants (Ki 
and Ki’), the initial rate of reaction was obtained by dividing the product concentration by 
incubation time. The linearity of kinetics during such periods of time had been 
confirmed. The Vmax and Km values were obtained by fitting initial rates v.s. substrate 
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concentrations (in the absence of inhibitor) into Michaelis-Menten equation. Once the 
Vmax and Km are determined, the initial rates v.s. substrate concentrations in the presence 







=         (2) 
where V and [S] are initial rate and substrate concentration, respectively; Vmax and Km are 
pre-determined; α and α' are used to calculate Ki and Ki’ using equations (3) and (4): 
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All non-linear fittings were carried out using the ‘nlinfit’ function of Matlab. 
Differential scanning fluorimetry 
The method was modified based on a published protocol (Niesen et al. 2007). 
Wildtype Scp1 was mixed with rabeprazole in the reaction containing 20 mM HEPES 
pH7.5, 50 mM NaCl, 1% DMSO, and 5× SYPRO orange dye. The final concentrations of 
protein and rabeprazole were 20 µM and 100 µM, respectively. The unfolding process of 
protein was monitored during the temperature increase from room temperature to 85 °C 
by LightCycler 480 machine (Roche). The protein only, protein with 1% DMSO and 
protein with 1 mM peptide were used as controls. The denature process of the protein was 
fitted into a monophase graph and the Tm was derived using the LightCycler 480 Protein 
Melting Software. 
Crystallization and structure determination  
Wildtype Scp1 was crystallized in 30% PEG 3350 and 0.2 M magnesium acetate. 
Crystals were transferred to a stabilizer consisting of the same buffer condition and 0.1–1 
mM inhibitor. After soaking for 2–12 hrs, crystals were transferred to a cryo-protecting 
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stabilizer containing 30% (v/v) glycerol, 25% (w/v) PEG 3350, and 0.2 M magnesium 
acetate. After a brief period of equilibration, crystals were frozen in nylon loops in liquid 
nitrogen and stored in liquid nitrogen prior to data collection. Crystallographic data were 
collected at 100 K on beam-line 5.0.2 of the Advanced Light Source (ALS). Diffraction 
data were processed with HKL2000 (Otwinowski et al. 1997). The complex crystal 
structures of Scp1 were determined by molecular replacement (MR) using the Scp1D96N 
structure as a search model (PDB code: 2ghq) using the program PHASER (McCoy et al. 
2007) available in the CCP4 software package (CCP4 1994). MR solutions were refined 
using REFMAC5 (Vagin et al. 2004), reserving 5% of the measured and reduced 
structure factor amplitudes as an unbiased test set for cross validation (Rfree) (Brunger 
1992). The inhibitor library was created by SKETCHER also available in the CCP4 
software package. The model was built by COOT (Emsley et al. 2004) and refined by 
REFMAC5. The buried contact area of Scp1 by the compound and shape 
complementarity (Sc) were calculated by AREAIMOL (Lee et al. 1971) and SC 
(Lawrence et al. 1993) available in the CCP4 software package. 
ACCESSION CODE 
Coordinates of the Scp1-rabeprazole complex structure have been deposited in the 
Protein Data Bank with the accession number 3PGL. 
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Chapter 5:  Potential Secondary Regulatory Site of Scp1 
INTRODUCTION 
Accurate transcription of genetic information is essential for cell survival. In 
eukaryotes, the major player of transcription is RNA polymerase II, responsible for the 
transcription of protein-coding genes as well as mammalian snRNA genes and yeast 
snoRNA genes (Egloff et al. 2008). The C-terminal domain (CTD) of RNA polymerase II 
forms a tail-like peptide chain extended from the catalytic core and resides closed to the 
RNA exit channel of the enzyme. In addition, a wealth of evidence reveals that CTD is an 
important mediator in coupling mRNA transcription, mRNA processing, DNA repair and 
other cellular processes (Egloff et al. 2008). This unusual structure serves as a docking 
platform for a variety of factors involved in transcriptional and co-transcriptional events. 
Although the CTD undergoes very complicated modifications and regulates 
various cellular processes, the primary sequence of the CTD is surprisingly simple. The 
CTD consists of multiple tandem heptapeptide repeats of the consensus sequence: 
Tyr1Ser2Pro3Thr4Ser5Pro6Ser7. The number of repeats is different from species to species 
(Egloff et al. 2008). There is a minimum length of the CTD, which is required for normal 
cell growth and function in many species (Chapman et al. 2007). All the transcriptional 
events are highly related to the conformations and modifications, particularly 
phosphorylation patterns, of the CTD. Different phosphorylation patterns are the major 
component of the “CTD code” which orchestrates the function of RNA polymerase II 
(Figure 5-1). Moreover, different phosphorylation patterns could specifically recruit 
essential factors to the vicinity of genes, conferring success and possessiveness of 
transcriptional and co-transcriptional events. 
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Figure 5-1: Schematic diagram of “CTD code” and its important role in modulating 
RNA polymerase II activity. 
Although there are five potential phosphorylation sites in the CTD consensus 
sequence, including Tyr1, Ser2, Thr4, Ser5 and Ser7, CTD phosphorylation occurs mainly 
at residues Ser2 and Ser5 in vivo (Figure 5-1). In each round of transcription, Ser5 
phosphorylation occurs in promoter-proximal regions coincident with initiation and 
facilitates mRNA capping via recruiting capping enzymes (Cho et al. 1997; Komarnitsky 
et al. 2000). During the process in which the transcription complex moves away from the 
initiation site, Ser5 gradually becomes hypophosphorylated, whereas Ser2 gradually 
becomes hyperphosphorylated. Ser2 phosporylation is the predominating pattern on both 
elongation and termination steps. Ser2 phosphorylation ensures efficient 3'-RNA 
processing by triggering the recruitment of 3'-RNA processing machinery. Ser2 and Ser5 
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phosphorylation have been extensively studied; however, until recently the biological 
functions of phosphorylation at sites other than Ser2 and Ser5 have not been fully 
addressed. Only recently, Tyr1, Thr4 and Ser7 have also been observed being 
phosphorylated in vivo in certain scenarios (Chapman et al. 2007; Hsin et al. 2011; 
Hintermair et al. 2012; Mayer et al. 2012). Two recent works suggest that Ser7 
phosphorylation occurs during transcription and is required for snRNA expression in 
humans. It is shown that Ser7 phosphorylation occurs on both mRNA and snRNA genes 
and facilitates interaction with the snRNA gene-specific integrator complex (Chapman et 
al. 2007; Egloff et al. 2007). 
A range of enzymes participate in the dynamic modifications of the CTD, 
including kinases and phosphatases responsible for the addition and removal of 
phosphates (Bataille et al. 2012). The CTD is principally phosphorylated by cyclin-
dependent kinases (CDKs). Specifically, Ser5 phosphorylation is mainly catalyzed by the 
general transcription factor IIH (TFIIH) which contains Cdk7/cyclin H subunits (Lu et al. 
1992; Hengartner et al. 1998); Ser2 phosphorylation is mainly catalyzed by the positive 
transcription elongation factor b (P-TEFb) which contains Cdk9/cyclin T subunits (Zhou 
et al. 2000; Shim et al. 2002). Intriguingly, it is suggested that Cdk9 also makes a 
contribution to Ser5 phosphorylation (Garber et al. 2000; Gomes et al. 2006) and the 
relative contribution of TFIIH-associated Cdk7 varies between different genes based on 
experimental observations. Moreover, the CTD can also be phosphorylated at both Ser2 
and Ser5 by Cdk8, and preferentially be phosphorylated at Ser5 by mitogen-activated 
protein kinase 2 (MAPK2/Erk2). Recently, TFIIH-associated Cdk7 kinase has also been 
identified to phosphorylate Ser7 in vivo (Glover-Cutter et al. 2009). 
Dephosphorylation negatively controls the activity of RNA polymerase II and 
makes a significant contribution to the changes in the “CTD code”. More importantly, it 
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is thought to be essential in recycling RNA polymerase II, because the CTD has to be 
dephosphorylated at the end of transcription in order to actively restart a new round of 
transcription. In humans, Transcription factor II F (TFIIF) interacting CTD phosphatase 1 
(Fcp1), which is required for general transcription and cell viability, was the first 
discovered CTD-specific phosphatase with the catalytic preference for phospho.Ser2. 
Later on, Ssu72 was identified to be a CTD-specific phosphatase, targeting on the 
phospho.Ser5 (Krishnamurthy et al. 2004). Like Fcp1, Ssu72 is also considered to be a 
house-keeping gene whose deletion will result in cell death in yeast. On the contrary, a 
group of phosphatases called small CTD phosphatases (Scp’s), which are also identified 
to dephosphorylate Ser5, function at the epigenetic level and regulate the expression of a 
subset of genes. Scp’s were identified to inhibit neuronal gene transcription in non-
neuronal cells by acting as a co-repressor in REST/NRSF complex (Yeo et al. 2005). 
Scp’s are expressed broadly in non-neuronal tissues but are largely excluded from the 
adult nervous system. The expression pattern of Scp’s in human tissues parallels with that 
of REST/NRSF [which stands for repressor element 1 (RE-1)-silencing transcription 
factor/neuron-restrictive silencer factor] complex, the best-characterized transcription 
factors that regulate the expression of neuronal genes globally. Interestingly, dominant 
negative form of Scp1 (Scp1D96N) can de-repress the neuronal differentiation. 
Although a large body of knowledge regarding the function of CTD has 
accumulated, there remains many questions to be answered in order to fully decipher the 
CTD code, for example, how the CTD enzymes are targeted to regulate general or gene-
specific transcription, how Scps respond to the bivalent modification marks, etc. 
Previously, we have shown the complex structures of Scp1 and CTD-derived peptides, 
providing a detailed binding mode of the CTD. Although CTD peptides with different 
lengths and phosphorylation patterns were soaked into the Scp1 crystals, the same 
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binding mode in multiple crystals was observed. The S2P3T4(p.S5) adopts a beta turn 
conformation which is recognized by the active site groove of Scp1. The trans Pro3 at the 
N-terminal of the phospho.Ser5, which is accommodated by the adjacent hydrophobic 
pocket, is crucial for the substrate specificity. However, one point worth mentioning is 
that the CTD is a very long tail and thus may have larger content area with Scp1. 
Therefore, in this study, we extended our studies to further investigate the binding mode 
of the CTD with Scp1 as well as how Scp1 functions on the CTD. Interesting 
observations were made based on X-ray crystallographic study. In addition, detailed 
kinetic studies were performed to further demonstrate the functional mode of Scp1 on the 
CTD. 
RESULTS AND DISCUSSION 
Complex structures of Scp1D96N mutant and the CTD-derived peptides 
Obtaining the complex structure of Scp1 and its substrate CTD is of necessity to 
understand how Scp1 recognizes and regulates the CTD. In our previous study, we 
crystallized the dominant negative mutant of Scp1, Scp1D96N, and the CTD peptides 
through crystal soaking method (Zhang et al. 2006). These peptides were different in 
length and modification (Table 5-1). The structures of multiple crystals complexed with 
different peptides were solved. There are two interesting observations from these crystal 
structures. Firstly, consistent with the kinetic study that Scp1 is much more active toward 
phospho.Ser5, only the phospho.Ser5 is observed in the active site whereas the 
phospho.Ser2 flips out of the active site, making no direct interaction with the protein 
(Zhang et al. 2006). Secondly, in both 9-mer and 14-mer phospho.Ser5 peptides, only 
eight residues [Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7] showed strong electron density (Zhang et al. 
2006), indicating that this segment is stably bound by the protein. 
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Number Length Sequence 
Previous Structural Study 
1 9-mer                               Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
2 9-mer                            Pa6Sa7Yb1(p.Sb2)Pb3Tb4(p.Sb5)Pb6Sb7 
3 14-mer               Ya1Sa2Pa3Ta4(p.Sa5)Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
4 14-mer               Ya1Sa2Pa3Ta4Sa5Pa6Sa7Yb1(p.Sb2)Pb3Tb4(p.Sb5)Pb6Sb7 
5 14-mer               Ya1(p.Sa2)Pa3Ta4Sa5Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
Current Structural Study 
6 17-mer          Sz5Pz6Sz7Ya1Sa2Pa3Ta4Sa5Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
7 20-mer  Sz2Pz3Tz4Sz5Pz6Sz7Ya1Sa2Pa3Ta4Sa5Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
Current Kinetic Study 
8 14-mer                  Ya1Sa2Pa3Ta4Sa5Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
6 17-mer          Sz5Pz6Sz7Ya1Sa2Pa3Ta4Sa5Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
9 17-mer       Sz5Pz6(p.Sz7)Ya1Sa2Pa3Ta4Sa5Pa6Sa7Yb1Sb2Pb3Tb4(p.Sb5)Pb6Sb7 
Table 5-1: CTD peptides used in the previous and current studies. 
 
But we reasoned that since the CTD is very long, there may be extended contact 
area between the CTD and Scp1 in the cells. To test this hypothesis, Scp1D96N mutant 
crystals were soaked in the buffer containing 17-mer or 20-mer synthetic peptide with a 
single phospho.Ser5 (Table 5-1). These two peptides contain two full repeats and several 
more residues at the N-terminus. Expectantly yet still intriguingly, in both crystals, we 
observed strong and beautiful electron density of seventeen residues from Serz5 to Serb7 
(Figure 5-2). The crystallographic statistics of the Scp1D96N and 17-mer peptide 
complex are summarized in Table 5-2. Compared with the previous complex structure of 
Scp1D96N and the 14-mer peptide, the complex structure of Scp1D96N and the 17-mer 
phospho.Ser5 peptide has nine more residues clearly shown, although only three more 
residues (Sz5Pz6Sz7) were included in the 17-mer peptide. The newly obtained complex 
structures implied the existence of larger contact area and more stable binding formed 
between Scp1 and the CTD. It is surprising to see such large contact area by extending 
only three residues of the peptide. It is possible that these three additional residues make 
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important interactions with the protein; however, it is also likely that these three residues 
are not very important per se but facilitate the interaction between other residues and the 
protein. Besides the original interactions observed in the previous structures, the 
additional eight residues largely form hydrophobic interactions with the protein. The 
phenol ring of Tyrb1 of the peptide and the side chain of Ile120 of Scp1 forms amino-
aromatic interaction (Figure 5-3). The Proa6 and the imidazole ring of His125 form a pi-
stacking interaction (Figure 5-3). There are also some hydrophilic interactions involved. 
For instance, the side chain of Sera7 is 2.6 Å away from the carbonyl oxygen of Asp121, 
indicating the possibility of forming hydrogen bonds (Figure 5-3). The total buried 
surface of the protein by binding to the peptide is about 701.3 Å2, and it has a surface 
complementarity (Sc) value of 0.814. 
Figure 5-2: Complex structure of Scp1 and the 17-mer peptide. 
Interestingly, in the crystal soaked with 17-mer peptide, a tetrahedral shaped 
electron density was observed in between the protein and the peptide. In the 
crystallization condition, there was an excess amount of ammonium sulfate as the 
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precipitant, therefore we built a sulfate group into the density. However, when 
considering the environment in the cell, this sulfate-binding pocket might incorporate a 
phosphate group of the phosphorylated CTD. If so, this interaction might position Scp1 in 
the vicinity of other phosphorylation sites on the CTD for essentially higher local 
concentration of substrate. Because of the close proximity between the observed sulfate 
group and Ser7, it is reasonable to hypothesize that phospho.Ser7 might occupy this 
pocket and recruit Scp1 to the CTD. Moreover, it also possible that such phospho.Ser7 
might function as a docking site for Scp1 so that Scp1 can catalyze the dephosphorylation 
of Ser5 on multiple sites of the CTD without dissociating from it (Figure 5-4). This 
notion is strongly fortified with the recent discovery that TFIIH can phosphorylate both 
Ser5 and Ser7, making the co-existence of phospho.Ser5 and Ser7 a very common species. 
Therefore, it is highly plausible that Ser7 phosphorylation might play a role in the 
phosphorylation state of Ser5. 
 
Figure 5-3: Some potential interactions between the 17-mer peptide and Scp1. 
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Figure 5-4: Proposed processivity model of Scp1. 
Kinetic analysis of the possible processivity model of Scp1 dephosphorylation 
To initially examine whether the phospho.Ser7 can contribute to the substrate 
binding, we tested the steady-state kinetics of Scp1 toward these two peptide substrates: 
one with both Ser5 and Ser7 phosphorylated, and the other with only Ser5 phosphorylated 
(Table 5-1). If phospho.Ser7 enhances the reactivity of CTD peptide towards Scp1, some 
increase of activity, most likely through decreased Km, is expected. However, no 
difference was observed by comparing the kinetic parameters (Figure 5-5). There are two 
possibilities that can account for the data. One is that the Ser7 phosphorylation has no 
effect on the substrate binding since the alternative binding site may not recognize 
phospho.Ser7 at all. The other (unlikely but intriguing explanation) is that phospho.Ser7 
binds to the alternative binding site extremely tight so that the effect of this binding is not 
apparent in a multi-turnover reaction. If the second scenario is true, we would expect 
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dramatic processivity of Scp1 in true processivity assays. To perform these assays, 
phosphorylated substrates with multiple repeats were prepared. 
GST-CTD was used as a model substrate in our processivity assays. In this 
system, yeast full length CTD was expressed as a fusion protein with GST to mimic the 
native Rpb1-CTD as well as ensure good solubility. Previous studies have shown that 
Erk2-treated GST-CTD is phosphorylated at Ser5 in each repeat, and TFIIH-treated GST-
CTD is phosphorylated at both Ser5 and Ser7. If the kinase treatment is done in the 
presence of radio-labeled ATP, [γ-32P]ATP, we can then monitor the dephosphorylation 
of these two substrates by radioautography. The yeast GST-CTD was expressed in E.coli, 
purified to ≥90% homogeneity, and fully treated with TFIIH or Erk2 in the presence of 
[γ-32P]ATP. The treated substrates were used in the following experiments. 
 
Figure 5-5: Steady-state kinetics of Scp1 toward 17-mer Ser5Ser7 phosphorylated 
peptide and Ser5 phosphorylated peptide. 
We first tested the activity of Scp1 toward these two GST-CTD substrates 
(phosphorylated by Erk2 and TFIIH) by varying the protein concentrations while keeping 
the substrate concentration constant. The result clearly showed that the TFIIH-treated 
substrate, which has both Ser5 and Ser7 phosphorylated, is a better substrate for Scp1 
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(Figure 5-6). But whether this observation is due to the binding between the alternative 
binding site and phospho.Ser7 still remains a question. In order to test our processive 
model, a rapid dilution assay was performed. In this assay, Scp1 and TFIIH-treated GST-
CTD were mixed at high concentration, incubated for a short period of time, and then the 
mixture was diluted 50-fold with the buffer. After dilution, a fraction of the mixture was 
taken out at each time point, quenched by protein gel loading dye, and resolved by SDS-
PAGE. If our processive model is true, we would expect that the koff rate between the 
GST-CTD and the protein is very low. And in this case, if we allow the protein and 
substrate to bind with each other at high concentration, they should form very stable 
complex. Even if the mixture is diluted, they should still associate with each other and the 
reaction can proceed in the diluted mixture. However, it is important to make sure that 
new complexes between the protein and substrate are not formed in the diluted mixture. 
To make sure this is the case, in the control group, diluted GST-CTD and Scp1 were 
directly mixed to the final volume. 
 
Figure 5-6: Activity of Scp1 on the GST-CTD substrates treated with different kinases.  
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Our result showed that, after the dilution, the reaction no longer continued 
(Figure 5-7). If the binding pocket has a low koff, we would expect to see decreasing of 
band intensity over time in the rapid dilution group. However, this result did not 
completely disprove our model as there are two explanations for this result. One 
possibility is that the enzyme is distributive. The other possibility is that: the enzyme is 
processive and is extremely fast. The second scenario means that either the enzyme and 
substrate do not meet with each other, or when they meet, the enzyme completely 
dephosphorylates the substrate rapidly. 
To discriminate the above two possibilities, we performed a gel shift assay. The 
prerequisite of this assay is that GST-CTD substrates with different numbers of 
phosphorylations have different migration rates on SDS-PAGE and will appear at 
different positions on the gel. If our processive model is true, we should see two major 
species on the gel after dilution with one corresponding to fully phosphorylated GST-
CTD, the other corresponding to hypophosphorylated GST-CTD. On the contrary, if the 
enzyme is distributive, then we would expect to see a smear on the gel, indicating various 
intermediates with different numbers of phosphorylation sites. In this assay, the density 
of each band on the gel was converted to a peak for easy observation and analysis. The 
result showed that there were different intermediates present in the mixture over time as 
indicated by the peak shift (Figure 5-8). This experiment, together with the previous 
supporting experiments, demonstrates that Scp1 is a distributive enzyme rather than a 
processive enzyme when dephosphorylating TFIIH-treated CTD substrate. 
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Figure 5-7: The result of rapid dilution assay showed that the reaction no longer 
continued after the dilution.29  
The sulfate group may be a mimic of phosphate group from sites other than Ser7  
Though our kinetic analysis indicated that the sulfate group is not a mimic of 
phospho.Ser7 to confer processivity of Scp1, it could be a mimic of phosphate group from 
other sites. Since more and more modifications on the CTD have been discovered, the 
combinatory effects between two or more modifications of the CTD on its binding 
proteins seem plausible. We then wanted to see if any of the combinatory effects were 
present that could potential affect the dephosphorylation by Scp1. The possible 
phosphorylation sites other than Ser7 would be Tyr1 and Ser2. The synthetic peptides with 
both Ser5 and Tyr1 phosphorylated or Ser5 and Ser2 phosphorylated (Table 5-1) were 
used as substrates in our steady-state kinetic analysis. However, no substantial change of 
Scp1 activity was observed. Scp1 is not a processive enzyme in all of our assays, but it 
might be processive in cells in the presence of some binding partners. 
                                                 
29 The protein and the GST-CTD peptide were pre-incubated for about 8 min. 
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Figure 5-8: The result of the gel shift assay. The intensity of each band was converted to 
the peak on the right.  
The extra three residues of the 17-mer peptide provide additional contact 
Since the kinetic analysis demonstrated that the additional phosphorylation from 
any of the three residues (i.e. Ser7, Tyr1 and Ser2) does not influence the activity of Scp1, 
we turned our focus to the extra three residues of the 17-mer peptide compared with the 
14-mer peptide. Steady-state kinetics experiments were performed to probe whether this 
extra contact was biochemically relevant, and not just a crystallographic artifact. The 
activity of Scp1 toward the 14-mer and the 17-mer peptide was tested. As expected, the 
extra three residues makes the 17-mer peptide a much better substrate as indicated by 




Figure 5-9: Steady-state kinetics of Scp1 toward 14-mer peptide (a) and 17-mer peptide 
(b). 
We next measured the binding affinity between Scp1 and the 14-mer or 17-mer 
peptide. While the Kd value between Scp1 and the 14-mer peptide was about 261 ± 21 
µM, the Kd value between Scp1 and the 17-mer peptide was greatly reduced to 46 ± 8 
µM. These results demonstrated that the contact between the extra three residues of the 
17-mer peptide and the protein is indeed present in solution, at least in our in vitro 
system. The additional contact makes the 17-mer peptide bind to Scp1 much better, 
resulting in a faster dephosphorylation by the protein. 
The repetitive nature of the CTD may require modifying enzymes, e.g. kinases 
and phosphatases, to function in a processive way to ensure efficient control of the 
transcription during the transcription cycle. Based on our crystallographic results, we 
hypothesized that Scp1 could be a processive enzyme by binding strongly to the 
phospho.Ser7. However, in our in vitro system, we did not observe a strong processivity 
of Scp1 in the presence of phosphorylated Ser7, Tyr1 or Ser2. On the other hand, the 
combinatory effect of the phosphorylation of the residues besides Ser5 was not observed 
a b 
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for Scp1. All other potential phosphorylations on the CTD besides Ser5 did not influence 
the activity of Scp1 in vitro. In cells, the activity of Scp1 may be regulated by other 
modifications on the CTD via regulation of its binding partners. Moreover, other 
phosphatases, for example Ssu72, may be processive enzymes or be significantly 
regulated by other modifications on the CTD. Our data for the first time demonstrate that 
the long CTD has additional contact area with the protein in addition to the interaction at 
the active site. The large contact area makes the CTD bind to the Scp1 much better and is 
more readily dephosphorylated by the Scp1. In addition, our results show that there is a 





Data collection Scp1-17-mer peptide complex 
Space group C2 
Cell dimensions:           a, b, c (Å) 124.9, 78.3, 62.8 
                     α, β, γ (°) 90.0, 112.6, 90.0 
Resolution (Å) 50.0–2.29 (2.33–2.29) 
No. of unique reflections 25291 
Rsym or Rmerge (%) 10.0 (48.9) 
I/σ(I) 12.8 (2.2) 
Completeness (%) 99.7 (99.9) 
Redundancy 3.7 (3.7) 
Refinement  
Resolution (Å) 64.8-2.29 
No. of reflections (test set) 24000 (1288) 
Rwork / Rfree (%) 18.0/23.3 
No. of atoms:              Protein 2928 
                         Mg2+ 2 
                         Ligand 181 
                         Water 166 
B-factors (Å2):              Protein 30.2 
                          Mg2+ 24.1 
                          Ligand 42.9 
                          Water 36.4 
R.m.s deviations:   Bond lengths (Å) 0.022 
                 Bond angles (°) 1.941 
Ramachandran plot (%): Most favored 87.2 
               Additionally allowed 11.6 
                 Generally allowed 1.2 
Table 5-2: Crystallographic data statistics.30 
METHODS 
Cloning, protein expression and purification 
Wildtype and mutant Scp1 were purified using the method described previously 
in Chapter 3. Yeast CTD was sub-cloned from Saccharomyces cerevisiae (S. cerevisiae) 
genomic DNA into a pGTVL2 vector which contains a His-tag followed by a GST-tag at 
                                                 
30 Highest resolution shell is shown in parenthesis. Rfree is calculated with 5% of the data omitted. 
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the N-terminus. The GST-CTD fusion protein was expressed in E.coli BL21(DE3) strain 
and purified using the same method for Scp1. 
Malachite green assay 
The activity of Scp1 toward the CTD peptides was measured in Assay Buffer (see 
Chapter 4) with 5 ng of Scp1 at 37 oC in 20 µl volume. The reactions were quenched by 
adding 40 µl of malachite green reagent. The release of free inorganic phosphate was 
determined by measuring the absorbance at 620 nm. 
X-ray crystallography 
For crystal soaking, the Scp1D96N proteins were crystallized in previously 
identified conditions. The crystals soaked with 20-mer peptide were crystallized in the 
buffer containing 0.5–0.8 M ammonium sulfate, 100 mM HEPES-Na+ pH 7.0, and 0.2 M 
lithium sulfate. The crystals soaked with 17-mer peptide were crystallized in a different 
condition containing 25% polyethylene glycol (PEG) 3350 and 0.2 M magnesium 
acetate. Crystals were transferred to a cryo-protecting stabilizer containing 30% (v/v) 
glycerol, 25% (w/v) PEG 3350, and 0.2 M magnesium acetate. After a brief period of 
equilibration, crystals were frozen in nylon loops in liquid nitrogen and stored in liquid 
nitrogen prior to data collection. Crystallographic data were collected at 100 K on beam-
line 5.0.2 of the Advanced Light Source (ALS). Diffraction data were processed with 
HKL2000. The complex crystal structures of Scp1 were determined by molecular 
replacement (MR) using the Scp1D96N structure as a search model (PDB ID: 2ghq) 
using the program PHASER available in the CCP4 software package. MR solutions were 
refined using REFMAC5, reserving 5% of the measured and reduced structure factor 
amplitudes as an unbiased test set for cross validation (Rfree). The model was built in 
COOT and refined by REFMAC5. The buried contact area of Scp1 by the peptide and 
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shape complementarity (Sc) were calculated by AREAIMOL and SC available in the 




GST-CTD was treated with either TFIIH (Millipore) or MAPK2/Erk2 (NEB) in 
the presence of [γ-32P]ATP and 2 mM cold ATP. The labeling reactions were carried out 
at 30 °C overnight to ensure complete phosphorylation. 
Phosphatase assay using labeled GST-CTD 
All the dephosphorylation reactions (20 µl total volume) were performed in the 
Reaction Buffer containing 50 mM Tris-HCl pH 7.9, 10 mM MgCl2, 20% glycerol, 
0.02% triton X-100, 20 mM KCl, and 5 mM Dithiothreitol (DTT). Each reaction 
contained about 1 pmol 32P-labeled GST-CTD and a certain amount of Scp1 (0-1.34 
pmol). The reactions were carried out in 30 °C for different periods of time. At each time 
point, 5 µl of the reaction was taken out and quenched by adding 2x Laemmli buffer. The 
reaction products were resolved on a 12 % SDS-PAGE gel. The gel images were 
developed by radioautography. The gel shift assay was done using the similar procedure, 
but the SDS-PAGE was supplemented with 50 mM phosphate-binding compound (AAL-
107) in the presence of Mn2+. 
Rapid dilution assay 
Comparable amount of Scp1 and CAK-treated 32P-labeled GST-CTD (~1 pmol) 
were pre-incubated in the 1x Reaction Buffer in 20 µl total volume either in the presence 
or absence of Mg2+ for 8 min. The reactions were rapidly diluted by 50-fold by the 
addition of 0.98 ml of 1x Reaction Buffer. After the rapid dilution, the reactions were 
incubated in 30 °C. As a control, the same amount of Scp1 in 0.5 ml of 1x Reaction 
Buffer was mixed with GST-CTD in 0.5 ml of 1x Reaction Buffer without further 
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dilution. A fraction of each reaction was taken out every 5-10 min and quenched by 
adding 2x Laemmli buffer. The products in each reaction were analyzed by SDS-PAGE. 
Fluorescence polarization 
The 14-mer and 17-mer Ser5 phosphorylated CTD peptides labeled with 5-
carboxylfluorescein (5-FAM) at the N-terminal were used in this assay. The peptide with 
a final concentration of 1 µM was mixed with various amount of the dominant negative 
form of Scp1 D96N mutant in 20 µl reactions. The final binding buffer was 20 mM Tris 
pH 8.0, 50 mM NaCl, 10 mM BME and 20 mM MgCl2. The fluorescence signal was 
monitored at 485/535 nm (excitation/emission) wavelength using Tecan Infinite F200 









where Signalparallel and Signalcross are the signals parallel and cross to the incident 
light, respectively. G is the G-factor which equals to 1.138 on the instrument used. 
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SSU72 PHOSPHATASE 
Reversible phosphorylation of the C-terminal domain (CTD) of eukaryotic RNA 
polymerase II largest subunit represents a critical regulatory mechanism during the 
transcription cycle and mRNA processing. Ssu72 is an essential phosphatase conserved in 
eukaryotes that dephosphorylates phosphorylated Ser5 (phospho.Ser5) of the CTD 
heptapeptide. Unlike Scps, Ssu72 is a house-keeping phosphatase for RNA polymerase 
II-mediated transcription. The function of Ssu72 is implicated in transcription initiation, 
elongation and termination as well as RNA processing. In this section, I will focus on 
Ssu72 phosphatase, introducing its characteristics both structurally and functionally. 
Chapter 6:  Crystal Structure of Ssu72 in Complex with a Transition 
State Analogue 
INTRODUCTION 
Dynamic reversible phosphorylation of the CTD plays an essential role, not only 
in the recruitment and assembly of transcription complexes, but also in the temporal 
control of transcription and mRNA processing (reviewed in (Fuda et al. 2009)). Ser5 
phosphorylation is required for assembly of the pre-initiation complex (PIC), and 
facilitates mRNA capping via recruitment of capping enzymes. As the transcription 
complex moves away from the initiation site, Ser5 gradually becomes dephosphorylated, 
whereas Ser2 is phosphorylated. Ser2 phosphorylation is the predominant CTD pattern on 
both elongating and terminating RNA polymerase II, which ensures efficient 3’-RNA 
processing by triggering the recruitment of 3’-RNA processing machinery. Non-
phosphorylated CTDs are necessary for the recycling of RNA polymerase II and its 
subsequent binding to a promoter (see Chapter 1).  
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Phosphorylation/dephosphorylation of the CTD is catalyzed by cyclin-dependent 
kinases and CTD-specific phosphatases (Majello et al. 2001). The best characterized 
CTD-specific phosphatases are the Fcp/Scp family members. Fcp1 is essential for cell 
survival in budding and fission yeasts presumably due to its function in RNA polymerase 
II recycling (Archambault et al. 1997). Small CTD phosphatase (Scp) has been identified 
as a phospho.Ser5 phosphatase (Yeo et al. 2003), but it only affects a subset of genes 
involved in neuronal differentiation (Yeo et al. 2005). It is a component of the neuronal 
silencing complex REST and prohibits the inappropriate differentiation of neuronal cells 
(Yeo et al. 2005). Scp1 and Fcp1 share the same active site topology and reaction 
mechanism (Zhang et al. 2006; Ghosh et al. 2008), but are distinct in preferences for Ser2 
or Ser5 dephosphorylation and domain architecture (Zhang et al. 2010). Interestingly, 
Scps which exhibit a strong preference towards phospho.Ser5 are conserved in higher 
eukaryotes but not in yeast. Inactivating Scp genes will promote neurogenesis but does 
not lead to cell death (Yeo et al. 2005). It is also observed that even though neuronal gene 
expression can be de-repressed upon Scp inactivation, general transcription in the cell is 
not eliminated (Pfaff, SL, personal communication). Therefore, eukaryotes must have 
other Ser5 phosphatases which function as house-keeping proteins for RNA polymerase II 
recycling, while Scps function at an epigenetic level and only specifically affect the 
expression profile of a subset of genes.  
A novel phosphatase, Ssu72, was identified as the Ser5 phosphatase in yeast 
whose phosphatase activity is identified as essential for cell survival and transcription 
cycling (Sun et al. 1996; Krishnamurthy et al. 2004). Ssu72 belongs to a highly 
conserved protein family found in eukaryotes. Compromising Ssu72 phosphatase activity 
results in the accumulation of a hyperphosphorylated Ser5 form of the CTD 
(Krishnamurthy et al. 2004). Ssu72 was first identified by its genetic interaction with the 
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transcription factor TFIIB, as a mutation in Ssu72 disrupted this interaction and affected 
the accuracy of start site selection (Sun et al. 1996). Further studies identified Ssu72 as a 
subunit of the cleaving and processing factor (CPF) complex, indicating its participation 
in mRNA processing regulation (He et al. 2003). Ssu72 may also be involved in 
transcription termination, as the mutations at Ssu72 directly alter the termination of the 
expression of snoRNA (Kim et al. 2006). Interestingly, the prolyl-isomerization 
regulation of the CTD, mediated by Ess1 in yeast, is also linked functionally to the 
phosphatase activity of Ssu72 (Krishnamurthy et al. 2009). It has been proposed that Ess1 
can change the balance of the cis-trans conformation of proline by adjusting the 
conformation suitability of Ser5-Pro6 as Ssu72 substrate, which in turn determines the 
pathway selection for transcriptional termination (Krishnamurthy et al. 2009). Therefore 
the effectiveness of Ssu72 mediated dephosphorylation of Ser5 of the CTD can be 
modulated by the prolyl-isomerization state of the CTD. Recently, an atypical 
phosphatase, Rtr1, has been defined as a CTD phosphatase, but its biological role is not 
fully understood (Mosley et al. 2009). 
To gain insight into the molecular mechanism of phosphoryl transfer by the Ssu72 
phosphatase family and the substrate recognition of Ssu72, we purified recombinant 
yeast, Drosophila and human Ssu72 to examine their catalytic activities and kinetic 
properties against a generic phosphatase substrate and their natural substrate CTD 
peptides. Furthermore, the X-ray crystal structures of Drosophila Ssu72 were obtained. 
The structure of Ssu72 clearly indicates it is a unique member of the low molecular 
weight tyrosine phosphatase (LMWPTP) superfamily, and further exhibits a deep groove 
that may potentially bind to the CTD of RNA polymerase II. A complex structure of 
Ssu72 with vanadate highlights the formation of a phosphoryl-cysteine intermediate and 
mimics the transition state of the phosphoryl transfer reaction. A unique “cap” domain 
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excludes direct access to the active site of Ssu72 by substrate and provides a possible 
explanation for the selectivity of Ssu72. We have also identified several residues in the 
CTD binding groove that play essential roles for substrate recognition. 
RESULTS AND DISCUSSION 
Phosphatase activity of Ssu72 from various organisms and the overall structure of 
Drosophila Ssu72 
The sequence alignment of ten Ssu72 phosphatases from various organisms in the 
NCBI database (Figure 6-1) shows a high degree of conservation from yeast to human 
(43% identity yeast to human, 60% identity Drosophila to human), consistent with the 
proposed biological role of Ssu72 as an essential phosphatase for the C-terminal domain 
of RNA polymerase II. To study the phosphatase activity and structure of the Ssu72 
family, the genes derived from Saccharomyces cerevisiae, Drosophila melanogaster and 
Homo sapiens were cloned and overexpressed in E. coli. The proteins were purified to 
homogeneity, and phosphatase activities were evaluated by pNPP assay which is a 
generic phosphatase assay. All three enzymes exhibit phosphatase activity with an 
optimal pH around 6.0–6.5 (data not shown). Yeast Ssu72 has the lowest enzymatic 
activity with a kcat of 0.090 ± 0.002 s
-1, and Km of 38 ± 3 mM (Figure 6-2c). For 
Drosophila Ssu72, much higher activity is observed with the kcat and Km determined to be 
1.30 ± 0.04 s-1 and 11.5 ± 0.9 mM (Table 6-1, Figure 6-2a). The kcat and Km of human 
Ssu72 is comparable to Drosophila homologue, and was determined to be 0.47 ± 0.01 s-1 
and 11.0 ± 0.8 mM (Figure 6-2b). Our kinetic data for Ssu72 are consistent with 
previously reported results on yeast and human Ssu72 (Meinhart et al. 2003). The results 









                                                 
31 Sequence alignment of Ssu72 from Drosophila (Dro, NP_608342), Homo sapiens (Hom, NP_054907), 
Saccharomyces cerevisiae(Sce, NP_014177), Schizosaccharomyces pombe (Spo, NP_594076), Rattus 
norvegicus (Rat, NP_001020828), Bos Taurus (Bos, XP_595220), Gallus gallus (Gal, NP_001007876), 
Salmo salar (Sal, NP_001136192), Xenopus laevis (Xen, NP_001084864) and Arabidopsis thaliana (Ara, 
NP_177523). Helices and strands are indicated by coils and arrows, respectively. Active site residues are 
marked with filled triangles below the alignment. The residues (also included in the mutagenesis study) for 
the tentative substrate CTD proline binding are marked by hollow triangles. 
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32 The data points were fitted into Michaelis–Menten equation by Origin7.5. 
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Table 6-1: Probing the residues that are important for the substrate CTD peptide 
binding.33 
Drosophila Ssu72 was crystallized, and the diffraction of apo crystals was 
processed to resolution at 2.85 Å. The protein crystallizes in space group P21212 (unit 
cell: a = 158.1 Å, b = 101.9 Å, c = 65.6 Å; α = β = γ = 90.0º) with four molecules per 
asymmetry unit. The protein structure consistently exhibits a high thermal factor (Table 
6-2). This may also explain the difficulty in obtaining a high resolution structure for apo 
Ssu72 as well as the crystal’s high sensitivity to environmental changes. The four 
molecules in each asymmetry unit are highly identical with the exception of two flexible 
loops (residues 47–53 and 127–134). The topology can be roughly divided into two 
portions with a deep groove cutting through the surface of the molecule, separating the 
protein into the “cap” and the “core” domains (Figure 6-3a). The connections between 
the “core” and “cap” domains are two flexible loops, suggesting that the individual 
                                                 
















Km (mM) kcat (s
-1) Km (mM) kcat (s
-1) Km (mM) kcat (s
-1) 








M17A 17 ± 2.6 0.28 ± 0.02 N.A. N.A. N.A. N.A. 
P46A 17.8 ± 1.7 0.69 ± 0.02 N.A. N.A. N.A. N.A. 
D51A 5.5 ± 0.7 1.34 ± 0.05 N.A. N.A. N.A. N.A. 
Y56A 144.2 ± 
21.2 
0.35 ± 0.04 N.A. N.A. N.A. N.A. 
Y77A 35.8 ± 1.9 1.39 ± 0.03 N.A. N.A. N.A. N.A. 
L82A 4.6±0.6 1.31±0.04 1.9±0.1 0.53±0.03 0.38±0.05 0.47 ± 0.04 
M85A 34.9 ± 2.5 0.48 ± 0.02 N.A. N.A. N.A. N.A. 
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domains can move in a hinge-like motion to desolvate the active site and impose 
selectivity toward substrates. The essential catalytic residue, Cys13, whose substitution 
results in loss of phosphatase activity and death of yeast strains (Sun et al. 1996), is 
located at the tip of the groove (Figure 6-3a). The “core” domain of the protein has a 
typical Rossmann fold with a series of twisted beta-strands sandwiched by alpha helices 
at each side (Figure 6-3b). The “cap” portion (residue 41–92), which is well conserved 
among Ssu72 from different species, is unique with no similar sequence or structure 
identified in other protein families (Figure 6-1 and 6-3c). When we color the protein 
according to residue conservation, the highly conserved residues are localized around the 
groove dividing the “cap” and “core” domains of the protein, indicating the functional 
















Data Statistics Apo Complex (Ssu72–vanadate) 
Source 
Advanced Light Source 
5.0.1 
Advanced Light Source 
5.0.1 
Wavelength (Å.) 0.9774 0.9765 
Resolution (Å.) 48.3-2.85(2.90–2.85) 48.5- 2.35 (2.39–2.35) 
Space group P21212 P21212 
Unit cell (Å.) a, b, c 158.1, 101.9, 65.6 157.6, 102.3, 65.8 
Number of unique reflections 24877 45695 
Redundancy 5.0 (4.6) 6.6 (6.1) 
Completeness (%) 94.6 (96.2) 99.9 (98.4) 
I/σ 21.8 (1.3) 36.5/1.5 
Rsym (%) 8.7 (76.7) 7.0 (76.1) 
Refinement Statistics   
Resolution limits (Å.) 48.3–2.85 48.65–2.35 
Number of reflections (test) 23460 (1194) 45556(2295) 
R work/ Rfree (%) 21.6 / 27.7 20.5 / 26.7 
Number of atoms protein/water 6216/15 6236/171 
B factors for protein atoms (Å2) 83.7 62.5 
B factors for ligand/water (Å2) -/66.7 54.0/60.8 
Bond rmsd length(A)/angles (°) 0.008/1.2 0.018/2.1 
Most favored 88.4% 87.7% 
Additionally allowed 10.7% 11.1% 
Generously allowed 0.6% 1.1% 
Disallowed region 0.3% 0 
Table 6-2: Crystallographic data statistics.34 
 
                                                 
34 Parentheses indicate statistics for highest resolution shell. 
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Figure 6-3: Structures of Ssu72.35 
Ssu72 is a low molecular weight tyrosine phosphatase 
Unlike kinases which evolve from the same ancestor and therefore maintain the 
same three-dimensional topology, protein phosphatases adapt different catalytic 
mechanisms for the phosphoryl-transfer reaction. Three different catalytic mechanisms 
are identified among protein phosphatases (Figure 6-4). The first category, called 
                                                 
35 (a) Surface representation of Drosophila Ssu72 apo protein structure. The signature motif residue 
arginine is highlighted in orange, and the nucleophilic cysteine is highlighted in red. (b) Ribbon 
representation of Drosophila Ssu72 structure. The active site essential residues are shown in stick 
representation. (c) Surface representation of the conserved residues (shown in orange) on Drosophila Ssu72 
structure. Partially conserved residues are shown in light blue. (d) Superimposition of Drosophila Ssu72 
(core domain in pale green, cap domain in cyan, finger region in yellow) and human LMWPTP 1 (PDB 
code: 1xww, core domain in white, a short helix that differs in different isoforms colored in red). 
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cysteine-based phosphatases, utilizes cysteine as the nucleophile at the active site (Denu 
et al. 1995; Tonks 2006). The well-studied mechanism establishes that the phosphate 
group from the substrate is transferred to the thiol group as a phosphoryl-intermediate, 
which in turn undergoes hydrolysis. On the other hand, Ser/Thr phosphatases such as PP1 
and PP2 utilize a dramatically different strategy for the hydrolysis of phosphate 
monoesters by using di-metal ions and activating a water molecule to directly break the 
P–O bond without a phosphoryl-protein intermediate (reviewed in (Shi 2009)). The third 
category, HAD-like phosphatases, including the CTD phosphatase Scp/Fcp family, 
resembles the two-step reaction mechanism of cysteine-based phosphatases, but utilizes 
aspartic acid as a nucleophile (Allen et al. 2004). 
The cysteine-based protein phosphatases are further divided into three sub-
families based on the relative location of the signature motif, termed “PTP” loop (–
CX5R–), and their preferences for substrates. The first subfamily, classical tyrosine 
phosphatase, is usually around 30 kDa with the PTP loop close to the middle of the 
protein, and it specifically dephosphorylates phosphoryl tyrosine. Dual specificity protein 
phosphatases, on the other hand, recognize both tyrosine and serine/threonine 
phosphorylation, as indicated by the name, with the PTP loop situated closer to the C-
terminal end of the protein. The third family, low molecular weight tyrosine phosphatases 
(LMWPTP), has a single catalytic phosphatase domain of around 18 kDa. The PTP loop 
is located at the N-terminus of the LMWPTP, with nucleophile cysteine usually in the 
vicinity of the 10–15th residues. LMWPTP favors phosphoryl-tyrosine as a substrate, 
even though high concentrations of phosphoryl-serine/threonine are also subjected to 





Figure 6-4: Summary of three different catalytic mechanisms identified among protein 
phosphatases. 
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Although Ssu72 exhibits very low primary sequence identity with proteins from 
any of the cysteine-based phosphatase families, the fold of the core domain is highly 
identical to that of LMWPTP (Figure 6-3d). A –CX5R– signature motif is located at the 
N-terminus of the protein. With the primary sequence consensus of only 15%, the overall 
fold of Ssu72 exhibits a Z score of 11.6 in DALI search (Holm et al. 2010) and a RMS 
deviation of 1.7 Å when superimposed with the main chain of LMWPTP (PDB code: 
1xww) (Ssu72 6–195 excluding residue 41–96; LMWPTP 1–157 excluding residue 50–
67). 
Complex structure of Ssu72 with inhibitor vanadate 
Another characteristic of cysteine-based phosphatases is their sensitivity to 
oxoanion compounds such as vanadate, tungsten and molybdate (Lindqvist et al. 1994). 
These compounds can inhibit cysteine-based phosphatases by forming transition states or 
product analogs with cysteine nucleophiles. In order to better understand the reaction 
mechanism and roles of catalytic residues, apo Ssu72 crystals were transferred to 
crystallization medium that contained 2mM Na3VO4. A structure of Ssu72 in which 
VO4
3- was coordinated in the active site was then compared to the apo Ssu72 structure. 
Interestingly, the incorporation of the vanadate ion stabilizes the crystal, which exhibits a 
higher resolution and lower thermal factor than apo Ssu72 crystals (Table 6-2). 
The structure of the Ssu72-vanadate complex was solved using apo Ssu72 as a 
search model in molecular replacement, and refined to a resolution of 2.35 Å (Figure 6-
5a). The refined model is almost identical to apo Ssu72 with the signature motif (–CX5R–
) located at the crevice. Strong positive electron density can be observed close to the 
nucleophilic cysteine (Cys13), with a characteristic trigonal bipyramidal coordination 
(Figure 6-5b). A vanadate group can be built into the electron density with three oxygen 
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atoms at equatorial positions, and a cysteine sulfur atom, as well as another oxygen atom 
at each side of the apical position (Figure 6-5c). The distance of vanadium to sulfur is 
refined to 2.3–2.4 Å, and the other four oxygen atoms are all about 1.9 Å away, 
consistent with a previously published vanadate adduct with bovine LMWPTP (Zhang et 
al. 1997). The bond length of S–V suggests the existence of covalent bond formation 
between the compound and the active site residue of Ssu72, explaining the inhibitory 
effect of vanadate compounds on Ssu72 (Figure 6-5c). 
The other conserved residue of the signature motif, Arg19, is located close to the 
nucleophilic cysteine (Figure 6-5c), and has dual functions in the phosphoryl transfer 
reaction which is conserved in all cysteine-based phosphatases (Zhang 2002). First, the 
positively charged arginine side chain can help recruit the phosphate group to the active 
site through electrostatic interactions. More importantly, the side-chain of arginine has 
the potential to stabilize the tetrahedral intermediate by forming hydrogen bonds with 
vanadate (Zhang et al. 1992) (Figure 6-5d). The stability of the coplanar bidentate is 
essential for the phosphoryl transfer reaction since lysine replacement of arginine cannot 
fully replace the arginine function in Yersinia PTPase (Zhang et al. 1992). Indeed, in the 
complex structure of Ssu72 with vanadate, the two nitrogen atoms of the guanidinium 
group from the highly conserved Arg19 pair with two equatorial oxygen atoms in the 
vanadate group (Figure 6-5d). The pairing of the vanadate oxygen and side chain of 
Arg19 constitutes a six-membered ring hydrogen bonding network that presumably 
reduces the free energy activation for the phosphoryl transfer reaction. The structure 
mimics the formation of the trigonal-pyramidal transition state in the phosphoryl transfer 
reaction, and explains how such a high-energy state is stabilized in Ssu72. Additional 
hydrogen bonding occurs between the backbone amides of the PTP loop and the 
equatorial oxygen atoms (Figure 6-5d). As found in other cysteine-based phosphatases, a 
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serine residue is located after this arginine and potentially stabilizes the thiolate anion of 
nucleophile cysteine by lowering its pKa (Peters et al. 1998). Indeed, in our structure, the 
hydroxyl group of the Ser20 side chain forms a hydrogen bond with nucleophile Cys13, 
which can potentially promote the deprotonated state of cysteine and facilitate the 
nucleophilic attack on phosphorus (Figure 6-5e). The elimination of this hydrogen bond 
by replacing Ser20 with Ala abolished the phosphatase activity of the protein in our 
pNPP assay (data not shown). 
Asp-containing flexible loop 
In addition to the –CX5R– PTP motif, another highly conserved residue in all 
LMWPTP is an aspartic acid residue, usually 110 amino acids away from the nucleophile 
cysteine. The three-dimensional position of this aspartic acid is conserved in all cysteine 
based phosphatases. In Yersinia PTPase, this conserved aspartate accounts for the basic 
limb of the pH dependence curve (Zhang et al. 1994). This aspartate residue fills the role 
of a general acid to provide the proton for the substrate-leaving after phosphoryl transfer 
(Zhang 2002). In the primary sequence of Drosophila Ssu72, two aspartate residues, 
Asp141 and Asp144 (Asp140 and Asp143 in human), are highly conserved in this area. 
The mutation of either of these two aspartate residues in human Ssu72 reduced the kcat/Km 
of Ssu72 by about 20 fold (Meinhart et al. 2003). To identify which is the general acid for 
phosphoryl transfer reaction, we inspected the interaction of the transition state analogue 
vanadate with active site residues. In the complex structure of Ssu72 and vanadate, this 
highly conserved position is occupied by Asp144, which can make two potential 
hydrogen bonds with vanadate (Figure 6-5c). However, Asp141 is 12.7 Å away from the 
vanadate group (Figure 6-5e). Therefore, we conclude that the Asp144 is the general acid 
that contributes to the reaction, and the loss of activity of Asp141 mutation might be 
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caused by structural disruption. Indeed, when we mutated Asp141 to Ala, the proteins can 
be expressed (as detected by SDS-PAGE), but are not accumulated in soluble fraction, 
likely due to issue with protein folding.  
In other cysteine-based phosphatases, this loop containing general acids/bases is 
presumably highly flexible, and can adopt the active conformation upon ligand binding or 
swing away when the active site is empty. For example, in classical protein tyrosine 
phosphatases, this aspartate is 10 Å away from the active site in the absence of substrate 
and only extends into the active site when occupied (Zhang 2002). In our crystal structure 
of Drosophila Ssu72 complexed with vanadate, the loop is in the “active” form with 
Asp144 extending into the active site, mimicking the conformation of an active site for 
phosphoryl transfer (Figure 6-5c). Without the vanadate compound, the loop still extends 






Figure 6-5: Complex structure of Ssu72 and vanadate.36 
                                                 
36 The green dashed lines indicate hydrogen bonds. The numbers are the distances of hydrogen bonds in Å. 
(a) Stereoview of 2Fo-Fc electron density of active site residues contoured at 2σ. The nucleophile cysteine is 
in yellow. (b) 2Fo-Fc electron density map of vanadate contoured at 1.6σ. (c) The interactions between 
vanadate and Cys13/Asp144. The S–V bond between Cys13 and vanadate (blue dashed line) is within 
covalent bond range. (d) The vanadate mimics the formation of the trigonal pyramidal transition state in 
phosphoryl transfer. (e) The hydroxyl group of the Ser20 side chain forms a hydrogen bond with the 
nucleophile Cys13. Asp141 is located distal to the active site with its carbon atom colored blue. 
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To confirm that the addition of transition state analog vanadate stabilizes the 
conformation of the loop containing the aspartate biochemically, we used DSF to assay 
the effect of an oxoanion compound on the folding of Ssu72 (Niesen et al. 2007). In this 
method, fluorescence from a dye with affinity for hydrophobic surface is monitored. The 
fluorescence increases upon the exposure of hydrophobic surfaces during protein 
unfolding. In our experiment, the incorporation of the vanadate compound consistently 
stabilized Ssu72 and increased the Tm. For yeast Ssu72, Tm increased from 37.8 ± 0.2 ºC 
to 43.5 ± 0.3 ºC upon vanadate addition. Similar trends were observed in human Ssu72 
(Tm increased from 44.0 ± 0.3 ºC to 49.2 ± 0.5 ºC) and Drosophila Ssu72 (Tm from 42.5 ± 
0.2 ºC to 45.6 ± 0.4 ºC) (Figure 6-6a, b and c). We also used CD to detect the effect of 
the vanadate compound and to correlate with our DSF results. Even though the buffer 
condition is slightly different, the stabilization effect of vanadate is consistent with a Tm 
of Drosophila Ssu72 increase from 44.0 ± 0.3 ºC to 46.2 ± 0.2 ºC (Figure 6-6d). We 
reason that the binding of vanadate stabilizes the flexible loop containing general acid 
Asp144 through hydrogen bonding, thereby enhancing protein folding. 
The “cap” region 
Unlike the bottom core portion of the Ssu72 protein whose topology is highly 
conserved in all cysteine-based phosphatase, the “cap” region (residue 41–92) of Ssu72 is 
unique and shows no structural similarity to any other protein (less than 4.0 in Z score) in 
DALI search (Holm et al. 2010). From residue Glu41 to Glu57, two short anti-parallel β-
strands are connected by an extended flexible loop resembling a “finger”, comprising the 
most dynamic portion of the Ssu72 structure (Figure 6-3d). This mobile tip excludes the 
active site pocket from the bulk solvent, and limits access to the binding pocket for 
Ssu72. When we mutated a residue at the tip of the finger, Asp51 to Ala, the binding to 
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CTD substrate was greatly reduced, even though the phosphatase activity was not 
affected when tested by the pNPP assay (Table 6-1). Consistent with our mutagenesis 
result, a complex structure of human Ssu72 with the substrate CTD and the scaffold 
protein symplekin was recently determined, showing the incorporation of the substrate 
CTD close to this flexible region (Xiang et al. 2010) (Figure 6-7a). 
 
Figure 6-6: Differential scanning fluorimetry and circular dichroism spectra of Ssu72 in 
the absence or presence of sodium vanadate. 
Unlike Ssu72, the active site in LMWPTP (PDB code: 1xww) is highly exposed 
(Figure 6-3d). Such architectural design is consistent with the substrate specificity of 
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these phosphatases. LMWPTP target receptor tyrosine kinases such as platelet-derived 
growth factor receptor, insulin receptor (Chiarugi et al. 1997), ephrin receptor (Stein et al. 
1998), and fibroblast growth factor receptor (Rigacci et al. 1999). Therefore, the active 
site of LMWPTP needs to be accessible and open to accommodate such bulky substrates. 
On the other hand, the only substrate Ssu72 recognizes in vivo is the CTD of RNA 
polymerase II, which is a highly disordered peptide and presumably adopts a long 
extended loop to fit into the more exclusive active site of Ssu72. 
One important regulatory mechanism for LMWPTP activity is through the 
differential phosphorylation of Tyr131 and Tyr132 (Bucciantini et al. 1999). These two 
sites are proposed to increase the activity of the phosphatase or to recruit the SH2 domain 
of Grb2 to LMWPTP (Bucciantini et al. 1999). In contrast, no phosphorylation regulation 
has yet been observed for Ssu72. The flexible loop, containing two tyrosine residues 
(Tyr131 and Tyr132) in LMWPTP, is substantially shorter in Ssu72, with the two 
tyrosine residues omitted in the Ssu72 sequence (Figure 6-7b). We speculate that instead 
of using phosphorylation as regulatory mechanism, Ssu72 adapts the unique “cap” 
domain to modulate phosphatase activity and substrate selectivity. Use of divergent cap 
domains to limit the accessibility of the active site is a common strategy in biology. For 
example, the HAD super family, a large family of proteins for phosphoryl transfer, 
utilizes different “cap” domains to mediate different phosphoryl transfers of different 
substrates (Allen et al. 2004). A core domain with Rossmann fold is conserved among all 







Figure 6-7: Important residues for Ssu72 function.37 
Potential proline binding pocket  
Ssu72 can dephosphorylate the hyperphosphorylated CTD in vitro 
(Krishnamurthy et al. 2004). To test the activity of Drosophila Ssu72 towards the CTD, 
                                                 
37 (a) Superimposition of Drosophila (Dro) Ssu 72 and human Ssu72-CTD complex (PDB code: 3o2q). 
Dro. Ssu72 is in light blue color, and human Ssu72 is in salmon color. The CTD peptide is in white stick. 
The flexible loop region (indicated by “Finger”) encloses the CTD binding site in the human Ssu72-CTD 
peptide complex structure. (b) Superimposition of the active sites of Ssu72 (cyan) and LMWPTP (PDB 
code: 1xww, pink). The key residues are shown in white stick in LMWPTP, and in orange stick in Ssu72, 
respectively. The vanadate is shown in yellow to indicate the active site. (c) Stereo figure of the CTD 
binding groove presented by superimposition of the CTD peptide from the symplekin-Ssu72-CTD complex 
structure (PDB code: 3o2q) into Drosophila Ssu72 structure. The residues in the mutagenesis study are 
shown in stick. 
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we used CTD derived peptides with different lengths and phosphorylation patterns to 
identify the optimal minimal length for the CTD recognition. It has been noticed that the 
binding of CTD by Ssu72 is highly dependent on the Tyr from the following repeat of 
phospho.Ser5 (Hausmann et al. 2005). This is quite different from human Scp, in which 
the Pro3 N-terminus from the phospho.Ser5 is essential for the CTD recognition (Zhang et 
al. 2006). To evaluate this, we first tested against a 17-mer CTD peptide with 
phospho.Ser5 site (SPSYSPTSPSYSPTpSPS), which is the optimal substrate for Scps. 
However, the activity is relatively low with a kcat of 0.19 ± 0.01 s
-1 and Km of 0.85 ± 0.09 
mM. Consistently, when using a singly phosphorylated double repeats peptide 
(YSPTSPSYSPTpSPS) as the substrate, the kcat is measured to be 0.44 ± 0.03 s
-1 and Km 
is 1.2 ± 0.2 mM. The best activity is obtained when both Ser5 are phosphorylated in the 
double repeats CTD peptide (YSPTpSPSYSPTpSPS) which results in a kcat of 0.397 ± 
0.004 s-1 and Km of 0.152 ± 0.006 mM (Table 6-1, Figure 6-8). This turnover rate is 20 
times better than the previously reported yeast Ssu72 (kcat estimated to be 0.02 s
-1) 
(Hausmann et al. 2005), and comparable to the other Ser5 phosphatases, Scps (Km = 0.21 
± 0.05 mM and kcat = 2.44 ± 0.04 s
-1) (Zhang et al. 2006). We further identified a minimal 
optimal peptide (10-mer, YSPTpSPSYSPT) which shows comparable activity with Km = 
0.96 ± 0.03 mM and kcat = 0.42 ± 0.04 s
-1 (Table 6-1). This result suggests different 
recognition element requirements to Scp and Ssu72 for substrate binding, even though 
they both dephosphorylate phospho.Ser5 of the CTD. The residues that contribute greatly 
to the binding of CTD by Scp are primarily located at the N-terminal to the phospho.Ser5 
subject to dephosphorylation (Zhang et al. 2006). Conversely, Ssu72 requires certain C-




Figure 6-8: Steady-state kinetics of Drosophila Ssu72 towards CTD peptide.38 
Most recently, the complex structure of human Ssu72 bound to CTD and scaffold 
protein symplekin was reported (Xiang et al. 2010). A particularly interesting question 
about Ssu72 is the identity of residues that play essential roles in the substrate 
recognition. We reasoned that such residues would not interfere with active site 
phosphatase activity, as characterized by the pNPP assay, but should exhibit much lower 
activity towards CTD peptides. To investigate which residues are important specifically 
for the substrate recognition of Ssu72, we made mutations of residues that are located in 
the substrate binding groove. We are particularly interested in the residues that might 
contribute to the binding of Pro6 in the CTD sequence. Unlike any other CTD bound 
proteins such as Scp1 or Cgt1 (Zhang et al. 2010), Pro6 exhibits a unique cis 
conformation upon Ssu72 binding (Xiang et al. 2010). Through mutagenesis and steady-
                                                 
38 The CTD peptide sequence is YSPTpSPSYSPTpSPS. 
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state kinetics, we identified five residues that play pivotal roles for the specific activity 
towards the CTD (Table 6-1). A pair of Met residues, Met17 and Met85, clamp on Pro6 
of the CTD, with Pro46 from the opposite side, through hydrophobic interactions (Figure 
6-7c). The mutation of either of the two Met residues, or Pro46 to Ala results in the loss 
of Ssu72 activity towards the CTD peptide, even though the activity towards pNPP is 
unaffected or insignificantly reduced (Table 6-1). On the other hand, the loss of activity 
due to Tyr77 mutation is surprising, since Tyr77 does not directly contribute to the 
substrate binding. Instead, it orients the side chain of Asn54 with hydrogen bonding, and 
stabilizes the conformation of the highly flexible region (residues 41–57). The 
comparison of the human Ssu72-CTD complex structure and our Drosophila structures 
discloses that Ssu72 structure is highly conserved upon vanadate incorporation, with the 
only difference found at this highly flexible region (residues 41–57) enclosing the CTD 
substrate in the complex structure (Figure 6-7a). This region is formed by two anti-
parallel beta-strands with a flexible loop, and is highly dynamic in apo structure (Figure 
6-3d). The phosphate group of phospho.Ser5 of the CTD is found at the location of the 
vanadate ion in our structure. Residues on this flexible loop are particularly important for 
the function of Ssu72. Asp51Ala mutant exhibits comparable phosphatase activity with 
the wildtype Ssu72 in the pNPP assay, but its activity is greatly compromised when 
phosphoryl CTD peptides are used as the substrate (Table 6-1, Figure 6-7c). Another 
mutation, Tyr56Ala, disrupts the protein activity in both the pNPP assay and malachite 
green assay (Table 6-1). Not all residues located in the groove contribute to Ssu72 
activity. For example, the Ala mutation of Leu82, which is located very close to the 
substrate CTD, results in no loss of phosphatase or specificity activity (Table 6-1).   
Ssu72 is an essential protein in eukaryotes whose phosphatase activity plays a key 
role in RNA polymerase II recycling and the selection of the transcription termination 
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pathways. In the present study, we successfully solved the high resolution X-ray crystal 
structures of Drosophila Ssu72 in complex with vanadate, mimicking the transition state 
of the phosphoryl transfer. This structure shows that Ssu72 is a unique subfamily of 
LMWPTP with a “cap” domain to confer its substrate specificity. Moreover, kinetic 
studies of Drosophila Ssu72 using Ser5-phosphorlated peptides as the substrates 
demonstrated that Ssu72 can dephosphorylate phospho.Ser5 of the CTD peptide. A deep 
groove engulfing the nucleophile Cys13 between the core domain and the “cap” domain 
was observed in the Ssu72 structures and is predicted to be the binding site for the CTD 
peptide. In addition, the complex structure of Ssu72 and vanadate mimics the formation 
of the trigonal pyramidal transition state in the phosphoryl transfer reaction, and explains 
how such a high-energy state is stabilized in Ssu72. 
METHODS 
Cloning and protein purification 
The Ssu72 genes from various organisms were cloned from Saccharomyces 
cerevisiae genomic DNA, Drosophila melanogaster synthetic genes (Drosophila 
Genomics Resource Center) and Homo sapiens cDNA (Origene). The genes encoding 
Ssu72 were amplified by PCR using primers with convenient ligation-independent 
cloning sites and corresponding templates. The PCR products were directly inserted into 
an in-house-generated pET28b derivative vector, pETHis8-SUMO, which was linearized 
with T4 DNA polymerase. The resulting expression plasmid pETHis8-SUMO-ssu 
encodes a corresponding Ssu72 fusion protein with an N-terminal 124-amino-acid tag 
consisting of a His8 leader (MGSSHHHHHHHHSSGSDSEVNQEAKP) followed by an 
86-amino-acid SUMO (small ubiquitin-related modifier) fragment and a PreScission 
protease recognition sequence (ALEVLFQGPGSG). Escherichia coli BL21 (DE3) were 
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transformed with the pETHis8-SUMO-ssu vectors and grown in Luria–Bertani medium 
containing 50 µg/ml kanamycin at 37 °C until the OD600 reached 0.6–1.0. The cultures 
were supplemented with 0.5 mM IPTG (isopropyl β-D-thiogalactopyranoside) and then 
grown at 16 °C for 16 h. The induced cells were harvested with centrifugation (5000 
rev./min, Beckman Avanti J-26, JLA 8.1 rotor) and disrupted by sonication on ice 
(Misonix sonicator 4000, amplitude 90%) for 5 cycles (30 sec/cycle, with 1 sec on/off 
pulses, and a 4 min pause between cycles). The recombinant Ssu72 protein was affinity 
purified using a Ni-NTA (Ni2+-nitrilotriacetate) column (Qiagen) and eluted with buffer 
A [250 mM imidazole, 500 mM NaCl, 100 mM Tris/HCl (pH 8.5) and 10 mM 2-
mercaptoethanol]. A final concentration of 3 mM EDTA was added to the eluted protein 
to eliminate any residual nickel ion. The eluted protein was then dialysed against buffer B 
[20 mM Tris/HCl (pH 8.5), 100 mM NaCl and 10 mM 2-mercaptoethanol] and digested 
with PreScission protease (GE Healthcare) at 4 °C overnight. The truncated tag and 
untruncated protein were removed by reloading the digested sample on a second Ni-NTA 
column equilibrated with buffer C [30 mM imidazole, 20 mM Tris/HCl (pH 8.5), 100 
mM NaCl and 10 mM 2-mercaptoethanol]. Flow-through fractions were pooled and 
applied on a MonoQ column, and proteins were eluted with a NaCl gradient. Ssu72 
proteins were further purified by gel filtration using a Superdex-75 column (GE 
Healthcare) equilibrated against buffer D [25 mMHepes (pH 7.5), 80 mM NaCl and 1 
mM DTT (dithiothreitol)]. Finally, the pure Ssu72 proteins were concentrated with a 10 
kDa Vivaspin-20 concentrator (GE Healthcare) to ∼10 mg/ml. 
Crystallization and compound soaking 
Crystallization trials were carried out using sitting-drop vapour diffusion at 4 °C. 
An initial Ssu72 crystal was identified from the Classics suite crystal screen (Qiagen) by 
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mixing equal amounts of protein solution (10 mg/ml) and reservoir solution containing 
0.1 M Hepes sodium salt (pH 7.5), 10% (v/v) propan-2-ol and 20% (w/v) PEG 
[poly(ethylene) glycol] 4000. Subsequently, production of the crystal was optimized 
under the following conditions: 0.1 M Hepes sodium salt (pH 7.5), 10% (v/v) propan-2-ol 
and 14–18% (w/v) PEG 4000. Crystals appeared within 1 week and grew for 10 more 
days. A 20–25% (v/v) glycerol was supplemented with crystallization conditions as the 
cryoprotectant for all crystals used in the experiments. To obtain the complex structure of 
Ssu72 with vanadate, apo crystals were soaked in mother liquor containing 2 mM sodium 
orthovanadate solution for 2 h prior to cryoprotection. X-ray diffraction data were 
collected at beamline 5.0.1 (Advanced Light Source) using a 2×2 ADSC CCD (charge-
coupled device) detector. Data were processed with HKL2000 and are summarized in 
Table 6-2. 
Structure determination and refinement 
The crystal structures of Drosophila Ssu72 were determined by molecular 
replacement using a low-resolution structure (PDB code 3FMV; 3.3 Å) from Northeast 
Structure Genomic Consortium as the initial search model using the program Phaser from 
the CCP4 package. Initial refinement was carried out using the Phenix refinement suite 
under NCS (non-crystallographic symmetry) restraints with a 5% test set (reflections) 
excluded for Rfree cross-validation. Electron-density maps σA-weighted 2Fo −Fc and Fo 
−Fc maps were calculated after each cycle of refinement and inspected to guide model 
rebuilding using Coot. For the complex structure of Ssu72 and vanadate, the locations of 
the vanadate group were clear in Fo −Fc maps. The inhibitor model was built into the 
electron density using Coot. The final models were evaluated by PROCHECK. 
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Refinement statistics are summarized in Table 6-2. PyMOL was used to produce 
molecular graphics renditions. 
Phosphatase activity assays 
An assay for non-specific phosphatase activity was carried out using the general 
substrate pNPP (p-nitrophenyl phosphate) (Fluka, Sigma–Aldrich) in 0.2 ml of reaction 
mixture containing 0.1 M citrate buffer (pH 6.0), 1 mM DTT, various pNPP 
concentrations (0–40 mM for Drosophila and human Ssu72, 0–320 mM for yeast Ssu72), 
and 2.0 µg of the enzyme. After incubation at 28 °C (or 37 °C for human Ssu72) for 15 
min, the reaction was terminated by adding an equal volume of 2.0 M NaOH, and the 
released pNPP was measured at 405 nm using a Tecan infinite 200 microplate reader. 
The optimum pH for enzyme activity was determined in 0.1 M citrate buffer, 0.1 M Mes 
buffer and 0.1 M Tris/HCl (adjusted in the range of pH 4–9) at 28 °C (or 37 °C for 
human Ssu72) with 2.4 mM pNPP as the substrate. Temperature effects on activity were 
measured in 0.1 Mcitrate buffer (pH 6.0) at different temperatures. Michaelis–Menten 
kinetic parameters for purified Ssu72 towards pNPP were determined by measuring 
initial reaction rates at various pNPP concentrations in the above reaction buffer. Data 
were fitted to the Michaelis–Menten equation with the program Origin7.5 (OriginLab). 
The substrate specificity of the Drosophila Ssu72was examined using Ser5-
phosphorylated CTD peptides (Anaspec) by malachite green colorimetric assay. The 
assay was performed in a 200 µl PCR tube in 20 µl of assay buffer [0.1 M Mes (pH 6.0) 
and 1 mM DTT] containing various concentrations of Ser5-phosphorylated CTD peptide 
in the absence and the presence of purified Ssu72 at 100 ng per reaction. The assay tubes 
were incubated in a PCR machine (Bio-Rad) at 28 °C for 10 min. It was stopped with 80 
µl of malachite green reagent (Biomol Green), and the absorbance was read at 620 nm 
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according to the manufacturer’s instructions. Kinetic data were analysed according to the 
Michaelis–Menten equation with the program Origin7.5. 
Differential scanning fluorimetry 
Yeast, Drosophila and human Ssu72s with various concentrations (1–50 µM) 
were mixed with 1 mM sodium vanadate in 96-well low-profile PCR plates (ABgene, 
catalogue number AB-0700) and incubated on ice for 30 min. SYPRO orange dye was 
added into each well immediately before placing the plate in LightCycler 480 (Roche). 
The protein unfolding experimentwas carried out with an increase of temperature from 
20 °C to 85 °C. The melting temperature curves of Ssu72s were monophasic and Tm 
values were derived from the curves. 
CD-monitored thermal denaturation 
Drosophila Ssu72 (43 µM) was incubated with 1 mM sodium orthovanadate in 20 
mM Hepes buffer (pH 7.5). CD spectra were monitored at 220 nm with an AVIV model 
420 spectropolarimeter equipped with a thermoelectric temperature control unit. Data 
points were collected every min/°C as the sample temperature increased from 30 to 70 °C 
(1 °C per min). Melting temperature was obtained by fitting the data to a Boltzman 
sigmoidal function by Origin7.5. 
ACCESSION CODE 
The atomic coordinates and structure factors (codes 3OMW and 3OMX) have 
been deposited in the Protein Data Bank. 
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HUMAN PROLYL-ISOMERASE PIN1 
The CTD of eukaryotic RNA polymerase II is an essential regulator for RNA 
polymerase II-mediated transcription. It is composed of multiple repeats of a consensus 
sequence Tyr1Ser2Pro3Thr4Ser5Pro6Ser7. CTD regulation of transcription is mediated both 
by phosphorylation of the serines and prolyl isomerization of the two prolines. 
Interestingly, the phosphorylation sites are typically close to prolines, thus the 
conformation of the adjacent proline could impact the specificity of the corresponding 
kinases and phosphatases. Experimental evidence of cross-talk between these two 
regulatory mechanisms has been elusive. Pin1 is a highly conserved phosphorylation-
specific peptidyl-prolyl isomerase (PPIase) that recognizes the phospho-Ser/Thr 
(pSer/Thr)-Pro motif with CTD as one of its primary substrates in vivo. In this chapter, 
we provide structural snapshots and kinetic evidence that support the concept of cross-
talk between prolyl isomerization and phosphorylation. We determined the structures of 
Pin1 bound with two substrate isosteres that mimic peptides containing pSer/Thr-Pro 
motifs in cis or trans conformations. The results unequivocally demonstrate the utility of 
both cis- and trans-locked alkene isosteres as close geometric mimics of peptides bound 
to a protein target. Building on this result, we identified a specific case in which Pin1 
differentially affects the rate of dephosphorylation catalyzed by two phosphatases (Scp1 
and Ssu72) that target the same serine residue in the CTD heptad repeat but that have 
different preferences for the isomerization state of the adjacent proline residue. These 
data exemplify for the first time how modulation of proline isomerization can kinetically 
impact signal transduction in transcription regulation. 
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Chapter 7:  Structural and kinetic analysis of prolyl-
isomerization/phosphorylation cross-talk in the CTD code 
INTRODUCTION 
The unique chemical structure of the proline residue makes it the only amino acid 
enabling the Xaa-Pro peptide bond (where Xaa is any amino acid residue) to adopt a cis 
conformation to a significant extent (10-30%) (Brandts et al. 1975). The transition 
between cis and trans conformations of the prolyl peptide bond occurs at a slow rate, and 
phosphorylation of the serine or threonine preceding the proline (pSer/Thr-Pro) can 
further slow the transition (Schutkowski et al. 1998). Since protein kinases or 
phosphatases are specific for the proline isomeric state (Lu et al. 2002), it is possible that 
kinases and phosphatases could recognize the same Ser/Thr position but with different 
preferences for the isomerization state of the adjacent Pro. In other words, since proline 
isomerases can be dependent on the phosphorylated state, these enzymes may act as 
molecular ‘switches’ that govern the downstream recognition and kinetics of 
phosphatases.   
To the extent this hypothesis is true, the conformation of the peptide bond should 
impact the substrate recognition of at least some modifying enzymes. Pin1 is a highly 
conserved peptidyl-prolyl isomerase (PPIase) that specifically recognizes the pSer/Thr-
Pro motif and catalyzes faster transition between the two isomeric states, and thereby 
regulates protein functions. The isomerization of the pSer/Thr-Pro motif mediated by 
Pin1 is especially important for biological processes, e.g. cancer and neurodegenerative 
diseases such as Alzheimer’s (Lu et al. 1996; Lu 2004). In humans, one of the most 
significant substrates of Pin1 is RNA polymerase II, the central molecule for eukaryotic 
transcription (Yaffe et al. 1997). The signature motif recognized by Pin1 is highly 
enriched in the C-terminal domain (CTD) of RNA polymerase II, which consists of 26-52 
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tandem heptapeptide repeats with the general consensus sequence from yeast to human, 
Tyr1Ser2Pro3Thr4Ser5Pro6Ser7 (Corden 1990). CTD phosphorylation is a major 
mechanism by which cells regulate gene expression, with serines at positions 2 and 5 as 
the primary phosphorylation sites (Dahmus 1996). The conformational states of the 
prolines in the CTD also represent a critical regulatory checkpoint for transcription 
(Dahmus 1996; Palancade et al. 2003; Meinhart et al. 2005). By adjusting the cis-trans 
conformation of a proline adjacent to a phosphorylated serine, the interaction of the CTD 
and the binding partners it recruits can be modulated (Morris et al. 1999; Wu et al. 2000). 
These CTD binding proteins are involved in a variety of processes during the 
transcription. However, nearly all the complex structures of CTD-binding proteins and 
the CTD peptides solved so far contain the pSer-Pro motif in trans conformation (Zhang 
et al. 2010). Some examples of these CTD-binding proteins include Pcf11 (Meinhart et 
al. 2004), a subunit of yeast cleavage and polyadenylation factor I, and mRNA capping 
enzyme Cgt1 (Fabrega et al. 2003). 
Substantial evidence has been accumulated that Pin1 modulates the 
dephosphorylation of the CTD of RNA polymerase II (Wu et al. 2000; Palancade et al. 
2003; Xu et al. 2003; Xu et al. 2007). Congruent with the hypothesis set out above, in the 
absence of Pin1-catalyzed cis/trans isomerization, a phosphatase might not be able to 
'undo' the phosphorylation catalyzed by the kinase, even though they recognize the same 
Ser/Thr. In other words, Pin1 might significantly affect the steady-state phosphorylation 
level of a protein even though it has neither kinase nor phosphatase activity. Notably, the 
function of Pin1 itself is tightly regulated in normal tissues on both expression level and 
post-translational modification level (Lu et al. 2007), indicating Pin1 as a regulatory 
switch of the isomeric states of pSer/Thr-Pro in signal transduction. 
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About a dozen CTD-specific kinases have been identified and characterized 
(Prelich 2002), but CTD phosphatases are understudied. Recently, our lab and others 
have structurally characterized two CTD-specific phosphatases: small CTD phosphatase 
1 (Scp1) (Yeo et al. 2003; Yeo et al. 2005; Zhang et al. 2006) and Ssu72 (Zhang et al. 
2011), and their interactions with phosphorylated CTD (Xiang et al. 2010; Werner-Allen 
et al. 2011). Scp1 was identified as a neuronal gene suppressor in non-neuronal cells as 
well as neuronal stem cells (Yeo et al. 2005), where it epigenetically regulates the 
expression of a subset of genes. Scp1 is the first structurally characterized CTD-specific 
phosphatase with its substrate bound in human (Yeo et al. 2003; Yeo et al. 2005; Zhang 
et al. 2006). In our high-resolution structure of the Scp1-CTD complex (PDB code 2ght), 
it is obvious that pSer5 is the site that undergoes dephosphorylation, while the pSer2 side 
chain extends outwards from the protein surface, even though it is also phosphorylated. 
The Pro3 and Pro6 are both in the trans conformation, and the conversion from trans to cis 
would make the substrate chain clash sterically with the protein unless dramatic 
conformational changes occurred (Zhang et al. 2006). Ssu72, on the other hand, has been 
recognized as a housekeeping gene that is pivotal to the general transcription cycle. It 
exhibits substrate specificity toward the cis conformation of its bound CTD peptide 
(Xiang et al. 2010; Werner-Allen et al. 2011). It recognizes pSer5-Pro6 motif only if Pro6 
adopts the cis conformation (Xiang et al. 2010). Based on the structure, the high energy 
cis-proline substrate can be stabilized in part by the intramolecular hydrogen bond 
between the hydroxyl side chain of Thr4 and the carbonyl group of Pro6. This is 
surprising since all previously identified CTD binding proteins are trans specific. Since 
the cis conformation only accounts for ~20% of the peptide, the unambiguous 
observation in crystal structures of the cis conformation binding in Ssu72 indicates 
selectivity, rather than an averaging effect of crystallography. The structures strongly 
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suggest that the cis or trans conformations of prolines upstream or downstream of a pSer 
site in the CTD can directly determine if the specific site can be subject to the 
dephosphorylation by the CTD phosphatases.   
We therefore hypothesized that prolyl isomerization has a substantial impact on 
dephosphorylation rates by changing the suitability of CTD as the substrate for CTD 
phosphatases, and thus affects the phosphorylation patterns of the CTD (Etzkorn 2006). 
In particular, Scp1 and Ssu72 might respond differently to the Pin1-mediated prolyl 
isomerization. However, structural and kinetic evidence were lacking. In order to test this 
hypothesis, we determined the structures of two conformational-locked alkene isosteres 
bound to Pin1 that mimic the two endpoints of the isomerization reaction: pSer-cis-Pro 
and pSer-trans-Pro (Wang et al. 2004). These structures not only provide insight into 
how Pin1 recognizes its substrates, but also demonstrate unequivocally the utility of both 
cis- and trans-locked alkene isosteres as close geometric mimics of peptide bonds bound 
to a protein target. We further show that cis-specific phosphatase Ssu72 was highly 
activated by Pin1 activity, but that trans-specific phosphatase Scp1 was not affected 
substantially. These data illustrate how the ability of Pin1 to ‘switch’ the cis and trans 
conformation of its substrates may have significant implications for the regulation of 
RNA polymerase II-mediated transcription. 
RESULTS AND DISCUSSION 
The binding of cis and trans isosteric compounds to Pin1   
In order to promote Pin1 crystals to endure prolonged chemical soaking, it was 
necessary to engineer Pin1 using an entropy reduction strategy (Zhang et al. 2007). R14A 
mutation of Pin1 has been shown to dramatically stabilize the protein crystal, yet it has 
little impact on the PPIase activity or WW domain binding on the substrates of Pin1 (Lu 
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et al. 1999). The R14A mutant also shows identical binding modes as wild-type protein 
when bound to high-affinity inhibitor Ac-L-Phe-D-pThr-L-Pipecolic acid-L-
Naphthylalanine-L-Gln-NH2 (D-PEPTIDE) (Zhang et al. 2007). Therefore, in our current 
investigation, crystals of this mutant were used to soak with cis and trans isosteric 
compounds. This strategy was extremely effective and the crystals diffracted to 2.1 and 
2.3 Å on an in-house X-ray source for cis and trans complexes respectively. 
The overall structure of Pin1 is highly consistent with previously reported 
structures. Briefly, human Pin1 has two distinctive domains, a WW domain that 
recognizes the signature motif pSer/Thr-Pro, and a PPIase domain that catalyzes the 
reaction of the prolyl-peptide. The linker between the two domains is highly flexible and 
disordered in all of the structures of Pin1 published thus far (Figure 7-1) (Ranganathan et 
al. 1997; Verdecia et al. 2000; Zhang et al. 2007). The flexible nature of the linker is 
inherited throughout the Pin1 family. The mobility of the linker and the inter-domain 
movement is proposed to be an integral regulatory mechanism for the communication 
between WW and PPIase domains and essential for the biological function of the protein 
(Li et al. 2005; Namanja et al. 2011). A PEG400 molecule, used as additive in the 
crystallization buffer, was found as usual in the groove between the two domains. This 
PEG400 molecule stabilizes the mobility between the two domains and enables the 
crystallization of Pin1 molecules. The only exception is the structure of Pin1 with the 
phosphoryl-peptide derived from the CTD of RNA polymerase II, in which case the 
peptide replaced the PEG molecule (PDB code: 1f8a) (Verdecia et al. 2000). 
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Figure 7-1: Overall structure of Pin1 represented by cartoon and surface.39 
The complex structures show that both cis and trans alkene compounds (Figure 7-
2) bind to the PPIase domain of the Pin1. The structures indicate that Pin1 recognizes 
both cis and trans substrates in very similar conformations, even though the mode of the 
proline 5-membered ring analogue bound to the proline binding pocket is slightly 
different. The PPIase domain has two distinctive binding areas for each residue of the 
signature motif, pSer/Thr-Pro. Three essential residues of the PPIase domain, Lys63, 
Arg68 and Arg69, form a positive triad pocket that specifically binds to the phosphate 
group (Figure 7-1). The elimination of any of these residues greatly diminishes the 
activity of the enzyme but does not totally abolish the isomerization activity (Lu et al. 
1999). However, eliminating two out of the three residues reduces the activity of the 
enzyme to an undetectable level (Lu et al. 1999). These residues, embracing the 
phosphate group of the substrate with electrostatic interactions, form a roomy and elastic 
                                                 
39 The PPIase domain is colored light pink, and the WW domain is colored light blue. The linker in 
between of the two domains is missing due to its high flexibility. The residues, Lys63, Arg68 and Arg69, 
that bind phosphate group is shown as sticks. The red arrow indicates the pocket that recognizes proline.  
PEG molecule is shown in green and red as sticks. 
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pocket that can accommodate “rolling” of the phosphate. When not occupied, the positive 
triad loop preserves an open conformation that can close up upon inhibitor binding 
(Figure 7-3) (Verdecia et al. 2000). A hydrophobic pocket that binds to the proline 
residue of the substrate is also accountable for the unique selectivity of Pin1 isomerase. 
This greasy pocket highly prefers hydrophobic residues like proline. When a proline-
containing compound is not provided in solution, density from additives sometimes can 
be found in the crystal structure, most likely due to non-specific binding. This implies a 
strong preference for hydrophobic interactions in this binding area and provides clues for 
inhibitor design (Zhang et al. 2007). 
 
Figure 7-2: Chemical structures of the cis and trans peptidomimetic inhibitors of Pin1: 




Figure 7-3: Superimposition of multiple Pin1 structures published in PDB shows “open” 
and “closed” conformations of the loop containing Arg68.40 
The Pin1 R14A-cis-isostere complex structure 
The cis isosteric inhibitor binds to the PPIase domain, as predicted based on the 
kinetic results that the compound is a competitive PPIase inhibitor (Wang et al. 2004). 
Three residues of the inhibitor are ordered and modeled in the density at the active site 
(Figure 7-4a). Even though it has been proposed that the presence of hydrophobic 
residues N-terminal to the signature motif can enhance binding (Yaffe et al. 1997), the 
two phenylalanine residues in the cis peptidomimetics are not visible in our structure. 
This is similar to another complex structure of Pin1 (PDB code: 2itk) with high affinity 
peptide inhibitor (Ki of 19 nM) where N-terminal hydrophobic residue (Phe) immediately 
preceding the pSer/Thr-Pro motif (PDB code: 2itk) was also disordered (Zhang et al. 
2007). The consistent lack of order in these amino acids suggests that the residue(s) N-
terminal to the pSer/Thr-Pro motif might contribute very little structurally to the tight 
binding between Pin1 and those inhibitors. We took advantage of this observation in our 
                                                 
40 The ones that have ligand bound at the phosphate-binding pocket (red arrow) include 1pin (green), 2itk 
(cyan), 1nmw (magenta), and 3jyj (yellow). The structure with PDB code 1f8a (pink) has no ligand at the 
phosphate-binding pocket, possessing the loop swung out about 23.5 Å from the “closed” conformation. 
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ensuing design of a reduced amide inhibitor of Pin1, Ac–pSer–Ψ[CH2N]-Pro–tryptamine 
(Xu et al. 2011). In this case, no hydrophobic residues were placed in front of the pSer, 
the resultant compound exhibited much improved solubility that allowed structural 
determination. 
Figure 7-4: Complex structures of Pin1 bound with cis or trans isosteres.41 
One interesting aspect of our structure is the conformation of Arg68 of Pin1, 
whose side chain was disordered in the previous PPIase complex structure (Zhang et al. 
                                                 
41 (a) Electron density map (2Fo-Fc) of cis isostere contoured at 1σ. (b) Superimposition of Pin1 bound 
with cis isostere (yellow) and L-PEPTIDE (magenta, PDB code: 2q5a). Pin1 bound with cis isostere is 
shown in pale green, and the Pin bound with L-PEPTIDE is shown in white. Arg68 in both structures is 
shown as sticks. The yellow dashed lines indicate the hydrogen bonds. (c) Hydrophobic pocket (pink 
surface) which recognizes Pro analogue of the peptidomimetic inhibitor. The key hydrophobic residues are 




2007). The loop containing the positively charged triad (Arg68, Arg69 and Lys63) forms 
favorable electrostatic interactions with phosphate group, stabilizing the interaction 
between protein and peptide inhibitor. The loop can adopt two dramatically different 
conformations, a closed conformation when a negatively charged group, such as 
inorganic sulfate or a phosphate group from substrate or substrate analogues, occupies the 
active site, and an open conformation when the site is unoccupied. Compared with the 
closed conformation, the tip of the loop swings 23.5 Å away when the pocket is empty 
(Figure 7-3). Furthermore, even in the closed conformation, the side chain of Arg68 is 
highly flexible in different structures, and it is usually totally disordered. However, in this 
pair of structures of Pin1 with substrate analogues, Arg68 covers the entrance of the 
active site cavity and provides a lid with hydrogen bonds to the amides of both inhibitors’ 
C-terminal arginine residues and phosphates (Figure 7-4b). The position of the Arg68 
side chain is also very close to the alkene bond that mimics the peptidyl-prolyl bond in 
the substrate. The highly mobile Arg68 side chain enables a very elastic binding pocket 
for phosphate, and permits the rotation of the phosphate group upon isomerization.  
The proline-binding pocket, on the other hand, is less flexible and favors certain 
positioning of proline over others. This pocket is composed of Phe125, Phe134, Met130 
and Leu122 (Figure 7-4c), which provides hydrophobic interactions with the proline-
mimic moiety of the inhibitors. Hydrophobic interactions usually grant high-affinity 
binding for inhibitors. For example, rapamycin presents a 0.2 nM Kd toward another 
PPIase, FKBP12 of the FK506 binding protein (FKBP) family, yet all the strong 
interactions are driven by hydrophobic interactions with only one potential hydrogen 
bond between the ligand and the enzyme (PDB code: 2dg3). Exploitation of the proline-
binding pocket in Pin1 will help us to design inhibitors for human Pin1 with stronger 
affinity and selectivity. Indeed, the high affinity of D- and L-PEPTIDE is at least partially 
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attributed to the exchange of proline residue by a 6-membered ring analogue of proline, 
pipecolic acid (Zhang et al. 2007). The natural substrate of Pin1 at this site, proline, 
actually has relatively weak binding to the PPIase domain, which is mimicked by the 
position of the proline analogue in our structure (Figure 7-4c). Instead, the WW domain 
shows a strong affinity for pSer/Thr-Pro sequences, and may function as a recruiter for 
natural substrates. Pin1 PPIase only binds substrate with Kd in millimolar range, therefore 
it is believed that the PPIase domain can only take the substrate after the WW domain 
targets the protein to the substrate (Ranganathan et al. 1997; Lu et al. 1999). This dual 
mode of action has been the center of investigation for human Pin1 function (Daum et al. 
2007; Namanja et al. 2011), but how the two domains communicate and coordinate 
catalysis remains to be elucidated. 
The Pin1 R14A-trans-isostere complex structure  
The structure of Pin1 bound to the inhibitor mimicking trans-proline exhibits a 
very similar conformation as its cis counterpart (Figure 7-4d). Consistently, Arg68 is 
ordered in this structure and covers the active site entrance. However, one interesting 
distinction from the cis complexes is the much weaker density at the alkene bond that 
mimics the prolyl peptide bond even though the densities of the compound at the 
phosphate binding site and proline binding pocket are rather strong. Considering that both 
complexes were obtained with similar amounts of soaking time at similar resolutions, this 
suggests that the isosteric bond is more ordered in the cis compound compared to the 
trans. The Ki of the trans compound is 23-fold higher than that of the cis compound, 
possibly due to the different binding modes of the proline residues as restricted by the cis 
or trans conformation. Alternatively, it is possible that the binding of the trans 
conformation of carbocyclic proline analogue exerts strain upon binding to Pin1, as 
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evidenced by the protein dynamics measured by NMR (Namanja et al. 2011). In contrast, 
the cis conformation of the alkene bond introduces less distortion, resulting in more 
favorable binding. 
Impacts on CTD dephosphorylation mediated by Scp1 and Ssu72 
Even though both cis- and trans-proline are suitable substrates for Pin1, as 
mimicked in our structures, the impact of isomerase activity is not the same on different 
enzymes recognizing different prolines. Since cis-proline is only a minor component in 
naturally occurring proteins, enzymes recognizing cis-proline as substrate will have their 
substrate pool greatly affected by Pin1 activity. Phosphatases targeting the same substrate 
sequence motif, but requiring different proline isomers, represent the best system to test 
this. Scp1 and Ssu72 are eukaryotic phosphatases recognizing the Ser5 position of the 
CTD. However, their complex structures suggest that Scp1 and Ssu72 prefer different 
proline conformations. We have examined how Pin1 activity affects the phosphatase 
activity of these enzymes.   
In order to investigate whether Pin1 can regulate the activity of CTD-specific 
phosphatases, we tested the dephosphorylation of a CTD-derived peptide using the 
malachite green assay. This peptide includes four repeats, (YSPTpSPS)4, with all four 
Ser5 phosphorylated. Previously, Ssu72 has been shown to be more active upon the 
addition of yeast homologue of Pin1, Ess1 (Werner-Allen et al. 2011). We asked whether 
similar effects would be observed when human Pin1 was used. The isomerization effects 
of Pin1 on another CTD phosphatase, transcription factor IIF-interacting CTD-
phosphatase 1 (Fcp1), have been controversial when both activation with human Pin1 
(Kops et al. 2002) and inhibition with yeast homologue Ess1 (Xu et al. 2003) have been 
observed. We reasoned that the discrepancy comes from the different recognition sites for 
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Fcp1 and Pin1. Pin1 binds the Ser5 of the CTD (Verdecia et al. 2000) whereas Fcp1 
highly favors Ser2, and only binds Ser5 weakly (Hausmann et al. 2002). When the same 
recognition motif is being recognized, the effect of the PPIase towards isomer-specific 
phosphatases should be more consistent between the yeast and human versions of the 
PPIase.   
In this study, we used Drosophila Ssu72 to test how Pin1 affects its activity. 
Drosophila Ssu72 shares 60% identity with human Ssu72, and structural conservation of 
0.56 Å in the main chain (Zhang et al. 2011). The active site superimposes perfectly 
between the Drosophila and human counterparts (Figure 7-5). The Drosophila version of 
Ssu72 has much higher thermostability, making it a better version to use for the kinetic 
experiments. Consistent with prior reports (Xiang et al. 2010; Werner-Allen et al. 2011), 
Ssu72 is activated upon Pin1 addition (Figure 7-6a) by about 3-fold. This result is 
consistent with a scenario in which Pin1 quickly converts the trans-Pro to cis-Pro, and by 
doing so, makes the cis-trans ratio reach equilibrium much faster than the uncatalyzed 
auto-conversion. Therefore, the consumable substrate concentration for Ssu72 was 
increased in the presence of Pin1, and led to the apparent increased activity of Ssu72. 
Such effect is specifically caused by the prolyl isomerase activity of Pin1, because when 
we used a truncated version of Pin1, PPIase domain, which cannot target CTD substrate 
to PPIase active site (Verdecia et al. 2000), the activation effect is lost (Figure 7-6a). 
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Figure 7-5: Superimposition of the active sites of the human (light blue, PDB code: 
3o2q) and Drosophila (light orange, PDB code: 3omw) Ssu72.42 
It should be noted that the fraction of peptide that was dephosphorylated by Ssu72 
(~1/3) consists of both substrate that was in cis-conformation initially [estimated to be 
~20%], and substrate that was auto-converted to cis-conformation during the process of 
the reaction. The difference between the reactions with and without Pin1 is caused by the 
effect of Pin1 'outracing' trans-to-cis auto-conversion.  
Combined with a previous experiment that a catalytically impaired mutant of 
yeast homologue of Pin1, Ess1, cannot activate Ssu72 (Werner-Allen et al. 2011), our 
result shows that it is the isomerization of the CTD that promotes the enhanced 
phosphatase activity of Ssu72, rather than stabilization of Ssu72 protein or reducing the 
non-specific adsorption of Ssu72 protein to the test tube. Furthermore, we ruled out the 
possibility that Pin1 activates Ssu72 by physically interacting with Ssu72. Firstly, Pin1 
specifically recognizes a Ser/Thr-Pro motif in its substrates only when the Ser/Thr is 
phosphorylated. However, Ssu72 contains no pSer/Thr-Pro motif in its primary sequence. 
                                                 
42 The three key residues at the active site are shown as sticks. The nucleophile Cys12 was mutated to Ser 
in the human Ssu72 in order to obtain the complex structure with the peptide (shown as yellow sticks). 
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Secondly, we tested whether Pin1 and Ssu72 can directly interact with each other to form 
a stable complex using gel filtration chromatography. In this experiment, roughly equal 
amount of Pin1 and Ssu72 (~300 µM each) were mixed together and incubated at 4 °C 
for 6 hr. The mixture was then loaded on Superdex 75 column (GE Healthcare). No peak 
corresponding to a possible Pin1-Ssu72 complex was observed (Figure 7-7). This 
experiment shows that the enhancement of Ssu72 activity is not due to its physical 
interaction with Pin1. 
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Figure 7-6: Effect of human Pin1 on the activities of Drosophila Ssu72 (a) and human 
Scp1 (b) phosphatases.43 
In contrast, when we tested human Scp1 in the same assay, the phosphatase 
activity is not significantly affected by Pin1 (Figure 7-6b). The insensitivity of Scp1 to 
Pin1 is consistent with the structural observations for prolyl isomeric states. Both Pro3 
and Pro6 of the CTD peptide exhibit only the trans conformation in the complex structure 
                                                 
43 The activities of both phosphatases toward a 28-mer peptide [sequence: (YSPTpSPS)4] were measured 
using malachite green assay. The Pin1 is wild-type full length protein and PPIase domain is a truncated 
version of Pin1 with residues 51-163. (a) The reaction (20 µL total volume) for Ssu72 was carried out in 
buffer containing 100 ng of Ssu72, 20 µM of peptide, 100 mM MES pH 6.5, and 10 ng of Pin1 or PPIase 
domain. (b) The reaction of Scp1 was performed in the buffer containing 5 ng of Scp1, 10 µM of peptide, 
50 mM Tris-acetate pH 5.5, 10 mM MgCl2 and 10 ng of Pin1 or the PPIase domain. The reactions were 
quenched by adding 40 µL of malachite green reagent at different time points. The release of inorganic 
phosphate was detected by measuring the absorbance at 620 nm. 
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of Scp1 and CTD peptide (Zhang et al. 2006). Unlike Ssu72, Pro3 two residues upstream 
of pSer5 is a recognition determinant for Scp1 binding. Since the majority of the peptide 
substrate [estimated to be 80%] has the proline in the trans conformation, Scp1 
recognizes the substrate readily and dephosphorylates the substrate. In this case the 
addition of Pin1 only marginally improves substrate accessibility of Scp1. The slight 
improvement is hard to distinguish due to the sensitivity level of malachite green assay 
and is thus insignificant. 
 
Figure 7-7: Gel filtration traces of Ssu72 (~23 kDa), Pin1 (~18 kDa) and Ssu72-Pin1 
mixture generated by Superdex 75 column (GE Healthcare).44 
                                                 
44 The wild-type Drosophila Ssu72 and human Pin1 were purified by following the same procedure 
described in Methods. Ssu72-Pin1 mixture was prepared by mixing nearly equal molar concentration 
(~300 µM) of Ssu72 and Pin1 in 4 °C and incubated for 6 hr. The arrows indicate where the standard 40 
kDa and 20 kDa protein should be. 
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Implication of Pin1 mechanism from the structures 
Both cis- and trans-prolines are subject to isomerization by Pin1 with cis and trans 
alkene inhibitors mimicking substrate/product of the Pin1 isomerization reaction. The 
pSer-Pro dipeptide with either cis or trans conformation is modeled, based on our present 
complex structures, in the Pin1 structure to illustrate the real substrate binding (Figure 7-
8b, c). The complex structures show that the same structural elements are used to 
recognize the substrate/product and interconvert the two species to reestablish the 
equilibrium cis:trans ratio. 
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Figure 7-8: Model of the cross-talk between Ser5 dephosphorylation and prolyl 
isomerization of the CTD.45 
                                                 
45 (a) The Pin1 acts as molecular switch that changes the isomeric state of the two prolines, resulting in 
recruitment of different transcription complex and therefore, different outcomes of transcription. (b) pSer-
cis-Pro dipeptide modeled in Pin1 structure. (c) pSer-trans-Pro dipeptide modeled in Pin1 structure. (d) 
Ssu72 is recruited with specific regulatory factors (colored shapes) to control general gene transcription in 
response to cis-proline. (e) Scp1 is recruited with a different set of regulatory factors (colored shapes) to 
control neuronal gene transcription in response to trans-proline. 
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A challenge of this field has been making substrates locked in only one 
conformation. Alkenes have a long history as peptide bond isosteres. The carbon-carbon 
double bond is close to the same length as the amide carbonyl-nitrogen bond, 1.40 Å vs 
1.32 Å, and the distance between the α-carbons is identical, 3.8 Å (Shue et al. 1993). The 
dynamics of both cis- and trans-locked ligands are dramatically affected by which 
conformation is bound to Pin1; cis is more rigid than trans, and the rigidity of bound cis 
results in 23-fold tighter binding (Wang et al. 2004; Namanja et al. 2011). The protein 
dynamics of a conduit between the PPIase and WW domains of Pin1 are also 
differentially affected by binding of cis- or trans-locked substrate isosteres (Namanja et 
al. 2011).   
Previously, we have obtained crystal structures of Pin1 complexed with two high 
affinity peptide inhibitors; Ac-Phe-(D/L)-pThr-Pip-Nal-Gln-NH2, (D-PEPTIDE or L-
PEPTIDE, respectively). Our new structures replace the prolyl-peptide which is subject 
to isomerization with non-rotatable carbon-carbon double bond, locking the two states of 
substrate-bound mode of Pin1. When we compared these two pairs of complex structures 
of Pin1, substrate-mimicking (cis and trans isosteres) versus high affinity inhibitors (D- 
and L-PEPTIDE), it has been observed that the phosphate positions of different Pin1 
inhibitors are highly diversified. The architecture of the triad positive residues allows the 
rolling of the phosphate group to form electrostatic interactions with Lys63, Arg68 and 
Arg69. The side chains of these three residues also adopt different conformations with 
each isomer to accommodate different positions of the phosphate of the substrate, 
allowing the rotation of the phosphate group, yet still within the pocket. On the contrary, 
the C-terminus of the signature motif (pSer/Thr-Pro) provides a strong hold for the 
peptide. The proline pocket does not accommodate free rotation of the proline and the 
hydrogen bonding between the carbonyl of proline and the amide of Gln131 is highly 
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conserved among all of our Pin1 structures (Figure 7-9). These observations suggest that 
dynamic interactions of the phosphate group and the protein allows the rotation of the 
prolyl peptide at the N-terminus of the peptide subject to isomerization, which echoes the 
discovery in NMR studies on the issue (Labeikovsky et al. 2007; Namanja et al. 2010). In 
addition, the flexibility of the interactions between the phosphate group and the positive 
triad during the rotation permits transition-state stabilization (Xu et al. 2011). 
 
Figure 7-9: Hydrogen bond (green dashed line) formed between the carbonyl of proline 
(or proline analogue) and the amide of Gln131.46 
Implications for the regulatory mechanism of CTD 
During the progression of the RNA polymerase II-mediated transcription cycle, 
many CTD-specific kinases and phosphatases are recruited to the CTD. The dynamic 
phosphorylation/dephosphorylation is a major regulatory mechanism of the CTD, greatly 
influencing transcription. However, various phosphatases and kinases may have different 
specificity toward the isomeric states of the prolines adjacent to the major 
                                                 
46 Shown here is an example from complex structure of Pin1 and L-PEPTIDE (PDB code: 2q5a). 
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phosphorylation sites. Even though cis and trans forms of proline can reach equilibrium 
slowly under thermal isomerization called auto-conversion, the rate is too slow to allow 
efficient signal transduction in cells. Therefore, Pin1-mediated prolyl isomerization of the 
CTD is necessary to couple with the phosphorylation regulation to generate suitable 
substrates for both cis- and trans-specific kinases/phosphatases (Figure 7-8a). The 
dynamic nature of the CTD phosphorylation states during transcription determines that 
different outcomes can be reached for different phosphatases when their proline isomeric 
specificity is different (Figure 7-8).   
In such a scenario, the prolyl isomerase activity can greatly affect the outcome 
when the pool of one species of the substrate is rapidly depleted. For a cis-specific 
enzyme, such as Ssu72, the isomerase activity of Pin1 guarantees the availability of cis-
form substrate that is rapidly depleted. On the other hand, since Scp1 utilizes the trans-
form CTD as substrate, which is the major species, the apparent dephosphorylation will 
not be affected much by Pin1. So even though both Scp1 and Ssu72 recognize the pSer5 
of CTD as substrate, their response towards Pin1 PPIase activity in cells will differ 
dramatically (Figure 7-8d, e). Their different responses will in turn affect the regulatory 
factors recruited to the vicinity of genes during transcription. Specifically, Ssu72 together 
with its binding partner, the scaffold protein symplekin (Xiang et al. 2010) and other 
regulatory factors from the cleavage/polyadenylation specificity factor (CPSF) complex 
(Krishnamurthy et al. 2004), will be recruited in response to pSer-cis-Pro, thus regulate 
general transcription. On the other hand, Scp1, together with REST complex (Yeo et al. 
2005), will be recruited in response to pSer-trans-Pro to turn off neuronal gene 
expressions. To a certain extent, the phosphorylation state of the CTD is governed not 
only by the phosphorylation/dephosphorylation mechanism, but also the prolyl 
isomerization mechanism (Figure 7-8). The combination of the various post-translational 
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modifications on CTD can lead to different transcription outcome and therefore, various 
fates for the cell. The recognition of both phosphorylation and isomerization states of 
CTD by partner proteins are very likely to be a general mechanism adopted by other 
CTD-binding proteins in transcription regulation, indicating a “combinatorial” CTD 
code. 
CONCLUSIONS 
In this study, we determined the complex structures of human Pin1 with two 
isomer-locked peptidomimetics that mimic the substrates in the cis or trans form of a 
pSer-Pro peptide bond. The recognition by Pin1 has an impact on the downstream 
regulatory phosphatases of CTD to a different extent based on their specificity towards 
proline isomeric states. The existence of Pin1 isomerase activity can greatly stimulate the 
activity of a cis-proline specific phosphatase by increasing the potential substrate pool. 
However, the Pin1 effect is more limited on trans-proline specific phosphatases. 
Therefore, the up-regulation of Pin1 activity can alter the signal transduction pathway in 
CTD-mediated transcriptional regulation. The cross-talk between prolyl-isomerase and 
CTD phosphatases can differentially lead to various transcriptional outcomes in cells. 
METHODS 
Synthesis of the cis and trans peptide mimetic inhibitors 
The cis and trans isosteres, Boc–Ser–Ψ[(Z/E)CH=C]-Pro–OH, where (Z) is the cis 
mimic, and (E) is the trans mimic, were synthesized as previously reported (Wang et al. 
2003). Both peptidomimetics (Figure 7-2), Ac–Phe–Phe–pSer–Ψ[(Z/E)CH=C]-Pro–Arg–
NH2, were synthesized using solid-phase peptide synthesis with the Fmoc-protected, 
block-phosphorylated isosteres as described previously (Wang et al. 2004).   
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Purification of human Pin1 and human Scp1 
The human Pin1 or Scp1 gene was sub-cloned in a pHIS8 vector, a derivative of 
pET28a vector (Novagene) (Jez et al. 2000). The Pin1 R14A mutant was produced using 
the QuikChange Site-Directed Mutagenesis Kit (Stratagene, CA). The purification of 
Pin1 R14A mutant or Pin1 PPIase domain (residue 51-163) was identical to the 
procedure previous reported (Zhang et al. 2007). Concisely, the protein was 
overexpressed using E. coli BL21(DE3) strain with isopropyl-β-D-thiogalactopyranoside 
(IPTG) induction at 16 °C overnight. The cells were pelleted and lysed with subsequent 
nickel affinity chromatography purification. After imidazole elution of the HIS-tagged 
recombinant protein, the N-terminal polyhistidine-tag was truncated with thrombin 
protease during dialysis at 4 °C, and subsequently purified on ion-exchange and size 
exclusion chromatography columns. The purified protein was homogenous on SDS-
PAGE gel.   
Purification of Drosophila Ssu72  
A pET28b derivative vector, pETHIS8–SUMO, encoding Drosophila Ssu72 
proceeded by an N-terminal 8xHIS-SUMO tag was constructed previously (Zhang et al. 
2011). The protein was overexpressed in E. coli BL21 (DE3). The cells were grown at 
37 °C in Luria-Bertani medium supplemented with 50 µg/mL kanamycin, then induced 
with 0.5 mM IPTG at 16 °C when the O.D. at 600nm reached 0.8. After overnight 
incubation, the cells were harvested by centrifugation and disrupted by sonication. 
Recombinant protein was initially purified with Ni-NTA column (Qiagen, Switzerland). 
The N-terminal 8xHIS-SUMO tag was then removed by PreScission protease (GE 
Healthcare). The protein was further purified by a size exclusion column Superdex-75 
(GE Healthcare), equilibrated with 25 mM Tris-HCl (pH8.0) and 200 mM NaCl buffer. 
The collected Ssu72 protein was passed through the Ni-NTA column again to remove 
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any heterogeneous proteins, as evaluated by SDS-PAGE gels. The pure Ssu72 protein 
was finally flash frozen in liquid nitrogen and stored at –80 °C. 
Crystallization, soaking and data collection  
The R14A variant of human Pin1 was crystallized by vapor diffusion using a 
hanging drop of 1 µL protein plus 1 µL well solution. The crystals were obtained at 1.9-
2.2 M ammonium sulfate, 1% PEG400 at pH 7.5 in 50 mM HEPES buffer. The crystals 
were then transferred to mother liquor containing 40% PEG400 and 50 mM HEPES pH 
7.5 with 0.2 mM of peptide mimetic inhibitor. The crystals were soaked for 4 weeks with 
buffer exchange using fresh mother-liquor containing peptide mimetic inhibitor every 
week. The crystals were then frozen in liquid nitrogen and subjected to in-house X-ray 
beam using DIP100 imaging plate (MacScience, CO) with data collection. Diffraction 
data were processed using HKL2000. The statistics of the data are summarized in Table 
7-1. 
Structure determination and analysis 
The complex structure of human Pin1 R14A with cis or trans peptide mimetic 
inhibitors were determined using molecular replacement with Pin1 complex structure 
with a high affinity inhibitor (PDB code: 2itk) as a search model. The solution of the 
structure was identified using AMoRe, a program in the CCP4 program suite (Navaza 
1994). The refinement of the complex structures was performed using the program 
refmac in CCP4 (Vagin et al. 2004). Electron density maps (sigmaA weighted 2Fo-Fc and 
Fo-Fc maps) were calculated after each cycle of refinement, and inspected to guide model 
rebuilding using Coot (Emsley et al. 2004). The quality of the final model was evaluated 
using Procheck (CCP4 1994). The statistics of the final model for both structures are 
summarized in Table 7-1. 
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Malachite green assay for Scp1 and Ssu72 
The activity of the CTD phosphatases Scp1 and Ssu72 in the presence or absence 
of Pin1 toward 28-mer CTD peptide was measured in this assay (Martin et al. 1985). The 
28-mer peptide contains 4 repeats of the consensus sequence with each Ser5 
phosphorylated: (YSPTpSPS)4. The reaction (20 µL total volume) for human Scp1 was 
carried out in buffer containing 5 ng of Scp1, 10 µM of peptide, 50 mM Tris-acetate pH 
5.5, 10 mM MgCl2 and 10 ng of Pin1 or the PPIase domain, and was incubated at 37 °C. 
The reaction (20 µL total volume) of Drosophila Ssu72 was performed in the buffer 
containing 100 ng of Ssu72, 20 µM of peptide, 100 mM MES pH 6.5, and 10 ng of Pin1 
or PPIase domain, and was incubated at 28 °C. The reactions were quenched by adding 
40 µL of malachite green reagent at different time points. The release of inorganic 
phosphate was detected by measuring the absorbance at 620 nm. 
ACCESSION CODE 
Coordinates of the Pin1-cis compound and Pin1-trans compound complex 




 Pin1 w/ cis compound Pin1 w/ trans compound 
Data collection   
Space group P3121 P3121 
Cell dimensions:  a, b, c (Å) 69.4, 69.4, 79.6 69.3, 69.3, 79.7 
α, β, γ (°) 90.0, 90.0, 120.0 90.0, 90.0, 120.0 
Resolution (Å) 50.00 – 2.10 (2.18 – 2.10) * 50.00– 2.26 (2.34 – 2.26) * 
No. of unique reflections 12458 (1106) 10488 (908) 
Rsym or Rmerge (%) 5.4 (47.6) 4.3 (30.1) 
I/σ(I) 26.4 (2.5) 33.2 (5.4) 
Completeness (%) 93.2 (84.8) 97.5 (85.9) 
Redundancy 5.5 (5.0) 4.6 (4.3) 
Refinement   
Resolution (Å) 33.19 – 2.10 47.95 – 2.27 
No. of reflections (test set) 10431 (1187) 9168 (1037) 
Rwork / Rfree (%) 
# 22.3 / 26.5 21.7 / 25.6 
No. of atoms:   Protein 1164 1164 
Ligand 30 39 
PEG 24 24 
Water 87 64 
B-factors (Å2):  Protein 32.6 29.0 
Ligand 47.0 55.6 
PEG 31.7 30.2 
Water 39.1 32.5 
R.m.s deviations: Bond lengths 
(Å) 
0.011 0.020 
Bond angles (°) 1.411 1.977 
Ramachandran plot (%): Most 
favored 
92.8 92 
Additionally allowed 6.4 7.2 
Generally allowed 0.0 0.0 
Disallowed a 0.8 0.8 
Table 7-1: Crystallographic data statistics.47 
                                                 
47 * Highest resolution shell is shown in parenthesis. # Rfree is calculated with 10% of the data randomly 
omitted from refinement. a Leu7 (chain A) in both structures is close to the N-terminus of Pin1. 
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The research described in this dissertation provided not only answers to several 
key questions regarding the function of Scps and the dynamic regulation of the CTD, but 
also a number of novel and powerful tools for the further study in these areas. 
Firstly, our understanding of the enzymatic mechanism of Scps was significantly 
deepened by our capture of the phosphoryl-aspartate intermediate of Scp1. This was the 
first definitive evidence for the previously debated two-step mechanism of Scps. 
Secondly, the first selective inhibitor of Scp1, which represents the first selective 
inhibitor of the Fcp/Scp-family protein serine/threonine phosphatases, was identified. 
This discovery not only defied many stereotypes of phosphatase inhibition, but also 
provided a stepping-stone to develop more potent inhibitors of Scp1 for neuron 
regeneration. Thirdly, the potential secondary binding pocket for the CTD was identified 
on Scp1, which provided new insight of CTD regulation and may even facilitate the 
development of more potent Scp1 inhibitors. Finally, the communication between two 
different regulatory mechanisms of the CTD, i.e. phosphorylation and prolyl-
isomerization, was established in our in vitro model system where Scp1, Ssu72 and Pin1 
were effectors. This simplistic model represented an elegant example to delineate ‘control 
at equilibrium’ and ‘control at steady-state’, a concept that may underlie many regulatory 
processes including the dynamic regulation of transcription through the CTD. 
These new findings and tools should enable us to ask deeper questions in these 
areas. With regard to the function of Scps, it would be interesting to identify all genes 
(other than neuronal genes) that are regulated by Scps. In addition, it is important to 
understand how Scp1 is recruited to the CTD and whether Scp1 displays processivity in 
the presence of binding partners. Moreover, the recent discovery of phosphorylation at 
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Tyr1, Thr4 and Ser7 residues also prompts the question of whether additional 
modifications in conjunction with Ser5 phosphorylation would influence the 
dephosphorylation of Ser5 by Scp1.  
Extraordinarily rapid progress has been made over the past few years in the field 
of CTD research; however, many important questions remain to be answered. One big 
hurdle is the inability of current technologies to identify the exact phosphorylation 
patterns across individual repeats at different stages during the transcription cycle. The 
ability to unambiguously identify (or ‘sequence’) the phosphorylation patterns at the 
resolution of individual repeats is likely to be essential to determine the existence and 
meaning of the postulated “CTD code”. As the field stands now, this remains one of the 
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